Clinical trial NCT02563548
Conditions: NSCLC Gastric Cancer
Sponsor: Halozyme Therapeutics
Start date: 2015-10-22; Completion date: 2019-03-26
Enrollment: 56 participants; Allocation: ; Intervention model: PARALLEL

Brief summary:
This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).

Detailed description:
Study involves dose escalation phase (completed in Nov-2016) to assess the safety and tolerability of PEGPEM (PEGylated recombinant human hyaluronidase \[PEGPH20\] combined with pembrolizumab \[Keytruda®\]) and to find the recommended Phase 2 dose (RP2D) ; and an expansion phase to assess the efficacy, safety and tolerability of PEGPEM in stage III b/IV NSCLC and relapsed/refractory GAC participants. Plan was to include approximately 51 HA-high participants (30 NSCLC and 21 GAC participants) in the dose expansion phase on the obtained RP2D from dose escalation phase of the study.

Arms: arm 1: Dose escalation part: Participants with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma (GAC) will receive PEGPH20 1.6 micrograms/kilogram (µg/kg) or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 milligrams/kilogram (mg/kg) every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory locally advanced or metastatic GAC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks). arm 2: Dose escalation part: Participants with relapsed/refractory Stage IIIB or IV non-small cell lung cancer (NSCLC) will receive PEGPH20 1.6 µg/kg or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 mg/kg every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory Stage IIIB or IV NSCLC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 46 weeks).
Interventions: intervention 1: PEGPH20 intervention 2: Pembrolizumab
Intervention descriptions: intervention 1: PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description. intervention 2: Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.

Protocol documents:
Prot_000.pdf: 
Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 1 of 112 
06 November 2017 
CLINICAL STUDY PROTOCOL 
Title: 
A Phase 1b Open-Label Study of PEGylated Recombinant 
Human Hyaluronidase (PEGPH20) Combined with 
Pembrolizumab in Subjects with Selected  
Hyaluronan-High Solid Tumors 
Phase 
1b 
Protocol Number: 
HALO-107-101 
Original Protocol Date: 
30 June 2015 
Protocol Amendment 1 Date: 04 January 2016 
Protocol Amendment 2 Date: 27 April 2016 
Protocol Amendment 3 Date: 21 November 2016 
Protocol Amendment 4 Date: 06 November 2017 
IND: 
102770 
Sponsor: 
Halozyme, Inc. 
11388 Sorrento Valley Road 
San Diego, CA 92121 
Office: 
 
Confidential: This document and the information it contains are the property of Halozyme, Inc. 
and are provided for the sole and exclusive use of Investigators in this clinical study. The 
information in this document may not be disclosed unless such disclosure is required by Federal 
or applicable State Law or Regulations, or unless there is prior written consent from Halozyme, 
Inc. Subject to the foregoing, this information may be disclosed only to those persons involved in 
the clinical investigation who need it, and who share the obligation not to disseminate this 
information further. 
NCT #: NCT02563548


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 2 of 112 
06 November 2017  
[Approval Signature Page to be Inserted here] 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4  
CONFIDENTIAL 
Page 3 of 112 
06 November 2017 
1. 
SYNOPSIS 
Sponsor/Company 
Halozyme, Inc.  
Protocol Number 
HALO-107-101 
Study Title 
A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) 
Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors 
Study Objectives 
Dose Escalation  
Primary: 
• To assess the safety and tolerability of PEGylated recombinant human hyaluronidase 
(PEGPH20) combined with pembrolizumab (Keytruda®) (PEGPEM) in subjects with 
relapsed/refractory non-small cell lung cancer (NSCLC) and relapsed/refractory 
gastric adenocarcinoma. 
• To determine the recommended Phase 2 dose (RP2D) of PEGPH20 when 
administered with pembrolizumab in subjects with relapsed/refractory NSCLC and 
relapsed/refractory gastric adenocarcinoma. 
Secondary: 
• To assess the pharmacokinetics (PK) of PEGPH20 when given in combination with 
pembrolizumab in subjects with relapsed/refractory NSCLC or relapsed/refractory 
gastric adenocarcinoma. 
• To obtain an early assessment of the antitumor activity of PEGPEM, as assessed by 
objective response rate (ORR), duration of response (DOR), disease control rate 
(DCR) and progression-free survival (PFS) based on Response Evaluation Criteria in 
Solid Tumors (RECIST) v1.1, and overall survival (OS) in subjects with 
relapsed/refractory NSCLC or relapsed/refractory gastric adenocarcinoma. 
Exploratory: 
• To assess the PK of pembrolizumab when given in combination with PEGPH20 in 
subjects with relapsed/refractory NSCLC or relapsed/refractory gastric 
adenocarcinoma. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 4 of 112 
06 November 2017  
Dose Expansion  
Note: The objectives described below will be evaluated in hyaluronan-high (HA-high) subjects 
with relapsed/refractory NSCLC and HA-high subjects with relapsed/refractory gastric 
adenocarcinoma. 
Primary: 
• To evaluate the efficacy of PEGPEM as assessed by ORR based on RECIST v1.1  
Secondary: 
• To evaluate the efficacy of PEGPEM as assessed by DOR, DCR and PFS based on 
RECIST v1.1, and OS 
• To evaluate the efficacy of PEGPEM as assessed by ORR, DOR, DCR and PFS based 
on immune-response related criteria (irRC) 
• To characterize the PK of PEGPH20 when given in combination with pembrolizumab 
• To evaluate the safety and tolerability profile of PEGPEM 
Exploratory: 
• To evaluate the efficacy of PEGPEM, as assessed by ORR, DOR, DCR and PFS 
based on RECIST v1.1 criteria and irRC, by programmed death-ligand 1 (PD-L1) 
expression levels 
• To assess the treatment effect of PEGPEM as follows: 
− Based on HA levels in plasma and tumors, or other potential biomarkers. 
− Based on tumor blood flow and metabolic activity as assessed by dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron emission 
tomography (PET)/computed tomography (CT) scans, respectively. 
• To assess the PK of pembrolizumab when given in combination with PEGPH20  
Study Design 
This Phase 1b study of PEGPEM will consist of 2 portions: 
• A Dose Escalation portion in subjects with relapsed/refractory Stage IIIB or IV 
NSCLC after failing at least 1 previous platinum-based chemotherapy regimen (refer 
to Inclusion Criterion #2) and subjects with relapsed/refractory locally advanced or 
metastatic gastric adenocarcinoma after failing at least 1 previous chemotherapy 
regimen for locally advanced or metastatic disease. 
• Followed by a Dose Expansion portion in: 
− Previously untreated, HA-high subjects with Stage IIIB or IV NSCLC  
− Previously treated, HA-high subjects with relapsed/refractory Stage IIIB or IV 
NSCLC having failed no more than 1 previous platinum-based chemotherapy 
regimen (refer to Inclusion Criterion #3) for locally advanced or metastatic disease 
and 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 5 of 112 
06 November 2017  
− HA-high subjects with relapsed/refractory locally advanced or metastatic gastric 
adenocarcinoma having failed no more than 2 previous chemotherapy regimens 
for locally advanced or metastatic disease. 
Note: In Dose Expansion, subjects will be selected for enrollment whose tumors are HA-high, 
using a co-developed investigational diagnostic assay. Subjects will be tested retrospectively for 
PD-L1 expression levels. 
Since PEGPH20 has not been evaluated in clinical studies in combination with pembrolizumab, 
this study will have a Dose Escalation portion to evaluate the safety and tolerability of PEGPEM 
treatment before the Dose Expansion portion is initiated. The Dose Escalation portion will also 
be used to determine the dose of PEGPH20 to be evaluated in the Dose Expansion portion. 
The treatment period will consist of 21-day cycles. 
In Dose Escalation, PEGPH20 will be administered on Day 1, Day 8 and Day 15 of each 21-day 
cycle (i.e. 3 doses/cycle) and pembrolizumab (2 mg/kg every 21 days) on Day 1 of each cycle 
(i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration (per Protocol 
Amendment 2). 
In Dose Expansion, 200 mg of pembrolizumab will be administered every 21 days (per Protocol 
Amendment 3 [see Section 4.6.4 for additional details]) and the dosing schedule will be as 
follows: 
• PEGPH20 will be administered on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 
3 doses/cycle) and pembrolizumab (200 mg every 21 days) on Day 1 of each cycle 
(i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. 
In Dose Expansion, an independent data monitoring committee (DMC) will review all available 
safety data from the first 3 NSCLC subjects and first 3 gastric adenocarcinoma subjects who have 
completed Cycle 1, to determine if the safety and tolerability profile of the PEGPEM 
combination is acceptable (refer to the DMC charter for additional details). The DMC will also 
continue to periodically review safety data to protect subject welfare and identify potential safety 
signals. 
Treatment in both portions of the study will continue until death, withdrawal of consent from the 
study, disease progression, or unacceptable toxicity; however, subjects with asymptomatic 
disease progression will be allowed to continue the study treatment at the Investigator’s 
discretion despite evidence of increasing tumor burden or appearance of new lesions for up to 
6 weeks if the subject is “clinically stable.” Clinically stable is defined as: 
• Absence of symptoms and signs indicating clinically significant progressive disease 
(PD) (including worsening of laboratory values) indicating disease progression; 
• No decline in Eastern Cooperative Oncology Group (ECOG) performance status; and 
• Absence of rapid progression of disease or of progressive tumor at critical anatomical 
sites (e.g., cord compression) requiring urgent alternative medical intervention. 
Dose interruptions and modifications of study treatment are permitted. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 6 of 112 
06 November 2017  
In single-agent studies of PEGPH20 and the combination study with gemcitabine (GEM), the 
dose-limiting toxicity (DLT) was musculoskeletal events (MSEs) of myalgia and muscle 
cramping. In clinical studies HALO-109-102, HALO-109-201 and HALO-109-202, 
dexamethasone was administered per protocol to attenuate the severity of MSEs. Since this study 
uses an immunotherapeutic agent and dexamethasone may suppress an immune response, it 
should only be used when prescribed by the Investigator and following a discussion with the 
Sponsor. 
Piroxicam and toradol have been investigated in an animal model of MSEs and may be helpful in 
decreasing the severity of MSEs in subjects (internal Halozyme report). Piroxicam (20 mg) will 
be administered at least 1-2 hours prior to PEGPH20 administration on the day of dosing (timing 
will be at the Investigator’s discretion based on the piroxicam manufacturer’s Prescribing 
Information and subject’s convenience) to minimize the severity of MSEs. Prophylactic use of a 
proton pump inhibitor is mandated for all subjects while receiving PEGPH20 (e.g. 20 mg 
omeprazole daily or over-the-counter [OTC] equivalent). 
Toradol may be given for severe pain as recommended in the Toradol Prescribing Information. 
Toradol should not be administered concurrently with piroxicam as per the Prescribing 
Information, as it is contraindicated to administer toradol simultaneously with other nonsteroidal 
anti-inflammatory drugs (NSAIDs) because of the cumulative risk of inducing serious 
NSAID-related side effects. 
To help minimize MSEs, prescribed medication such as narcotics, muscle relaxants and other 
analgesics (with the exceptions of steroids), OTC drugs and physical therapy can be used at the 
Investigator’s discretion. 
All NSCLC subjects will be given enteric-coated 81 mg of aspirin/day and all gastric 
adenocarcinoma subjects will be given enoxaparin 40 mg/day (pre-filled syringes of enoxaparin 
are allowed), for prophylaxis of thromboembolic (TE) events, given the high incidence seen in 
these tumor types. Subjects who experience any TE event requiring full-dose anticoagulants 
while on study will discontinue treatment with PEGPH20. Treatment with pembrolizumab, 
however, may continue at the Investigator’s discretion. 
In gastric adenocarcinoma subjects, if enoxaparin is discontinued for any reason, PEGPH20 will 
also be discontinued. Treatment with pembrolizumab, however, may continue at the 
Investigator’s discretion. 
Subjects who discontinue PEGPH20 and pembrolizumab treatment will have an End of 
Treatment Visit and enter long-term follow-up for survival. 
Subjects will be assessed for adverse events (AEs) and clinical laboratory evaluations as graded 
by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) 
v4.03. 
In both portions of the study, tumor response and progression will be assessed by the Investigator 
at the end of Cycle 2, Cycle 4 and then at the end of every fourth treatment cycle thereafter (i.e., 
Week 3 of Cycles 2, 4, 8, 12, 16 and beyond) based on RECIST v 1.1 criteria (Eisenhauer 2009; 
Appendix C) and irRC (Nishino 2013; Nishino 2014; Appendix E). Tumor assessment scans 
(CT/MRI of chest, abdomen, pelvis, and other areas of known or newly suspected disease) should 
be performed at Screening (within 28 days prior to first dose of study drugs) and obtained any 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 7 of 112 
06 November 2017  
time on or after Day 15 (of Cycles 2, 4, 8, 12, 16 and every fourth treatment cycle thereafter) to 
allow enough time for the scan to be reviewed locally prior to the subject’s next scheduled dosing 
visit. 
A CT/MRI brain scan must be performed at Screening (within 28 days prior to first dose of study 
drugs), to assess potential central nervous system disease and/or metastases. 
For the duration of the study (i.e., post-baseline), CT/MRI of the brain will be performed if 
clinically indicated, and within a target of 1 week after a subject achieves a complete response 
(CR). For NSCLC subjects with a history of treated brain metastases, brain scans will be 
performed at tumor assessment time points. 
To determine the best overall response, a confirmatory scan must be performed no sooner than 
28 days after the initial scan that showed a response (Partial Response [PR] or Complete 
Response [CR]) based on RECIST v1.1 and irRC. A confirmatory scan should also be performed 
to confirm disease progression based on irRC no sooner than 28 days after the initial scan that 
showed progression. 
Phase 1b Dose Escalation Portion 
This portion of the study is a single-arm, dose escalation study of PEGPH20 in combination with 
pembrolizumab. Using a standard 3+3 dose escalation design, approximately 3 to 6 subjects in 
each cohort will receive PEGPH20 + pembrolizumab. PEGPH20 will be administered on Day 1, 
Day 8 and Day 15 of each 21-day cycle to consecutive cohorts in increasing dose levels (1.6, 2.2, 
2.6, 3.0, and 4.0 µg/kg). Pembrolizumab will be administered on Day 1 of each cycle, 4-6 hours 
after the dose of PEGPH20. If the maximum tolerated dose (MTD) is not reached at 4.0 µg/kg, 
higher doses may be evaluated. If ≥2 subjects experience a DLT at the 1.6 µg/kg dose level, 
Cohort -1 will be opened and subjects will be dosed at 1.0 µg/kg on Day 1, Day 8, and Day 15 of 
each 21-day cycle. The RP2D of PEGPH20 will be the MTD determined in Dose Escalation or 
the Sponsor may decide to choose a dose lower than the MTD and which has completed 
evaluation in Dose Escalation and is found to be safe and tolerable to evaluate in Dose 
Expansion. 
The number of cohorts studied and number of subjects exposed to a given dose level will depend 
on the doses tested. It is anticipated that up to 5 dose levels will be studied for a total of 
approximately 30 subjects exposed to study medication. The dose allocation for 5 cohorts of 
subjects assigned to the 5 preselected dose levels and the -1 cohort assigned to the preselected 
dose of 1.0 µg/kg (if ≥2 subjects experience a DLT at 1.6 µg/kg dose level) is shown as an 
example in Table S-1. The study medication dosing and treatment schedule are shown in 
Table S-2. 
Safety data from all subjects dosed will be reviewed to determine the RP2D. Dose escalation will 
be guided by safety data from each subject during the 21 days following their first dose of 
PEGPH20. Intra-subject dose escalation to the next PEGPH20 dose studied may be allowed if the 
Investigator deems it in the best interest of the subject and after discussion with the Sponsor and 
provided the next PEGPH20 dose studied has been determined not to have exceeded the MTD. 
• If none of 3 subjects in a given cohort experience a DLT within 21 days of starting 
treatment, enrollment and dosing may proceed at the next planned dose level. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 8 of 112 
06 November 2017  
• If 1 of 3 initial subjects at a given dose level experiences a DLT within the first 
21 days of treatment, 3 additional subjects will be enrolled and dosed at the same dose 
level. If ≤1 of 6 subjects experiences a DLT, dose escalation may continue to the next 
planned higher dose. 
• If ≥2 subjects at a given dose level experience a DLT within the first 21 days of 
treatment, that dose level will be considered to have exceeded the MTD and dose 
escalation will be stopped. If the previous dose level did not already have 6 subjects 
treated with ≤1 DLT, enrollment and dosing will then resume in the previous dose 
level with additional subjects up to a total of 6 subjects. The highest dose level at 
which no more than 1 of 6 evaluable subjects has experienced a DLT in the first 
3 weeks of treatment will be considered the MTD for the PEGPEM combination. The 
RP2D will be based on the overall safety profile. 
• If ≥2 subjects at the 1.6 µg/kg dose level experience a DLT within the first 21 days of 
treatment, Cohort -1 will be opened at a lower dose level of 1.0 µg/kg. 
Note: Additional subjects may be enrolled in each cohort to further assess the tolerability of 
PEGPEM and determine an acceptable safety profile prior to the enrollment in the next dose level 
and expansion portion of the study. 
Definition of DLT 
DLTs will be assessed for each subject during the 21 days following their first PEGPH20 dose 
and will be defined as any of the following: 
• Any treatment-emergent Grade ≥3 toxicity that is considered related to either 
PEGPH20 or pembrolizumab or the combination of PEGPH20 and pembrolizumab 
(nausea, vomiting, musculoskeletal events and diarrhea will be considered DLTs only 
if they reach ≥ Grade 3 despite adequate supportive care measures). 
• Grade 3 MSEs are considered DLTs only if they do not reduce to ≤ Grade 2 within 
48 hours despite therapeutic intervention. 
• Hypersensitivity/infusion reactions related to PEGPH20 or pembrolizumab dosing 
will not be considered DLTs (hypersensitivity reactions are generally not related to 
the dose level of a drug since they can occur even upon a low level of exposure). 
To be considered evaluable for DLT assessment, subjects must receive 1 of the 3 full planned 
doses of PEGPH20 and 1 complete dose of pembrolizumab in Cycle 1. Subjects who experience 
a DLT within the first 21 days of treatment and withdraw from the study will be considered 
evaluable for DLT and will not be replaced. Subjects who withdraw within the first 21 days for 
reasons other than a DLT will be considered not evaluable and will be replaced. Any PEGPH20 
treatment-related AE that results in interruption or reduction of either PEGPH20 or 
pembrolizumab may be considered a DLT at the Investigator’s discretion. 
The Sponsor and the participating investigators will meet as soon as practical, post completion of 
a cohort, and no more than 10 business days after the end of the last cohort to determine an 
acceptable dose for the Dose Expansion portion after reviewing all available safety data from 
Cycle 1 from all subjects in the Dose Escalation portion. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 9 of 112 
06 November 2017  
Table S-1: 
Dose Allocation and Cohort Schedule - Dose Escalation Portion 
Cohort 
PEGPH20 µg/kg  
Pembrolizumab mg/kg  
-1 
1.0 
2 
1 
1.6 
2 
2 
2.2 
2 
3 
2.6 
2 
4 
3.0 
2 
5 
4.0a 
2 
Abbreviations: PEGPH20 = PEGylated Recombinant Human Hyaluronidase 
Note: Each treatment cycle is 21 days. Dose interruption and modifications are permitted. 
a If the MTD is not reached at 4.0 µg/kg, higher doses may be evaluated. 
Phase 1b Dose Expansion Portion 
Approximately 51 HA-high subjects will be studied in the Dose Expansion portion at the RP2D identified 
in the Dose Escalation portion: 
• Approximately 30 subjects with Stage IIIB or IV NSCLC, previously untreated or 
treated and having failed no more than 1 previous platinum-based chemotherapy 
(refer to Inclusion Criterion #3) 
• Approximately 21 subjects with relapsed/refractory gastric adenocarcinoma having 
failed no more than 2 previous chemotherapy regimens. 
The study medication dosing and treatment schedule are shown in Table S-2. 
Table S-2: 
Study Medication Dosing and Treatment Schedule – Dose Escalation and 
Dose Expansion 
Time point 
PEGPEM Treatment 
Subjects with NSCLC or Gastric Adenocarcinoma 
Cycle 1 and Beyond (Each Cycle 21 Days) 
Week 1 
Day 1 
PEGPH20 
Pembrolizumab (4-6 hours after PEGPH20) 
Week 2 
Day 8 
PEGPH20 
Week 3 
Day 15 
PEGPH20 
Abbreviations: PEGPEM = PEGPH20 in combination with pembrolizumab; PEGPH20 = PEGylated Recombinant 
Human Hyaluronidase; NSCLC = non-small cell lung cancer 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 10 of 112 
06 November 2017  
Notes: Dose interruption and modifications are permitted. 
On Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycle 2, measurements of total bilirubin, alkaline phosphatase (ALP), 
aspartate aminotransferase (AST), and alanine aminotransferase (ALT) (as part of blood chemistry) must be obtained 
prior to dosing (within 48 hours is acceptable). Dosing can only take place if total bilirubin, ALP AST, and ALT 
values are within the ranges specified in the Inclusion Criteria. If a subject has any of these values outside the 
specified ranges on Day 1 of Cycle 2, the Investigator should discuss further dosing plans for the subject with the 
Sponsor. 
Visit window is ±2 days of the specified times. 
Study Population 
Males and females aged 18 years and above. 
Phase 1b Dose Escalation: Subjects with relapsed/refractory Stage IIIB or IV NSCLC after 
failing at least 1 previous platinum-based chemotherapy regimen (refer to Inclusion Criterion #2) 
and subjects with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma after 
failing at least 1 previous chemotherapy regimen for locally advanced or metastatic disease. 
Phase 1b Dose Expansion: Subjects with HA-high Stage IIIB or IV NSCLC, previously untreated or treated 
and having failed no more than 1 previous platinum-based chemotherapy regimen, and who have tissue 
available for HA-selection and PD-L1 testing; and HA-high subjects with relapsed/refractory locally 
advanced or metastatic gastric adenocarcinoma having failed no more than 2 previous chemotherapy 
regimens for locally advanced or metastatic disease and who have tissue available for HA-selection and 
PD-L1 testing.  
Inclusion Criteria 
For both portions of the study (unless otherwise specified), subjects must satisfy all of the 
following inclusion criteria to be enrolled in the study: 
1. Written Institutional Review Board/Ethics Committee-approved Informed Consent form, 
signed by subject or legally authorized representative. 
2. Dose Escalation portion - Histologically confirmed and documented, previously treated 
stage IIIB or IV NSCLC having failed at least 1 previous platinum-based chemotherapy 
regimen for locally advanced or metastatic disease, or relapsed/refractory locally 
advanced or metastatic gastric adenocarcinoma having failed at least 1 previous 
chemotherapy regimen for locally advanced or metastatic disease. Subjects with NSCLC 
who are known to be epidermal growth factor receptor (EGFR)-mutation positive must 
have received an EGFR inhibitor and subjects known to be anaplastic lymphoma kinase 
(ALK)-mutation positive must have received an ALK inhibitor (subject’s documented 
EGFR/ALK mutation status and/or confirmation reports/molecular pathology/analysis 
reports should be included in the subject’s medical records and made available for 
Sponsor/Sponsor representative[s] review).  
a. Subjects with gastroesophageal junction (GEJ) tumors are eligible. 
b. For subjects with either NSCLC or gastric cancer, prior treatment administered in the 
adjuvant setting is permitted provided it was administered at least 6 months prior to 
first-line therapy for metastatic disease. 
c. For subjects with NSCLC, prior first-line treatment with bevacizumab (AVASTIN®) 
or biosimilars is allowed. 
d. For subjects with NSCLC, prior maintenance treatment with bevacizumab, 
pemetrexed (ALIMTA®), or erlotinib (TARCEVA®) is allowed.  


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 11 of 112 
06 November 2017  
e. For subjects with human epidermal growth factor receptor 2 positive (HER2+) gastric 
cancer, prior treatment with trastuzumab (HERCEPTIN®) is required (subject’s 
documented HER2 status and/or confirmation reports/molecular pathology/analysis 
reports should be included in the subject’s medical records and made available for 
Sponsor/Sponsor representative[s] review). 
3. Dose Expansion portion - NSCLC subjects: Histologically confirmed and documented, 
previously untreated or treated stage IIIB or IV NSCLC. Previously treated subjects must 
have failed no more than 1 previous platinum-based chemotherapy regimen for locally 
advanced or metastatic disease. Previously treated subjects with NSCLC who are known 
to be EGFR-mutation positive must have received an EGFR inhibitor and subjects who 
are known to be ALK-mutation positive must have received an ALK inhibitor (subject’s 
documented EGFR/ALK mutation status and/or confirmation reports/molecular 
pathology/analysis reports should be included in the subject’s medical records and made 
available for Sponsor/Sponsor representative[s] review). Gastric adenocarcinoma 
subjects: histologically confirmed and documented previously treated relapsed/refractory 
locally advanced or metastatic gastric adenocarcinoma having failed no more than 2 
previous chemotherapy regimens for locally advanced or metastatic disease. 
a. Subjects with GEJ tumors are eligible. 
b. For subjects with either NSCLC or gastric cancer, prior treatment administered in the 
adjuvant setting is permitted provided it was administered at least 6 months prior to 
first-line therapy for metastatic disease. 
c. For previously treated subjects with NSCLC, prior treatment with or without 
bevacizumab (AVASTIN®) or bevacizumab biosimilars is allowed. 
d. For previously treated subjects with NSCLC, prior maintenance treatment with 
bevacizumab, pemetrexed (ALIMTA®), or erlotinib (TARCEVA®) is allowed. 
e. For subjects with HER2+ gastric cancer, prior treatment with trastuzumab 
(HERCEPTIN®) is required (subject’s documented HER2 status and/or confirmation 
reports/molecular pathology/analysis reports should be included in the subject’s 
medical records and made available for Sponsor/Sponsor representative[s] review). 
4. Prior to enrollment, confirmation of the following must be obtained: 
a. Dose Escalation portion - Available tumor tissue in a formalin-fixed 
paraffin-embedded (FFPE) block or 5-10 unstained consecutive core biopsy slides 
from 1 tumor tissue block that meet specific tissue sample requirements are preferred 
but not mandatory for enrollment in this portion of the study. Note: Fine needle 
aspirates or brushing biopsies will not be acceptable. 
b. Dose Expansion portion - Available tumor tissue in FFPE block or 10-15 unstained 
consecutive tumor tissue slides from 1 tumor tissue block that meet specific tissue 
sample requirements are mandatory. Note: Fine needle aspirates or brushing biopsies 
will not be acceptable. Archived resection specimens from the primary tumor without 
radiologic evidence of metastasis at the time of resection are not suitable to establish 
histological confirmation and require new tumor tissue of a metastatic site. 
5. To be eligible for the Dose Escalation portion, subjects need only have evaluable disease 
(details in Section 8.2.15); to be eligible for the Dose Expansion portion, subjects must 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 12 of 112 
06 November 2017  
have measurable disease per RECIST v1.1. Previously irradiated tumors may be eligible 
if they have clearly progressed in size. 
6. ECOG Performance Status of 0 or 1. 
7. Life expectancy ≥3 months. 
8. Males and females aged ≥18 years. 
9. Resolution of all acute toxic effects of prior therapy or surgery to baseline. 
10. Screening clinical laboratory values are as follows: 
a. Total and indirect bilirubin ≤1.5 × upper limit of normal (ULN), except for Gilbert’s 
syndrome 
b. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase (ALP) ≤2.5 × ULN (<5 × ULN is allowed if liver metastases are present) 
c. Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥40 mL/min 
d. Serum albumin ≥3.0 g/dL 
e. Hemoglobin ≥10 g/dL (transfusion and erythropoietic agents allowed) 
f. Absolute neutrophil count ≥1500 cells/mm3 
g. Platelet count ≥100,000/mm3 
11. Female participants of childbearing potential (WOCBP) must have a negative urine or 
serum pregnancy test within 7 days before Day 1 (first dose of study medication). 
12. For WOCBP and for men, agreement to use an effective contraceptive method from the 
time of screening throughout the study until 4 months (WOCBP) or 3 months (men) after 
administration of the last dose of any study medication. Highly effective contraceptive 
methods consist of prior sterilization, intrauterine device (IUD), intrauterine hormone 
releasing system (IUS), oral or injectable contraceptives, and/or barrier methods. 
Abstinence alone is not considered an adequate contraceptive measure for the purposes of 
this study. 
13. Subjects must also satisfy the following inclusion criterion to be enrolled in the Dose 
Expansion portion of the study: 
a. Subjects (NSCLC and gastric adenocarcinoma) must be determined to have HA-high 
levels from their tumor biopsies. Tumor samples must meet the requirements noted in 
the Inclusion Criterion #4. 
b. NSCLC and gastric adenocarcinoma subjects must have tissue available for  
HA-selection and PD-L1 testing. Tumor samples must meet the requirements noted in 
the Inclusion Criterion #4.  
Exclusion Criteria 
Subjects are ineligible for enrollment if they meet any of the following exclusion criteria.  
1. Previous treatment with pembrolizumab, nivolumab, or other programmed cell death-1 
antibody (anti- PD-1) or PD-1 ligand 1 antibody (anti-PD-L1) agents. 
2. New York Heart Association Class III or IV (Appendix D) cardiac disease or myocardial 
infarction within the past 12 months before screening, or preexisting atrial fibrillation. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 13 of 112 
06 November 2017  
3. History of cerebrovascular accident or transient ischemic attack. 
4. NSCLC subjects with known brain metastases (exception below). 
a. Subjects with treated brain metastases who meet all of the following criteria are 
eligible: 
i.   Stable brain metastases for at least 1 month,  
ii.  No evidence of progression or hemorrhage after treatment, 
iii. No ongoing requirement for corticosteroids. 
5. Gastric adenocarcinoma subjects with brain metastases. 
6. History of active bleeding within the last 3 months requiring transfusion.  
7. Anti-angiogenic therapy within the last month. 
8. Known interstitial fibrosis or interstitial lung disease. 
9. History of pulmonary embolism or pulmonary embolism found on screening exam. 
10. Pre-existing carotid artery disease. 
11. History of DVT with contraindications to pharmacologic anticoagulation. 
12. History of: 
a. Pneumonitis that requires oral or IV steroids; 
b. Or known cases of hepatobiliary diseases (e.g., primary biliary cholangitis, primary 
sclerosing cholangitis, history of immune-mediated cholangitis); 
i.   Subjects with cholangitis attributed to infectious etiology (e.g., ascending 
cholangitis, bacterial cholangitis) are eligible if the infection has been fully 
resolved prior to the screening visit.  
c. Or known cases of drug-induced hepatobiliary toxicities. 
13. NSCLC subjects with hypersensitivity to aspirin. 
14. Gastric adenocarcinoma subjects with contraindications to enoxaparin. 
15. Autoimmune diseases: 
a. Active autoimmune disease requiring systemic treatment within the past 3 months 
b. Documented history of clinically severe autoimmune disease (e.g., colitis, Crohn’s 
disease)* 
16. Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. 
17. Known infection with human immunodeficiency virus, active infection with hepatitis B, 
or hepatitis C. 
18. Known allergy to hyaluronidase. 
19. Hypersensitivity to the active substance or ingredients of PEGPH20 and pembrolizumab. 
20. Known allergy to piroxicam or other NSAIDs. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 14 of 112 
06 November 2017  
21. Current use of megestrol acetate (within 10 days of Day 1). 
22. Chronic use of steroids for pain or emesis management. 
23. Women currently pregnant or breastfeeding. 
24. History of another primary cancer within the last 3 years that required treatment, with the 
exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated 
cervical carcinoma in situ. 
25. Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that lead to reasonable suspicion of a disease or condition that 
contraindicates the use of an investigational drug, may affect the interpretation of the 
results, or may render the subject at high risk for treatment complications. 
26. Subject inability to comply with study and follow-up procedures, as judged by the 
Investigator.  
*Any relevant diseases that are not listed as examples of exclusionary diseases are to be 
discussed with the Sponsor. 
Study Medication 
For this study, study medication will include PEGPH20 and pembrolizumab.  
PEGPH20: PEGPH20 drug product is supplied as an aqueous solution containing 0.3 mg/mL 
PEGPH20 with 10 mM succinic acid, 130 mM NaCl and 10 mM methionine at pH 6.2. Each vial 
contains 1.2 mL (0.36 mg) of PEGPH20 drug product. PEGPH20 drug product is provided as a 
refrigerated formulation and should be stored at 2°C to 8°C before use. 
PEGPH20 mixing instructions will be provided to sites in the pharmacy manual. PEGPH20 will be 
administered on Day 1, Day 8 and Day 15 of each 21-day cycle as an intravenous (IV) infusion over 10 
minutes, approximately 1 mL/minute (a window of +2 minutes is allowed, i.e., infusion can be 10 to 
12 minutes). The dose for the escalation portion will depend on the escalation process. The PEGPH20 
dose for the expansion portion will be the MTD established in the escalation portion or a dose lower 
than the MTD and which has completed evaluation in Dose Escalation and found to be safe and 
tolerable. 
Pembrolizumab: In Dose Escalation, pembrolizumab 2 mg/kg will be administered as an IV infusion over 
30 minutes every 21 days on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 
administration (Keytruda® US Prescribing Information 2015). In Dose Expansion, 200 mg of 
pembrolizumab will be administered as an IV infusion over 30 minutes every 21 days on Day 1 of each 
cycle, 4-6 hours after the completion of PEGPH20 administration (see Section 4.6.4 for additional 
details). 
Refer to pembrolizumab Prescribing Information for a description of the drug (Keytruda® US 
Prescribing Information 2017). 
Study Duration 
The study will consist of an optional prescreening period for HA-testing in Dose Expansion (per 
Protocol Amendment 3), a screening period of up to 28 days, a treatment period (21-day cycles), 
a 30-day post-treatment period (after last dose) for collection of AEs and long-term follow-up. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 15 of 112 
06 November 2017  
Subjects will be allowed to continue treatment on study until unacceptable toxicity or disease 
progression. Subjects with asymptomatic disease progression however, will be allowed to 
continue the study treatment at the Investigator’s discretion despite evidence of increasing tumor 
burden or appearance of new lesions for up to 6 weeks if the subject is clinically stable. 
Clinically stable is defined as: 
• Absence of symptoms and signs indicating clinically significant PD (including 
worsening of laboratory values) indicating disease progression; 
• No decline in ECOG performance status; and 
• Absence of rapid progression of disease or of progressive tumor at critical anatomical 
sites (e.g., cord compression) requiring urgent alternative medical intervention. 
Disease progression will be defined by the presence of 1 or both of the following, based on the 
Investigator’s assessment: 
• 
Disease progression documented by CT scan/MRI scan based on RECIST v1.1. 
• 
Clinical tumor-related progression that is well documented in the absence of radiological scans 
demonstrating disease progression. 
Investigators may also discontinue study treatment if it is no longer in the best interest of the 
subject. 
Subjects who discontinue treatment with PEGPH20 and pembrolizumab will be followed every 
12 weeks for survival until death, withdrawal of consent, or lost to follow-up. 
Criteria for Evaluation 
Study Endpoints 
Dose Escalation 
Primary: 
• Dose-limiting toxicity, MTD, and RP2D. 
Secondary: 
• PK parameters of PEGPH20: maximum observed concentration (Cmax), minimum 
observed concentration (Cmin), terminal elimination half-life (T1/2), area-under-
the-concentration time curve (AUC), volume of distribution (VD) and clearance (CL). 
• ORR, DOR, DCR, and PFS based on RECIST v1.1. 
• OS. 
Exploratory: 
• PK parameters of pembrolizumab: Cmax, Cmin, T1/2, AUC, VD and CL. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 16 of 112 
06 November 2017  
Dose Expansion 
Primary: 
• ORR based on RECIST v1.1  
Secondary:  
• DOR, DCR and PFS based on RECIST v1.1, and OS 
• ORR, DOR, DCR, and PFS based on irRC 
• PK parameters of PEGPH20: Cmax, Cmin, T1/2, AUC, VD and CL. 
• Incidence of AEs 
• Changes in clinical safety laboratory values 
• Changes in cardiovascular parameters (electrocardiogram [ECG]) and vital signs 
Exploratory: 
• ORR, DOR, DCR, and PFS based on RECIST v1.1 criteria and irRC by PD-L1 
expression levels. 
• Changes from pre-treatment in plasma HA and tumor HA (when available). 
• Correlation between plasma HA levels pre-dose, post-dose and any pharmacodynamic 
response. 
• Changes in tumor blood flow as measured by DCE-MRI. 
• Changes in tumor metabolism as measured by PET/CT. 
• Correlation of biomarkers in plasma and tumor biopsy to study endpoints. 
• PK parameters of pembrolizumab: Cmax, Cmin, T1/2, AUC, VD and CL. 
Safety Assessments 
The safety and tolerability of PEGPEM will be assessed by evaluation of serious and non-serious AEs, 
clinical monitoring, concomitant medications, dose modification / interruption / discontinuation of study 
treatment, clinical laboratory tests (hematology, blood chemistry thyroid function tests), blood glucose 
(either as part of chemistry or single assessment), 12-lead ECGs, vital sign measurements, and PEGPH20 
anti-drug antibodies, as specified in the Study Schedule of Events. 
Efficacy Assessments 
Subjects will be evaluated for efficacy endpoints ORR, DOR, DCR and PFS per both RECIST v 1.1 and irRC 
criteria that are based on radiological assessments of the disease; see the Study Schedule of Events. 
Subjects may be evaluated for efficacy endpoints ORR, DOR, DCR and PFS based on RECIST v1.1 criteria 
and irRC, by PD-L1 expression levels.  


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 17 of 112 
06 November 2017  
Pharmacokinetic Assessments 
Plasma PEGPH20 and serum pembrolizumab concentrations will be measured as specified in the Study 
Schedule of Events. 
Biomarker and Pharmacodynamic Assessments 
The treatment effect of PEGPEM will be evaluated based on pre- and post-treatment measurement of 
HA in plasma and tumor as well as change in potential biomarkers of pembrolizumab and/or PEGPH20 
activity in plasma and tumor biopsies, blood flow as measured by DCE-MRI, and tumor metabolism as 
measured by PET/CT. 
Statistical Methods 
Planned Total Sample Size 
In the dose escalating portion, there may be up to 5 dose levels for a total of approximately 
30 subjects. 
In the Dose Expansion portion, approximately 51 subjects will be enrolled (approximately 30 with HA-high 
tumors in NSCLC cohort and approximately 21 with HA-high tumors in the gastric adenocarcinoma 
cohort). 
KEYNOTE-001 study data presented at the American Society of Clinical Oncology 2016 (Hui 2016) showed 
that when treated with pembrolizumab alone, treatment naïve subjects who had evaluable PD-L1 Tumor 
Proportion Score [TPS] levels had an ORR of 29% and previously treated subjects who had evaluable PD-L1 
TPS levels had an ORR of 21%. Under the assumption that no more than 40% of the subjects enrolled in 
this study will be treatment naïve, ORR in the combined NSCLC population is expected to be 
approximately 24% when treated with pembrolizumab alone. A 20% improvement in ORR is considered 
clinically meaningful when PEGPH20 is added to pembrolizumab. Under these conditions, 30 NSCLC 
subjects would provide approximately 80% power at the hypothesized ORR of 44% when the null 
hypothesis H0: ORR ≤24% is tested against H1: ORR >24% using an exact one-sided binomial test at a 10% 
significance level. 
KEYNOTE-012 study data showed that the ORR in PD-L1 positive gastric cancer subjects is about 22% 
(Muro 2016). Since subjects will not be selected based on PD-L1 expression levels prospectively in this 
study, in order to accommodate all subjects (irrespective of PD-L1 expression levels), a conservative ORR 
of 15% is assumed with pembrolizumab treatment alone and it is further assumed that the addition of 
PEGPH20 to pembrolizumab will lead to a clinically meaningful improvement of 20% in ORR to 35%. 
Under these assumptions, 21 subjects will provide approximately 80% power at the hypothesized ORR of 
35% when the null hypothesis H0: ORR ≤15% tested against H1: ORR >15% using an exact one sided 
binomial test at a 10% significance level. 
Analysis Populations 
Safety Population: All subjects who receive any study medication. The Safety Population will be used for 
subject disposition, demographics and safety analyses. 
DLT Evaluable Population: All subjects who receive at least 1 of the 3 full planned doses of PEGPH20 and 
1 complete dose of pembrolizumab in Cycle 1 and have been followed for the first 21 days of treatment 
or have experienced a DLT during the initial 21 days (Cycle 1) of the study. The DLT Evaluable Population 
will be used for DLT analysis. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 18 of 112 
06 November 2017  
PK Analysis Population: All subjects who receive any PEGPH20 and have measurable PEGPH20 
concentrations in at least 1 sample collected for PK analysis. PK Analysis Population will be used for PK 
analysis. 
Efficacy Evaluable Population: All HA-high subjects who receive at least 1 dose of the RP2D of PEGPH20 
and at least 1 dose of pembrolizumab. The efficacy evaluable population will be used for all efficacy 
analyses. 
Tumor Response Evaluable Population: Subjects in the Efficacy Evaluable Population who have at least 
one post-baseline tumor assessment. Tumor Response Evaluable Population will also be used for overall 
tumor response analysis. 
Analyses 
Analysis of Demographics and Baseline Characteristics 
Demographics and baseline characteristics will be summarized using safety population by dose level for 
subjects in the Dose Escalation portion and separately for all subjects in the Dose Expansion portion. The 
following demographic and baseline characteristics will be summarized: age, race, height, weight, 
medical history, disease characteristics, and treatment history. 
Efficacy Analyses 
All efficacy analyses will be conducted using the Efficacy Evaluable Population. ORR and DOR will also be 
analyzed using Tumor Response Evaluable population. 
The primary efficacy endpoint of the study is PEGPEM treatment effect on ORR based on RECIST v1.1. 
The statistical hypothesis tests for the primary endpoint are as follows: 
• 
NSCLC cohort: H0: ORR ≤23%; H1: ORR >23% 
• 
Gastric adenocarcinoma cohort: H0: ORR ≤15%; H1: ORR >15% 
The hypothesis tests will be conducted using the one-sided exact binomial test at the significance 
level of 0.1. 
ORR will be calculated as the number of subjects with a confirmed CR or PR divided by the number of 
subjects in the analysis population multiplied by 100. The exact 80% confidence interval of ORR will also 
be constructed. DCR and its exact 80% CI will be calculated. Median DOR, PFS and OS and their 
corresponding 80% confidence intervals will be estimated using the Kaplan-Meier method. 
Safety Analyses 
All safety parameters will be summarized using the Safety Population. 
All AEs will be presented in incidence tables coded by the Medical Dictionary for Regulatory Activities 
(MedDRA) Preferred Term and System Organ Class. Additionally, separate AE incidence tables, coded by 
MedDRA term, will be presented by: 1) toxicity grade (severity) graded by the CTCAE and 2) relationship 
to study medication (PEGPH20 and pembrolizumab). 
All AEs, serious adverse events, AEs leading to treatment discontinuation, and deaths occurring during 
the study will be summarized. 
Laboratory parameters and vital signs and the corresponding change from baseline over time will be 
summarized using descriptive statistics. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 19 of 112 
06 November 2017  
Pharmacokinetic and Pharmacodynamic Analyses 
For PEGPH20 noncompartmental and compartmental PK modeling will be performed. The AUC, the Cmax 
and T1/2 will be summarized from noncompartmental analysis along with descriptive statistics. Other PK 
analyses may be performed and population PK parameters including T1/2, VD, and CL will be evaluated 
and reported if the data are sufficient. For plasma HA, descriptive statistics will be used to summarize 
the measured plasma concentrations. 
Exploratory Analyses 
Descriptive summaries will be provided for all exploratory endpoint analyses. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 20 of 112 
06 November 2017  
2. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES 
TABLE OF CONTENTS 
1. 
SYNOPSIS ...................................................................................................................3 
2. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............20 
3. 
STUDY SCHEDULES OF EVENTS ........................................................................26 
4. 
BACKGROUND AND RATIONALE .......................................................................35 
4.1. 
Non-Small Cell Lung Cancer .....................................................................................35 
4.2. 
Gastric adenocarcinoma ..............................................................................................35 
4.3. 
Hyaluronan and Malignancy .......................................................................................36 
4.4. 
PEGylated Recombinant Human Hyaluronidase PH20 .............................................36 
4.4.1. 
PEGPH20 and Chemotherapy ....................................................................................36 
4.5. 
Clinical Experience with PEGPH20 and Clinical Development Plan ........................37 
4.5.1. 
Phase 1 Study HALO-109-101 ...................................................................................37 
4.5.2. 
Phase 1 Study HALO-109-102 ...................................................................................37 
4.5.3. 
Phase 1b Study HALO-109-201 .................................................................................38 
4.5.4. 
Phase 2 Study HALO-109-202 ...................................................................................38 
4.5.5. 
Phase 1b Study HALO-107-201 .................................................................................38 
4.5.6. 
Phase 3 Study HALO-109-301 ...................................................................................39 
4.5.7. 
Safety ..........................................................................................................................39 
4.5.7.1. 
Musculoskeletal Events ..............................................................................................39 
4.5.7.2. 
Thromboembolic Events .............................................................................................40 
4.5.8. 
Efficacy .......................................................................................................................41 
4.5.9. 
Clinical Pharmacokinetics ..........................................................................................42 
4.6. 
Study Rationale ...........................................................................................................42 
4.6.1. 
Pembrolizumab for Treatment of NSCLC ..................................................................42 
4.6.2. 
Pembrolizumab for Treatment of Gastric Adenocarcinoma .......................................43 
4.6.3. 
Use of PEGPH20 in HA-high Tumors .......................................................................44 
4.6.4. 
Rationale for Dose Selection ......................................................................................45 
5. 
STUDY OBJECTIVES AND ENDPOINTS ..............................................................46 
5.1. 
Study Objectives .........................................................................................................46 
5.1.1. 
Dose Escalation ..........................................................................................................46 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 21 of 112 
06 November 2017  
5.1.2. 
Dose Expansion ..........................................................................................................46 
5.2. 
Study Endpoints ..........................................................................................................47 
5.2.1. 
Dose Escalation ..........................................................................................................47 
5.2.2. 
Dose Expansion ..........................................................................................................47 
6. 
INVESTIGATIONAL PLAN .....................................................................................48 
6.1. 
Overall Study Design and Plan: Description ..............................................................48 
6.1.1. 
Phase 1b Dose Escalation ...........................................................................................52 
6.1.2. 
Phase 1b Dose Expansion ...........................................................................................54 
6.1.3. 
Study Duration ............................................................................................................54 
6.1.4. 
Disease Progression ....................................................................................................55 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS AND STUDY 
TERMINATION .........................................................................................................55 
7.1. 
Inclusion Criteria ........................................................................................................55 
7.2. 
Exclusion Criteria .......................................................................................................58 
7.3. 
Subject Withdrawal Criteria .......................................................................................59 
7.3.1. 
Discontinuation of Treatment .....................................................................................59 
7.3.2. 
Discontinuation from Study ........................................................................................60 
7.4. 
Sponsor Study Stopping Rules ...................................................................................60 
8. 
STUDY PROCEDURES AND ASSESSMENTS......................................................61 
8.1. 
Study Procedures by Visit ..........................................................................................61 
8.1.1. 
Screening ....................................................................................................................61 
8.1.1.1. 
Within 28 Days Prior to Day 1 (Unless Otherwise Indicated) ...................................61 
8.1.2. 
Treatment Period ........................................................................................................62 
8.1.2.1. 
Treatment Cycle 1 .......................................................................................................62 
8.1.2.2. 
Treatment Cycle 2 and Beyond (Repeats Every 3 weeks) .........................................65 
8.1.2.3. 
End of Treatment Visit ...............................................................................................68 
8.1.2.4. 
Long-Term Follow-Up ...............................................................................................68 
8.1.3. 
Procedures for Study Treatment Discontinuation .......................................................68 
8.2. 
Study Assessments......................................................................................................68 
8.2.1. 
Informed Consent .......................................................................................................68 
8.2.1.1. 
Prescreening Informed Consent in Dose Expansion ..................................................69 
8.2.2. 
Inclusion/Exclusion Criteria .......................................................................................69 
8.2.3. 
Medical History ..........................................................................................................69 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 22 of 112 
06 November 2017  
8.2.4. 
Concomitant Medications ...........................................................................................69 
8.2.5. 
Adverse Events ...........................................................................................................69 
8.2.6. 
Physical Examination .................................................................................................69 
8.2.7. 
Height and Weight ......................................................................................................69 
8.2.8. 
ECOG Performance Status .........................................................................................69 
8.2.9. 
Vital Signs ..................................................................................................................69 
8.2.10. 
12-lead ECG ...............................................................................................................70 
8.2.11. 
Hematology, Blood Chemistry, Glucose, Thyroid Hormones, Coagulation 
Parameters, and Urinalysis .........................................................................................70 
8.2.12. 
Pregnancy Test ............................................................................................................70 
8.2.13. 
Contraception ..............................................................................................................71 
8.2.14. 
Immunogenicity ..........................................................................................................71 
8.2.15. 
Imaging/Radiologic Evaluation ..................................................................................71 
8.2.16. 
Pharmacokinetic Assessments ....................................................................................72 
8.2.17. 
Biomarker Assessments ..............................................................................................73 
8.3. 
Study Drug Administration.........................................................................................74 
8.3.1. 
PEGPH20 ....................................................................................................................75 
8.3.1.1. 
PEGPH20 Administration ..........................................................................................75 
8.3.1.2. 
Hypersensitivity to PEGPH20 ....................................................................................75 
8.3.1.3. 
PEGPH20 Dose Modification Guidelines ..................................................................75 
8.3.2. 
Pembrolizumab ...........................................................................................................77 
8.3.2.1. 
Pembrolizumab Administration ..................................................................................77 
8.3.2.2. 
Identified Risks of Pembrolizumab Treatment ...........................................................78 
8.3.2.3. 
Pembrolizumab Dose Adjustment and Toxicity Management ...................................78 
8.4. 
Excluded Concomitant Medications and Study Restrictions ......................................78 
8.5. 
Treatment Compliance ................................................................................................78 
8.6. 
Randomization and Blinding ......................................................................................78 
9. 
STUDY DRUG AND MATERIALS .........................................................................79 
9.1. 
Study Drug Description ..............................................................................................79 
9.1.1. 
PEGPH20 ....................................................................................................................79 
9.1.2. 
Pembrolizumab ...........................................................................................................79 
9.2. 
Study Drug Packaging and Labeling ..........................................................................80 
9.2.1. 
PEGPH20 ....................................................................................................................80 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 23 of 112 
06 November 2017  
9.2.2. 
Pembrolizumab ...........................................................................................................80 
9.3. 
Study Drug Storage .....................................................................................................80 
9.3.1. 
PEGPH20 ....................................................................................................................80 
9.3.2. 
Pembrolizumab ...........................................................................................................80 
9.4. 
Study Drug Preparation ..............................................................................................81 
9.4.1. 
PEGPH20 ....................................................................................................................81 
9.4.2. 
Pembrolizumab ...........................................................................................................81 
9.5. 
Study Drug Accountability .........................................................................................81 
10. 
SAFETY ASSESSMENTS ........................................................................................81 
10.1. 
Management of Thromboembolic Events ..................................................................81 
10.2. 
Adverse Event Definitions ..........................................................................................82 
10.3. 
Reporting Serious Adverse Events .............................................................................83 
10.4. 
Reporting Adverse Events of Special Interest ............................................................83 
10.4.1. 
Thromboembolic Events .............................................................................................83 
10.4.2. 
Disease-Related Events That Are Endpoints ..............................................................85 
10.5. 
Adverse Events ...........................................................................................................85 
10.5.1. 
Classification of Adverse Events by Severity ............................................................86 
10.5.2. 
Classification of Adverse Events by Relationship to Study Drug ..............................87 
10.6. 
Abnormal Laboratory Results .....................................................................................87 
10.7. 
Pregnancy ...................................................................................................................88 
10.8. 
Overdose .....................................................................................................................88 
10.9. 
Data Monitoring Committee .......................................................................................89 
10.10. 
Unblinding ..................................................................................................................89 
10.11. 
Reporting Safety Information to the Regulatory Authorities and to the 
Institutional Review Board .........................................................................................89 
10.12. 
Concomitant Medications ...........................................................................................89 
10.12.1. 
Piroxicam and Toradol ...............................................................................................90 
10.12.2. 
Enoxaparin ..................................................................................................................90 
10.12.3. 
Aspirin ........................................................................................................................91 
10.12.4. 
Dexamethasone ...........................................................................................................91 
11. 
STATISTICS ..............................................................................................................91 
11.1. 
Statistical Methods ......................................................................................................91 
11.1.1. 
Randomization and Blinding ......................................................................................91 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 24 of 112 
06 November 2017  
11.1.2. 
Sample Size ................................................................................................................91 
11.1.3. 
Analysis Populations ..................................................................................................92 
11.1.3.1. 
Safety Population ........................................................................................................92 
11.1.3.2. 
DLT Evaluable Population .........................................................................................92 
11.1.3.3. 
PK Analysis Population ..............................................................................................92 
11.1.3.4. 
Efficacy Evaluable Population ...................................................................................92 
11.1.3.5. 
Tumor Response Evaluable Population ......................................................................92 
11.1.4. 
Subject Disposition .....................................................................................................92 
11.1.5. 
Analysis of Demographics and Baseline Characteristics ...........................................93 
11.1.6. 
Efficacy Analyses .......................................................................................................93 
11.1.6.1. 
Analyses of the Primary ORR Efficacy Endpoint ......................................................93 
11.1.6.2. 
Analyses of Secondary Efficacy Endpoints ................................................................93 
11.1.7. 
Analysis of Treatment Exposure ................................................................................94 
11.1.7.1. 
Pharmacokinetic Analyses ..........................................................................................94 
11.1.7.2. 
Plasma Hyaluronan .....................................................................................................94 
11.1.7.3. 
Exploratory Analyses ..................................................................................................94 
11.1.8. 
Safety Analyses ..........................................................................................................94 
11.1.9. 
Interim Analysis ..........................................................................................................95 
12. 
SPONSOR AND INVESTIGATOR RESPONSIBILITIES ......................................95 
12.1. 
Protocol Compliance ..................................................................................................95 
12.1.1. 
Protocol Waivers ........................................................................................................95 
12.1.2. 
Protocol Deviations ....................................................................................................95 
12.2. 
Study Monitoring ........................................................................................................95 
12.3. 
Data Collection and Electronic Case Report Forms ...................................................96 
12.4. 
Financial Disclosure ...................................................................................................96 
12.5. 
Investigator’s Final Report .........................................................................................96 
12.6. 
Data Disclosure and Publication .................................................................................96 
13. 
QUALITY CONTROL AND QUALITY ASSURANCE .........................................97 
14. 
ETHICS ......................................................................................................................97 
14.1. 
Institutional Review Board and Approval ..................................................................97 
14.2. 
Written Informed Consent ..........................................................................................98 
15. 
DATA HANDLING AND RECORD KEEPING ......................................................99 
15.1. 
Record Inspection .......................................................................................................99 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 25 of 112 
06 November 2017  
15.2. 
Study Documentation and Record Retention .............................................................99 
16. 
REFERENCES .........................................................................................................100 
17. 
APPENDICES ..........................................................................................................105 
APPENDIX A. ABBREVIATIONS .........................................................................................105 
APPENDIX B. EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCES STATUS ..................................................................................109 
APPENDIX C. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
(RECIST 1.1) ............................................................................................................110 
APPENDIX D. NEW YORK HEART ASSOCIATION CLASSIFICATIONS ......................111 
APPENDIX E. IMMUNE-RESPONSE RELATED CRITERIA .............................................112 
 
LIST OF TABLES 
Table 1: 
Study Schedule of Events: Screening (Dose Escalation and Expansion) ...................26 
Table 2: 
Study Schedule of Events: PEGPH20 Plus Pembrolizumab Treatment 
(Cycles 1 and Beyond) ................................................................................................28 
Table 3: 
Study Schedule of Events: Immunogenicity, Pharmacokinetic, Plasma HA, 
and Exploratory Biomarker Sample Collection ..........................................................33 
Table 4: 
Dose Allocation and Cohort Schedule - Dose Escalation Portion ..............................53 
Table 5: 
Study Medication Dosing and Treatment Schedule - Dose Escalation and 
Dose Expansion ..........................................................................................................54 
Table 6: 
PEGPH20 Dose Adjustment and Toxicity Management Guidelines .........................76 
Table 7: 
CTCAE Version 4.03 Grading for Thromboembolic Events .....................................84 
 
LIST OF FIGURES 
Figure 1: 
Study Design - Phase 1b Dose Escalation and Dose Expansion (HALO-107-
101) .............................................................................................................................51 
Figure 2: 
Structure of PEGPH20 ................................................................................................79 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 26 of 112 
06 November 2017  
3. 
STUDY SCHEDULES OF EVENTS 
Table 1: 
Study Schedule of Events: Screening (Dose Escalation and Expansion) 
Tests and Assessments 
Screening  
≤28 Days Prior to Day 1 
Sign and Date Informed Consent (Subject may provide consent for HA testing of tumor tissue on a separate, 
prescreening ICF in Dose Expansion [details in Section 8.2.1.1])a 
X 
Study Procedure-Associated SAE Recording 
X 
Inclusion/ Exclusion Criteria 
X 
Medical History 
X 
Prior Medication History 
X 
Confirm and Retrieve Tumor Tissueb 
X 
Disease Assessment (CT scan/MRI scan of chest, abdomen, pelvis, and other areas of known or newly suspected 
disease)c 
X 
CT/MRI Brain scan to assess potential CNS disease and/or metastases 
X 
PET/CTd 
X 
DCE-MRId 
X 
12-Lead ECG 
X 
Subject Registration into Interactive Web Response System following signing of ICF/prescreening ICF (if used in 
Dose Expansion) 
X 
Physical Examinationc 
X 
Vital Signsc 
X 
ECOG Performance Status 
X 
Heightc 
X 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 27 of 112 
06 November 2017  
Table 1: 
Study Schedule of Events: Screening (Dose Escalation and Expansion) (Continued) 
Tests and Assessments 
Screening  
≤28 Days Prior to Day 1 
Weightc 
X 
Urine/Serum Pregnancy Tests (WOCBP) (Local Laboratory)e 
X 
Central Laboratory Assessments 
 
Plasma HA Level and Exploratory Biomarkers  
X 
Hematology, Chemistry (Including Glucose), Urinalysis 
X 
Thyroid Function Testsf 
X 
Coagulation Tests 
X 
Abbreviations: CT = computed tomography; DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging; ECG = electrocardiogram; ECOG = Eastern 
Cooperative Oncology Group; HA = hyaluronan; PET = positron emission tomography; T3 = triiodothyronine; T4 = total thyroxine; TSH = thyroid stimulating 
hormone; WOCBP = women of childbearing potential; CNS = Central Nervous System; ICF = Informed Consent Form; SAE = Serious Adverse Event 
Note: Each treatment cycle is 21 days. Dose interruption and modifications are permitted. 
a The 28-day screening window will begin when the subject signs the study ICF (i.e., signature on the prescreening ICF does not initiate the screening window). 
b In Dose Escalation – Available tissue from the primary or a metastatic lesion is required. A formalin-fixed paraffin-embedded (FFPE) block or 5-10 unstained, 
consecutive core biopsy slides of 1 tumor tissue block (refer to Inclusion Criterion #4 for more details) are required to send to the central laboratory. Note: Fine 
needle aspirates or brushing biopsies will not be acceptable.  
 In Dose Expansion – Available tissue from the primary or a metastatic lesion is required. An FFPE block or 10-15 unstained, consecutive tumor tissue slides of 
1 tumor tissue block (refer to Inclusion Criterion #4 for more details) are required to send to the central laboratory. Note: Fine needle aspirates or brushing 
biopsies will not be acceptable. Archived resection specimens from the primary tumor without radiologic evidence of metastasis at the time of resection are not 
suitable to establish histological confirmation and require new tumor tissue of a metastatic site. Tumor tissue must be sent to central laboratory to assess HA 
status for eligibility into the Dose Expansion portion of the study. 
c If these procedures are performed as part of standard-of-care prior to the subject’s signing of the Informed Consent Form, the results may be used for screening 
purposes provided the procedures were performed within the screening window. 
d Optional procedure. PET/CT and DCE-MRI scans will be sent to the Central Imaging Vendor for analysis if they are conducted. DCE-MRI scans must be 
obtained within 14 days prior to Day 1 (first dose of study medication). 
e To be performed within 7 days prior to Day 1 (first dose of study medication). 
f   Blood samples will be collected for baseline testing of thyroid hormones (free T3, free T4; and TSH). 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 28 of 112 
06 November 2017  
Table 2: 
Study Schedule of Events: PEGPH20 Plus Pembrolizumab Treatment (Cycles 1 and Beyond) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 Weeks) 
Treatment Cycle 2 and 
Beyond (Repeats Every 
3 Weeks) 
28 Day 
Confirmatory CT 
Scan/MRI Scan 
End of 
Treatmentb 
Long-Term 
Follow-upc 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
1 
Wk 
2 
Wk 
3 
 
 
 
D1 
D2 
D8 
D15 
D18 
D1 
D2 
D8 
D15 
 
 
 
Confirm Eligibility 
Based on Inclusion/ 
Exclusion Criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
Physical Examination 
 
 
 
 
 
 
 
 
 
 
X 
 
Vital Signsd 
X 
 
X 
X 
 
X 
 
X 
X 
 
X 
 
ECOG Performance 
Status 
X 
 
 
 
 
X 
 
 
 
 
X 
 
Weight 
X 
 
 
 
 
X 
 
 
 
 
 
 
12-Lead ECGe 
 
 
 
 
 
 
 
 
 
 
Xe 
 
Disease Assessment – 
CT/MRI Scanf 
 
 
 
 
 
 
 
 
Xf 
 
Xg 
 
Response Confirmation 
Scan 
 
 
 
 
 
 
 
 
 
Xh 
 
 
CT/MRI Brain scani 
 
 
 
 
 
 
 
 
Xi 
 
 
 
PET/CT Scanj 
(Optional at Selected 
Sites) 
 
 
 
 
X 
 
 
 
X 
 
 
 
 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 29 of 112 
06 November 2017  
Table 2: 
Study Schedule of Events: PEGPH20 Plus Pembrolizumab Treatment (Cycles 1 and Beyond) (Continued) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 Weeks) 
Treatment Cycle 2 and 
Beyond (Repeats Every 
3 Weeks) 
28 Day 
Confirmatory CT 
Scan/MRI Scan 
End of 
Treatmentb 
Long-Term 
Follow-upc 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
1 
Wk 
2 
Wk 
3 
 
 
 
D1 
D2 
D8 
D15 
D18 
D1 
D2 
D8 
D15 
 
 
 
DCE-MRIk (Optional 
at Selected Sites) 
 
X 
 
 
X 
 
 
 
 
 
 
 
Urine/serum 
pregnancy test (local 
laboratory) before 
Dosing (WOCBP) 
 
 
 
 
 
X 
 
 
 
 
 
 
Central Laboratory Assessments 
Hematology 
X 
 
X 
X 
 
X 
 
X 
X 
 
X 
 
Blood Chemistry 
(Includes Glucose) 
Xl 
 
Xl 
Xl 
 
Xl 
 
 
 
 
X 
 
Blood Glucose 
 
 
 
 
 
 
 
X 
X 
 
 
 
Thyroid Function 
Testsm 
 
 
 
 
 
X 
 
 
 
 
 
 
Coagulation Tests 
X 
 
 
 
 
X 
 
 
 
 
X 
 
Immunogenicityn 
X 
 
 
 
 
X 
 
 
 
 
X 
 
PK, HA and Other 
Biomarker Analyses 
Refer to Table 3 for schedule of PK and biomarker sampling time points 
Optional Post-dose 
Tumor Biopsy 
 
 
 
 
Xo 
 
 
 
 
 
 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 30 of 112 
06 November 2017  
Table 2: 
Study Schedule of Events: PEGPH20 Plus Pembrolizumab Treatment (Cycles 1 and Beyond) (Continued) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 Weeks) 
Treatment Cycle 2 and 
Beyond (Repeats Every 
3 Weeks) 
28 Day 
Confirmatory CT 
Scan/MRI Scan 
End of 
Treatmentb 
Long-Term 
Follow-upc 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
1 
Wk 
2 
Wk 
3 
 
 
 
D1 
D2 
D8 
D15 
D18 
D1 
D2 
D8 
D15 
 
 
 
Piroxicam and Proton 
Pump Inhibitor 
Administrationp  
X 
 
X 
X 
 
X 
 
X 
X 
 
 
 
PEGPH20 
Administrationq 
X 
 
X 
X 
 
X 
 
X 
X 
 
 
 
Enteric-coated 
Aspirin 
Administration for 
NSCLC subjectsr 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
Enoxaparin 
Administration for 
Gastric 
adenocarcinoma 
subjectsr 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
Pembrolizumab 
Administration 
Xq 
 
 
 
 
Xq 
 
 
 
 
 
 
Concomitant 
Therapy/Procedure 
Recording 
X 
X 
X 
 
Adverse Event 
Recording 
X 
X 
X 
 
Long-Term Follow-
upc 
 
 
 
 
 
 
 
 
 
 
 
X 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; PEG = PEGylated Recombinant Human 
Hyaluronidase; CT = computed tomography; D = day; DLT = dose-limiting toxicity; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 31 of 112 
06 November 2017  
PET = positron emission tomography; DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging; DVT = deep vein thrombosis; HA = hyaluronan; 
PD = progressive disease; PEGPEM = PEGPH20 + pembrolizumab; PK = pharmacokinetics; T3 = triiodothyronine; T4 = total thyroxine; TSH = thyroid 
stimulating hormone; Wk = Week; NSCLC = non-small cell cancer. 
Note: Visit window is ±2 days of the specified times. 
a See Section 8.2 for details on individual assessments. 
b Subjects should return to the study site for an End of Treatment Visit within approximately 7 days after determination of PD or within 7 days after treatment 
discontinuation of PEGPH20 and pembrolizumab for other reasons. 
c After the End of Treatment Visit, subjects will enter long-term follow-up during which information on the subject’s survival and subsequent anti-cancer 
therapy will be obtained by the site every 12 weeks. Long term follow-up will continue until the subject dies, is lost to follow-up, or withdraws consent. 
d Vital signs will be done pre dose on Day 1, Day 8 and Day 15 of all cycles and End of Treatment Visit. On all other days, vital signs will be collected for 
clinically significant AEs. 
e 12-lead ECG will be done at end of treatment and on an as needed basis when clinically indicated.  
f Tumor assessment scans (CT/MRI of chest, abdomen, pelvis, and other areas of known or newly suspected disease) will be obtained and evaluated locally for 
response evaluation based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 criteria and irRC at the end of Cycle 2, Cycle 4 and then at the end 
of every fourth treatment cycle thereafter (i.e., Week 3 of Cycles 2, 4, 8, 12, 16 and beyond). Scans will also be sent to the Central Imaging Vendor (CIV) to be 
stored for possible central review at a later date, if needed. Scans may be obtained any time on or after Day 15 (of Cycles 2, 4, 8, 12, 16 and every fourth 
treatment cycle thereafter) to allow enough time for the scan to be reviewed locally prior to the subject’s next scheduled dosing visit. For subjects who are 
withdrawn from the study due to clinical disease progression, a CT/MRI scan should be requested as soon as possible after clinical progression is determined. 
g CT/MRI should only be done if radiologic progressive disease was not documented in the previous CT/MRI scan. 
h A confirmatory scan should be performed no sooner than 28 days after the initial scan that showed a response based on RECIST v1.1 (PR or CR) or irRC. A 
confirmatory scan should also be performed to confirm disease progression based on irRC no sooner than 28 days after the initial scan that showed progression. 
i CT/MRI of the brain will be performed for the duration of the study (i.e., post-baseline), if clinically indicated, and within a target of 1 week after a subject 
achieves a complete response (CR). For NSCLC subjects with a history of treated brain metastases, brain scans will be performed at tumor assessment time 
points. 
j Optional PET/CT will be performed at selected sites. The CIV will analyze PET/CT scans if they are conducted. 
k Optional DCE-MRI will be performed at selected sites. The CIV will analyze PET/CT and DCE-MRI scans if they are conducted. 
l On Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycle 2, measurements of total bilirubin, ALP, AST, and ALT (as part of blood chemistry) must be obtained 
prior to dosing (within 48 hours is acceptable). Local laboratories may be used for these measurements. Dosing can only take place if total bilirubin, ALP, AST 
and ALT values are within the ranges specified in the Inclusion Criteria. If a subject has any of these values outside the specified ranges on Day 1 of Cycle 2, the 
Investigator should discuss further dosing plans for the subject with the Sponsor. 
m Blood samples will be collected for testing of thyroid hormones (free T3, free T4, and TSH]) on Day 1 of Cycle 2 and every third cycle thereafter (i.e., Day 1 of 
Cycles 2, 5, 8, 11, 14, 17, 20, etc.). 
n Plasma samples for PEGPH20 immunogenicity will be drawn prior to PEGPH20 dosing on day 1 of every cycle and end of treatment. 
o Optional post-dose tumor biopsy should be done at the end of Cycle 1 (on or after Day 18) but prior to 1st PEGPH20 dose in Cycle 2. 
p Piroxicam (20 mg) will be administered at least 1-2 hours prior to PEGPH20 administration on the day of dosing (timing will be at the Investigator’s discretion 
based on the piroxicam manufacturer’s Prescribing Information and subject’s convenience), to minimize the severity of MSEs. Prophylactic use of a proton pump 
inhibitor is mandated for all subjects while receiving PEGPH20 (e.g. 20 mg omeprazole daily or over-the-counter [OTC] equivalent).  


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 32 of 112 
06 November 2017  
q  
PEGPH20 will be given in increasing doses (1.6, 2.2, 2.6, 3.0 and 4.0 µg/kg) in combination with 2 mg/kg pembrolizumab in the Dose Escalation portion of 
the study. If ≥2 subjects experience a DLT at the 1.6 µg/kg dose level, Cohort -1 will be opened and subjects will be dosed at 1.0 µg/kg. In the Dose Expansion 
portion of the study, PEGPH20 will be given at the RP2D identified in the Dose Escalation portion of the study with 200 mg pembrolizumab. 
r  
All NSCLC subjects will be given enteric-coated 81 mg of prophylactic aspirin/day and all gastric adenocarcinoma subjects will be given prophylactic 
enoxaparin 40 mg/day (pre-filled syringes of enoxaparin are allowed), for prophylaxis of TE events, given the high incidence seen in these tumor types. 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 33 of 112 
06 November 2017  
Table 3: 
Study Schedule of Events: Immunogenicity, Pharmacokinetic, Plasma HA, 
and Exploratory Biomarker Sample Collection 
Sampling 
Draw 
Number 
Time Point 
Screen 
Treatment 
Cycle 1 
(21 days) 
Treatment 
Cycles 2+ 
(Repeats Every 
21 days) 
End of 
Treatment 
Week 1 
Week 1 
D1 
D2 
D1 
D2 
 
Plasma Hyaluronan 
Exploratory 
Biomarkers 
HA 
Screening 
X 
- 
- 
- 
- 
- 
PEGPH20 
Pharmacokinetics 
1 
Pre PEGPH20 
Dose (within 
2 hours prior to 
dosing) 
- 
X 
- 
- 
- 
- 
Plasma Hyaluronan 
Exploratory 
Biomarkers 
Immunogenicitya 
1HAI 
Pre PEGPH20 
Dose (within 
2 hours prior to 
dosing) 
- 
X 
- 
X 
- 
- 
PEGPH20 
Pharmacokinetics 
2 
15 minutes Post 
PEGPH20 Dose 
(±5 minutes) 
- 
X 
- 
X 
- 
- 
PEGPH20 
Pharmacokinetics 
3 
1 hour Post 
PEGPH20 Dose 
(±15 minutes) 
- 
X 
- 
- 
- 
- 
PEGPH20 
Pharmacokinetics 
Plasma Hyaluronan 
Exploratory 
Biomarkers 
4 
2-4 hours Post 
PEGPH20 Dose 
- 
X 
- 
- 
- 
- 
Pembrolizumab 
Pharmacokinetics 
5 
Pre PEM Dose 
(within 2 hours 
prior to dosing) 
- 
X 
- 
X 
- 
- 
PEGPH20 
Pharmacokinetics 
6 
6-8 hours Post 
PEGPH20 Dose 
- 
X 
- 
X 
- 
- 
Plasma Hyaluronan 
Exploratory 
Biomarkers 
6HA 
6-8 hours Post 
PEGPH20 Dose 
- 
X 
- 
- 
- 
- 
Pembrolizumab 
Pharmacokinetics 
7 
0-2 hours Post 
PEM Dose 
- 
X 
- 
X 
- 
- 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 34 of 112 
06 November 2017  
Table 3: 
Study Schedule of Events: Immunogenicity, Pharmacokinetic, and HA 
Sample Collection (Continued) 
Sampling 
Draw 
Number 
Time Point 
Screen 
Treatment 
Cycle 1 
(21 days) 
Treatment 
Cycles 2+ 
(Repeats Every 
21 days) 
End of 
Treatment 
Week 1 
Week 1 
D1 
D2 
D1 
D2 
 
PEGPH20 
Pharmacokinetics 
8 
24-26 hours 
Post PEGPH20 
Dose 
- 
- 
X 
- 
X 
- 
Plasma Hyaluronan 
Exploratory 
Biomarkers 
8HA 
24-26 hours 
Post PEGPH20 
Dose 
- 
- 
X 
- 
- 
- 
PEGPH20 
Pharmacokinetics 
9 
28-32 hours 
Post PEGPH20 
Dose 
- 
- 
X 
- 
X 
- 
Pembrolizumab 
Pharmacokinetics 
10 
24-28 hours 
Post PEM Dose 
 
- 
- 
X 
- 
X 
- 
Immunogenicitya 
99 
End of 
Treatment 
- 
- 
- 
- 
- 
X 
PEGPH20 
Pharmacokinetics 
 
Immunogenicity 
Plasma Hyaluronan 
Exploratory 
Biomarkers 
Pembrolizumab 
Pharmacokinetics 
U# 
Unscheduled 
X 
X 
X 
X 
X 
X 
Abbreviations: D = day; HA = hyaluronan; PEM = pembrolizumab. 
a PEGPH20 Immunogenicity. 
Notes: Pembrolizumab PK samples will be collected and analyzed when a validated assay is available. If a subject 
discontinues PEGPH20 therapy, PEGPH20 PK samples will not be collected from that subject. However, if that 
subject continues on pembrolizumab therapy at the discretion of the Investigator, pembrolizumab PK samples must 
be collected. 
Plasma samples are required for PEGPH20 PK, plasma hyaluronan, biomarker, and PEGPH20 immunogenicity 
analysis; serum samples are required for pembrolizumab PK analysis. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 35 of 112 
06 November 2017  
4. 
BACKGROUND AND RATIONALE 
4.1. 
Non-Small Cell Lung Cancer 
Lung cancer accounts for about 27% of all cancer deaths and is by far the leading cause of cancer 
death among both men and women. An estimated 158,040 deaths (86,380 in men and 71,660 in 
women) are expected to occur in 2015 in the United States (US) alone. Although the incidence 
rate has been declining in recent times for both men and women, the American Cancer Society’s 
estimates that 221,200 new cases of lung cancer (115,610 in men and 105,590 in women) will be 
diagnosed in the US in 2015 (American Cancer Society 2015). 
Lung cancers are broadly classified into two types: small cell lung cancers (13%) and non-small 
cell lung cancers (NSCLC) (83%) for the purposes of treatment (American Cancer Society 2015). 
NSCLC, which arises from the epithelial cells of the lung of the central bronchi to terminal 
alveoli, is the most common type of lung cancer. The main types of NSCLC are adenocarcinoma 
(approximately 50% of cases), squamous cell (approximately 30% of cases), large cell 
(approximately 10% of cases) and bronchial alveolar carcinoma (now classified as 
adenocarcinoma in situ). 
The prognosis for NSCLC is poor (Jemal 2011), and at least 50% of patients treated for early 
stage disease will go on to experience progression or relapse to advanced disease (Sculier 2009). 
Seventy percent of patients present with advanced stage disease, for which the response rate to 
current standard combination chemotherapy is only 20% to 25%, and median survival is 10 to 
12 months (Gupta 2014). Clearly a plateau has been reached with traditional chemotherapy and 
further progress will depend upon identifying novel methods to target tumor cells. 
Harnessing the human immune system to target lung cancer could result in the development of 
effective treatment options against lung cancer and potentially enhance the effect of cytotoxic 
chemotherapy. 
4.2. 
Gastric adenocarcinoma 
Gastric cancer was the world’s third leading cause of cancer mortality in 2012 and was 
responsible for 723,000 deaths worldwide that year (Bass 2014). Although its incidence and 
mortality has declined since then, the American Cancer Society estimates that there will be 
24,590 new cases of gastric cancer reported in the US in 2015 along with 10,720 deaths 
(American Cancer Society 2015). Gastric adenocarcinoma is a malignant epithelial tumor, 
originating from glandular epithelium of the gastric mucosa. Ninety percent of all tumors of the 
stomach are malignant, and gastric adenocarcinoma comprises 95% of the total number of 
malignancies (Dicken 2005). 
The survival rates for gastric cancer are among the worst of any solid tumor (Yang 2011). For 
early-stage cancer, surgical resection remains the mainstay of curative-intent treatment 
(Wang 2015). Despite the success of modern chemotherapy in the treatment of large bowel 
cancers, the 5-year survival of patients with advanced gastric cancer is 3.1%. The role of surgery 
is also limited in advanced gastric cancer as only 23% of stage IV gastric cancer patients 
receiving a palliative gastrectomy are alive one year after surgery (Yang 2011). 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 36 of 112 
06 November 2017  
Current management strategies and treatments are limited primarily by lack of specificity to the 
cancer cells and by general treatment toxicities that limit full delivery of anticancer agents 
(Wang 2015). For these reasons, novel therapeutic strategies are urgently needed. 
4.3. 
Hyaluronan and Malignancy 
Hyaluronan (HA) is a high-molecular-mass polysaccharide found in the extracellular matrix of 
tumors. Accumulation of HA in several malignant diseases is associated with aggressive tumor 
type, cancer progression/metastasis, and poor prognosis (Toole 2008; Sironen 2011). Interaction 
of pericellular HA and CD44 has been shown to influence drug resistance (Misra 2003). Local 
aberrations of HA metabolism have been reported in many solid tumor malignancies, where 
elevated levels of HA frequently correlate with poor prognosis in tumors such as pancreatic 
(Kultti 2012; Whatcott 2011), breast (Auvinen 2000), gastric (Setälä 1999), colorectal 
(Ropponen 1998), ovarian (Anttila 2000), prostate (Bharadwaj 2009) and lung carcinoma 
(Chow 2010). Further information about HA in lung cancer is provided in Section 4.6.3. 
4.4. 
PEGylated Recombinant Human Hyaluronidase PH20 
Halozyme, Inc. (Halozyme) has developed an investigational new molecular entity, PEGylated 
recombinant human hyaluronidase PH20 (PEGPH20), which uses a novel mechanism of action 
to systemically target tumors that accumulate HA. In preclinical models, both tumor xenografts 
in immunocompromised mice and autochthonous tumors from genetically engineered KrasLSL-
G12D/þ; Trp53LSL-R172H/þ; Cre (KPC) mice, depletion of HA from the tumor microenvironment 
(TME) has been shown to inhibit the growth of tumors characterized by accumulation of HA 
(Thompson 2010; Jiang 2012; Provenzano 2012; Jacobetz 2013). 
The PH20 recombinant human hyaluronidase (rHuPH20) enzyme is a soluble domain of the 
endogenous human PH20 glycoprotein, devoid of its carboxy-terminal, lipid anchor attachment 
site. To increase the plasma half-life and enable systemic therapeutic exposure not possible with 
existing recombinant human PH20 (rHuPH20), Halozyme developed a PEGylated version of 
PH20. Like rHuPH20, PEGPH20 removes HA from the extra cellular matrix by depolymerizing 
the substrate (Thompson 2010). In many different tumor types tested in murine xenograft 
models, response to PEGPH20 has been shown to be more robust for tumors characterized by 
higher HA accumulation (Jiang 2012). PEGPH20 has a terminal plasma half-life of 
approximately 3.2 hours in rodents and 50 hours in monkeys. In humans, data from 2 subjects 
dosed with 50 μg/kg PEGPH20 in Study HALO-109-101 demonstrated a plasma half-life of 
2.5 to 4.8 hours for the initial phase and 26 to 49 hours (1 to 2 days) for the terminal phase (as 
compared with <5 min for rHuPH20 intravenous (IV) hyaluronidase [Wolf 1982]). The increased 
plasma half-life of PEGPH20 makes sustained depletion of tumor-associated HA feasible. 
4.4.1. 
PEGPH20 and Chemotherapy 
Enzymatic HA depletion from the TME, with PEGPH20 either alone or in combination with 
chemotherapy, represents an innovative potential treatment that could provide improved 
therapeutic outcomes for patients (Pillwein 1998; Baumgartner 1998; Klocker 1998), based on a 
reduction in interstitial fluid pressure, and the subsequent vascular decompression, increased 
blood volume, and concomitantly enhanced drug penetration into HA-rich tumors (Spruss 1995, 
Brekken 1998; Eikenes 2005; Thompson 2010), and on the reduction of tumor HA levels, which 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 37 of 112 
06 November 2017  
was reported to reduce in vitro tumor cell proliferation, motility, and invasion, and to reduce the 
growth of implanted tumors (Shuster 2002; Simpson 2002; Kim 2004; Nishida 2005; 
Udabage 2005; Li 2007; Thompson 2010; Provenzano 2012; Jacobetz 2013). 
In the autochthonous KPC pancreatic model, PEGPH20 treatment induced fenestrations and 
interendothelial junctional gaps in pancreatic endothelia (Jacobetz 2013). Independent studies in 
the same model reported that the increased vascular perfusion observed when PEGPH20 is given 
in combination with gemcitabine (GEM) persisted for weeks after therapy ceased, suggesting 
that the TME was permanently remodeled following PEGPH20 treatment (Provenzano 2012; 
Provenzano 2013). In mouse pancreatic xenografts, PEGPH20 treatment induced translocation of 
E-cadherin and β-catenin to the plasma membrane of cancer cells, suggesting at least a partial 
reversal of the classic epithelial-mesenchymal transition (EMT) observed during the progression 
of malignancy (Kultti 2014). Finally, in NSCLC patient-derived xenografts (PDx) the antitumor 
effect of PEGPH20 in combination with docetaxel (Doc) (Taxotere®) was evaluated 
(Halozyme Report 13036). In HA-high PDx tumors, PEGPH20 enhanced the effect of Doc, 
increasing tumor growth inhibition from 52.5% for Doc alone to 115% for PEGPH20 plus Doc, 
while concomitantly increasing survival by 50% (35d for Doc alone vs 70d for PEGPH20 plus 
Doc). 
4.5. 
Clinical Experience with PEGPH20 and Clinical Development Plan 
PEGPH20 is being developed as an investigational, novel therapeutic agent for use in 
combination with chemotherapy or other agents for the treatment of patients with cancers that 
accumulate HA. As of 13 February 2016, approximately 238 subjects had been exposed to at 
least 1 dose of PEGPH20 in 6 Sponsor clinical studies: in 2 Phase 1 studies as a single agent 
(HALO-109-101 and HALO-109-102), in combination with chemotherapy in a Phase 1b study in 
pancreatic cancer (HALO-109-201), in combination with chemotherapy in a Phase 2 study in 
pancreatic cancer (HALO-109-202), in combination with chemotherapy in a Phase 1b study in 
lung cancer (HALO-107-201) and in combination with an immunotherapeutic drug 
pembrolizumab in this Phase 1b study in lung cancer (HALO-107-101). The clinical 
development program also includes an ongoing Phase 3 study of PEGPH20 in combination with 
chemotherapy in HA-high subjects with pancreatic cancer. 
4.5.1. 
Phase 1 Study HALO-109-101 
This study enrolled 14 subjects with advanced malignancies (including one subject with NSCLC) 
who experienced disease progression after previous therapy. This study was amended due to the 
observation of severe musculoskeletal events (MSEs) and was closed due to these events and 
inability to dose escalate. 
4.5.2. 
Phase 1 Study HALO-109-102 
This study was initiated to evaluate the safety profile of PEGPH20 using the regimen of once or 
twice weekly PEGPH20 administration. Dexamethasone (pre- and post-PEGPH20 doses) was 
added to the regimen to alleviate musculoskeletal toxicities. PEGPH20 doses administered 
ranged from 0.5 to 5.0 μg/kg either once or twice weekly (Days 1 and 4) schedule for the first 
cycle (4 weeks) and once per week for subsequent cycles. In addition, subjects received 4 or 
8 mg dexamethasone 1 hour prior to and 8 to 12 hours after PEGPH20 administration. A total of 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 38 of 112 
06 November 2017  
26 subjects enrolled in this study, six were treated at 3.0 µg/kg once weekly and 15 received 
3.0 µg/kg twice weekly schedule. The maximum tolerated dose (MTD) was determined to be 
3.0 µg/kg once or twice weekly. 
4.5.3. 
Phase 1b Study HALO-109-201 
This study was initiated to identify the recommended Phase 2 dose (RP2D) of PEGPH20 in 
combination with GEM (Gemzar®) in subjects with metastatic pancreatic cancer. A total of 
28 subjects were treated with PEGPH20 administered by IV infusion twice per week for the first 
4 weeks, then weekly for three weeks, followed by one week rest. GEM was administered at 
1000 mg/m2 intravenously over 30 minutes once per week for 7 weeks followed by one week 
rest. Dexamethasone was used 1 hour pre and 8 hours post PEGPH20 dosing. From Cycle 2 
onward, PEGPH20 and GEM were administered once weekly for three weeks in a 4-week cycle. 
4.5.4. 
Phase 2 Study HALO-109-202 
This is an ongoing Phase 2 multicenter, open-label, randomized study which 
enrolled/randomized a total of 279 subjects with Stage IV previously untreated pancreatic ductal 
adenocarcinoma (PDA) who are receiving either PEGPH20 combined with nab-paclitaxel (NAB) 
plus GEM (PAG treatment) or NAB plus GEM (AG treatment). The study is blinded to the 
Sponsor.  
In April 2014, the HALO-109-202 Data Monitoring committee (DMC) reported an imbalance in 
TE events with a higher incidence in subjects treated with PAG than AG therapy alone (28.4% 
vs. 14.8%, respectively). Based on these findings, the study was placed on a temporary clinical 
hold. All 29 ongoing subjects in the PAG group stopped PEGPH20 therapy and remained on AG 
therapy alone. In June 2014, the temporary clinical hold was lifted and the study protocol was 
amended to: (1) include concomitant use of prophylactic enoxaparin for all subjects, (2) 
requirement to discontinue PEGPH20 permanently after a TE event occurred, and (3) exclude 
subjects with evidence of DVT or pulmonary embolism as well as those subjects determined to 
be at high risk of TE events s. Stage 1 of this study includes subjects who were enrolled prior to 
the clinical hold (N = 146 randomized). Stage 2 is ongoing and includes subjects enrolled after 
the clinical hold and subsequent protocol amendment (N = 133 randomized). 
A data analysis was performed as of a data cut of 16 December 2016. Interim safety and efficacy 
data from this study are presented in Section 4.5.7 Safety and Section 4.5.8 Efficacy. 
4.5.5. 
Phase 1b Study HALO-107-201 
This was a Phase 1b/2, randomized, multicenter study of PEGPH20 in subjects with recurrent 
previously treated locally advanced or metastatic NSCLC receiving either PEGPH20 combined 
with Doc or Doc alone.  
The study was designed to have a Phase 1b Dose Escalation portion and a Safety Evaluation 
portion, in all comers (i.e., subjects not selected based on HA status), and a Cohort Expansion 
portion in prospectively selected HA-high subjects followed by a Phase 2 portion.  
In the Phase 1b Dose Escalation portion, approximately 3 to 6 subjects/ cohort were to receive 
PEGPH20 at each increasing dose level (1.6, 2.2, 2.8 and 3.0 µg/kg) once/cycle in combination 
with standard dosing of docetaxel (75 mg/m2 every 21 days). Additional Safety Evaluation (in up 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 39 of 112 
06 November 2017  
to 20 subjects) and Cohort Expansion portions (in up to 50 subjects) were to further evaluate the 
safety and tolerability of PEGPH20 in combination with docetaxel (PDoc) treatment before 
initiating Phase 2. Safety and preliminary pharmacokinetic (PK) results from all subjects dosed 
in Phase 1b were to be used to determine the RP2D for the Phase 2 portion. In Phase 2, 
approximately 188 subjects prospectively selected for high HA levels were planned to be 
randomized in a 1:1 ratio to receive PDoc at the PEGPH20 dose selected in Phase 1b or 
docetaxel alone (Doc; 75 mg/m2 once in each 21-day cycle).  
This study was terminated during the Dose Escalation portion due to evolving standard-of-care 
in the NSCLC treatment landscape. At the time of termination, 16 subjects had been enrolled in 
the Dose Escalation portion, of which 15 were dosed at 3 different dose levels of PEGPH20  
(1.6, 3.0, and 2.2 µg/kg). Results are pending analysis at the time of writing this protocol 
amendment. TE event data are given in Section 4.5.7.2. Additional information is provided in the 
PEGPH20 Investigator’s Brochure. 
4.5.6. 
Phase 3 Study HALO-109-301 
This is an ongoing randomized, double-blind, placebo-controlled, multicenter study of PEGPH20 
(3.0 μg/kg) in combination with NAB (125 mg/m2) plus GEM (1000 mg/m2) (PAG treatment) 
compared with placebo plus NAB and GEM (AG treatment) in 420 and up to 570 subjects with 
HA-high Stage IV previously untreated PDA. 
Eligible subjects are randomized in a double-blind fashion to 1 of 2 treatment groups in a 
2:1 ratio for PAG:AG. Randomization is stratified by geographic region (North America, 
Europe, and Others). 
The Treatment Period consists of 4-week treatment cycles (28 days), with Week 4 of every cycle 
being a rest week (i.e., no treatment is given). PEGPH20 or placebo is administered as an IV 
infusion twice weekly for Weeks 1 to 3 of Cycle 1, then once weekly for Weeks 1 to 3 of Cycle 2 
and beyond; NAB and GEM is administered as IV infusions once weekly for Weeks 1 to 3 of all 
treatment cycles.  
4.5.7. 
Safety 
In more than approximately 238 subjects exposed to PEGPH20, either in the monotherapy or 
combination setting in Sponsor clinical studies, the most frequently reported adverse events 
(AEs) are fatigue, cytopenia (anemia, thrombocytopenia, neutropenia), gastrointestinal events 
(nausea, vomiting, and diarrhoea), and peripheral oedema. In addition to these common AEs, 
both MS events (primarily muscle spasms and myalgias) and thromboembolic (TE) events are 
considered identified risks of PEGPH20. Each of these AEs remain manageable with supportive 
therapy, considering the low rate (14%) of discontinuation due to any study drug related AE. 
Please refer to the Investigator’s Brochure for additional safety information. 
4.5.7.1. 
Musculoskeletal Events 
Prior to the initiation of study HALO-109-102, MSEs had been as severe as Grade 3/4; however, 
since the use of pre- and post-dose prophylaxis with dexamethasone in studies of PEGPH20 in 
combination with chemotherapy, the majority are Grade 1/2 in severity and, in general, have not 
led to treatment discontinuations. Since this study uses an immunotherapeutic agent and 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 40 of 112 
06 November 2017  
dexamethasone may suppress an immune response, it should only be used when prescribed by 
the Investigator and following a discussion with the Sponsor. 
Piroxicam and toradol have been investigated in an animal model of MSEs and may be helpful in 
decreasing the severity of MSEs in subjects (internal unpublished Halozyme report). In this 
study, piroxicam will therefore be administered to decrease the severity of MSE’s; toradol may 
be given for severe pain as recommended in the Prescribing Information (see Section 10.12 for 
additional details). 
4.5.7.2. 
Thromboembolic Events 
Thromboembolic events and their sequelae have been observed in clinical studies evaluating 
PEGPH20 monotherapy and combination therapies.  
In the 2 completed Phase 1 studies of PEGPH20 monotherapy in subjects with advanced solid 
tumors (HALO-109-101 and HALO-109-102; N = 40), TE events were observed in 1 subject 
who experienced embolism. 
In the Phase 1b Study HALO-107-201 in NSCLC, which was discontinued early by the Sponsor 
in August 2016 due to the changing treatment landscape for NSCLC, up to the date of study 
discontinuation, 4 of 15 (27%) treated subjects experienced a TE event, including deep vein 
thrombosis (DVT) and superficial thrombophlebitis. 
In completed Study HALO-109-201 of PEGPH20 in combination with gemcitabine in pancreatic 
cancer, the incidence of TE events was approximately 28%, the majority being of venous origin. 
Regarding the Phase 2 Study HALO-109-202 in pancreatic cancer, as discussed in Section 4.5.4, 
an imbalance was observed in the rate of TE events between the PAG and AG treatment arms 
(28.4% vs. 14.8%) in Stage 1 of the study that led to the implementation of risk mitigation 
measures, including the exclusion of high-TE event risk subjects and the administration of 
enoxaparin prophylaxis in all subjects. The majority of the TE events were of venous origin 
(DVT and pulmonary embolism); however, arterial events were also reported. Itis widely 
accepted that pancreatic cancer is a tumor type with a high TE event background rate. Published 
studies have reported a TE event incidence in these patients ranging from 17% to 57.7% 
(Khorana 2004; Bapat 2016). 
Since the implementation of the aforementioned measures in Stage 2 of HALO-109-202, the 
incidence of TE events has decreased considerably compared with that observed in Stage 1. 
Based on an analysis as of a data cutoff of 16 December 2016, the TE rate in the PAG and AG 
groups, respectively, decreased from 43% and 25% in Stage 1 (no enoxaparin prophylaxis) to 
10% and 6% in Stage 2 (with enoxaparin 1 mg/kg/day prophylaxis). Additional details are 
provided in the PEGPH20 Investigator’s Brochure. 
While the rate of TE events in pancreatic cancer is reported to be highest among malignancies 
(Pelzer 2015), rates of TE events in NSCLC and gastric cancer have also been reported to be 
elevated (Chew 2008 and Khorana 2012, respectively). Based on these data, the following safety 
measures will be taken to safeguard subjects: 
1. Subjects with a history of or presence of a pulmonary embolism at baseline will be 
excluded from this trial. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 41 of 112 
06 November 2017  
2. All NSCLC subjects will be given enteric-coated 81 mg of prophylactic aspirin/day and 
all gastric adenocarcinoma subjects will be given prophylactic enoxaparin 40 mg/day for 
TE event prophylaxis, given the high incidence seen in these tumor types, and closely 
monitored. PEGPH20 will be discontinued for subjects who experience any TE requiring 
full-dose anticoagulation while on study. Treatment with pembrolizumab, however, may 
continue as deemed appropriate by the Investigator. 
3. In gastric adenocarcinoma subjects, if enoxaparin is discontinued for any reason, 
PEGPH20 will also be discontinued. Treatment with pembrolizumab, however, may 
continue as deemed appropriate by the Investigator. 
4. Sites will report any TE event to the Sponsor immediately and no later than 24 hours of 
awareness. 
4.5.8. 
Efficacy 
In the Phase 1b study (HALO-109-201) in subjects with pancreatic cancer, responses were 
assessed by an independent central radiologist. Partial Response (PR) was reported in 10 of the 
24 subjects who received PEGPH20 at either the 1.6 or 3.0 µg/kg dose level. In addition, 
subjects who had HA high in tissue biopsies experienced better responses (5/6 subjects), which 
correlated with prolonged progression-free survival (PFS; 219 days) and overall survival (OS; 
approximately 395 days). PRs were seen in 4 of the 11 subjects who had lower HA in tissue 
biopsies. The PFS and OS in the low-HA group were 108 days and 174 days, respectively 
(Hingorani 2015). Further details about efficacy in early studies are provided in the PEGPH20 
Investigator’s Brochure. 
Halozyme has developed, in collaboration with a leading diagnostic company, Ventana Medical 
Systems, Inc., a novel co-developed investigational diagnostic assay (VENTANA HA RxDx 
assay [RxDx]) to identify subjects who might benefit most, based on HA tumor content, from the 
administration of PEGPH20 in conjunction with other cancer therapeutics. This assay uses an 
affinity-histochemistry-based staining method to evaluate HA levels in tumor biopsies.  
For Phase 2 HALO-109-202, a data analysis was performed as of a data cut of 
16 December 2016. Tumor samples from were collected and analyzed in a  
prospective-retrospective fashion using the RxDx assay. As of the data cutoff date, of the 
279 subjects comprising the ITT Population, 97% (270/279) of subjects in the Stage 1 + Stage 2 
combined were off treatment. Efficacy results for the combined Stage 1 + Stage 2 ITT HA-high 
Population (n = 84 [49 PAG, 35 AG]) indicate a statistically significant 77% improvement in 
PFS, with a median of 9.2 months for PAG vs. 5.2 months for AG (HR: 0.51; p-value: 0.048). 
Despite the limitations of the Stage 1 data set due to the clinical hold (e.g., subjects discontinuing 
PEGPH20 and continuing on AG alone), there was a 35% improvement in median OS which was 
11.5 months with PAG vs. 8.5 months with AG (HR: 0.96). 
Based on the data from the Stage 2 population in HA-high subjects (median PFS and OS 
4.5 months and 7.8 months, respectively) vs. HA-low subjects (7.2 months and 10.2 months, 
respectively) within the AG group, HA-high tumors may have a worse prognosis when treated 
with the standard of care AG therapy, suggesting that high levels of HA are a potential negative 
prognostic biomarker in PDA and supporting the rationale for the addition of PEGPH20 
treatment to anti-cancer therapies in PDA. The substantial improvements seen with PAG, 
compared with AG, in both median PFS and median OS in the Stage 2 HA-high population 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 42 of 112 
06 November 2017  
confirm the hypothesis of HA being a potential predictive biomarker for subject selection for 
PEGPH20 treatment. Additional details are provided in the PEGPH20 Investigator’s Brochure. 
4.5.9. 
Clinical Pharmacokinetics 
Subjects enrolled in the Phase 1 studies received PEGPH20 at doses ranging from 0.5 to 
50 μg/kg with or without dexamethasone. Blood samples were collected at scheduled time 
points, and plasma was analyzed for PEGPH20 concentrations. PK analysis suggests that a linear 
PK model adequately described the available PEGPH20 plasma concentration versus time 
profiles. The maximum plasma concentrations were estimated to be between 0.4 and 1.0 hours 
after dosing. Subjects dosed with 50 μg/kg PEGPH20 in Study HALO-109-101 demonstrated a 
plasma half-life of 2.5 to 4.8 hours for the initial phase and 26 to 49 hours (1 to 2 days) for the 
terminal phase. Estimates for initial distribution volume were consistent with expectations for 
therapeutic macromolecules. The prolonged plasma half-life of PEGPH20 makes sustained 
depletion of tumor-associated HA feasible. Clinical experience to date (largely involving 
combination therapy with GEM) indicates that the linear PK characteristics of PEGPH20 given 
alone are maintained in combination therapy. Details of the PK characteristics of PEGPH20 are 
provided in the PEGPH20 Investigator’s Brochure. 
4.6. 
Study Rationale 
Therapy with mAbs directed against multiple check-point receptors involved in the immune 
response (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], programmed cell 
death‑1 [PD-1] and PD-1 ligand 1 [PD-L1]) has changed the treatment paradigm for advanced 
melanoma and NSCLC. However, when used as single agents, in advanced previously treated 
NSCLC patients, these compounds have lower response rates (<25%) and may have considerable 
systemic toxicity (Brahmer 2012; Brahmer 2014; Garon 2015). These compounds are currently 
either approved or in development by pharmaceutical companies for numerous indications 
including NSCLC, renal cell cancer, head and neck cancer and lymphoma. The rationale for 
combining PEGPH20 with such immunotherapies is based on nonclinical data indicating that 
addition of PEGPH20 to such therapies leads to increased accessibility of natural killer (NK) 
cells to HA-high tumor cells in vitro and in vivo, increased accessibility of antibodies to HA-high 
tumor cells (e.g. trastuzumab [Herceptin®]), increased antibody-dependent killing of HA-high 
tumor cells in vitro (e.g. trastuzumab and cetuximab [ErbituxTM], increased antibody- and NK-
dependent tumor growth inhibition in xenograft models (Singha 2015), increased tumor growth 
inhibition of anti-CTLA4 in a syngeneic murine colon cancer model (unpublished internal 
report) and increased accumulation of a salmonella-based therapeutic and neutrophils in 
orthotopic pancreatic tumors (Manuel 2014). 
This Phase 1b study will test the safety and early biological activity of PEGPH20 combined with 
the immunotherapeutic mAb pembrolizumab (Keytruda®) (the combination is hereafter referred 
to as PEGPEM) in subjects with HA-high solid tumors. 
4.6.1. 
Pembrolizumab for Treatment of NSCLC 
Platinum-based chemotherapy, with or without maintenance therapy, subsequently followed by 
second-line cytotoxic chemotherapy, is standard treatment for most patients with advanced  
non-small cell lung cancer, with a median survival of approximately 1 year. One hallmark of 
cancer is immune evasion, in which the immune system does not mount an effective antitumor 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 43 of 112 
06 November 2017  
response. PD-1 is a negative costimulatory receptor expressed primarily on the surface of 
activated T-cells. The binding of PD-1 to one of its ligands, PD-L1 or PD-L2, can inhibit a 
cytotoxic T-cell response. Tumors can co-opt this pathway to escape T-cell–induced antitumor 
activity. Pembrolizumab, a highly selective, humanized monoclonal IgG4 kappa isotype 
antibody against PD-1, can disrupt the engagement of PD-1 with its ligands and impede 
inhibitory signals in T-cells, with resultant tumor recognition by cytotoxic T-cells. 
The efficacy and safety of PD-1 inhibition with pembrolizumab was assessed in patients with 
advanced NSCLC in a Phase 1 study in which 495 patients were assigned to receive 
pembrolizumab at a dose of either 2 mg or 10 mg per kg of body weight every 3 weeks or 10 mg 
per kg every 2 weeks (Garon 2015). The primary objectives of the study were to evaluate the 
safety, side-effect profile, and antitumor activity of pembrolizumab. The study also sought to 
define and validate an expression level of the PD-L1 that is associated with the likelihood of 
clinical benefit.  
Among all the patients, the ORR observed was 19.4%, and the median duration of response 
(DOR) was 12.5 months. The median PFS was 3.7 months, and the median OS was 12.0 months. 
PD-L1 expression in at least 50% of tumor cells was selected as the cutoff. Among patients with 
a proportion score of at least 50% the response rate was 45.2%. Among all the patients with a 
proportion score of at least 50%, median PFS was 6.3 months; median OS was not reached. 
Common side effects attributed to pembrolizumab were fatigue, pruritus, and decreased appetite. 
In conclusion, pembrolizumab had an acceptable side-effect profile and showed antitumor 
activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% 
of tumor cells correlated with improved efficacy of pembrolizumab. 
4.6.2. 
Pembrolizumab for Treatment of Gastric Adenocarcinoma 
Treatment choices for gastric cancer depend on tumor type and stage. The only hope for cure 
currently rests on removal of the malignant tissue either endoscopically or by surgical resection. 
For advanced disease, treatment is largely palliative and consists of a combination of surgery, 
chemotherapy, and radiation. Overall, the results of current therapy for advanced disease are 
poor with low 5 years survivals. Immunotherapy provides another dimension to the prevention 
and management of gastric cancer and offers hope of breaking through current constraints 
(Matsueda 2014). 
The safety and efficacy of pembrolizumab was assessed in a phase 1b study in patients with 
advanced gastric cancer in KEYNOTE-012 (Clinicaltrials.gov identifier NCT01848834). Using a 
prototype immunohistochemistry assay, PD-L1 expression was assessed in archival tumor 
samples from patients with recurrent/metastatic adenocarcinoma of the stomach or 
gastroesophageal junction. Eligible patients with PD-L1 staining in stroma or ≥1% of tumor cells 
were enrolled and treated with pembrolizumab 10mg/kg every 2 weeks for up to 24 months or 
until complete response (CR), disease progression or unacceptable toxicity. AEs were monitored 
and graded per the National Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI CTCAE c4.0). Radiographic imaging was performed every 8 weeks. Primary efficacy 
endpoint was ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 
Of the 162 patients screened, 65 (40%) were PD-L1 positive. Of these 65 patients, 39 enrolled. 
The number of prior therapies for advanced disease ranged from 0 to 5; 67% received ≥2 prior 
therapies. Median follow-up duration was 8.8 months (range 6.2-12.6); 13 patients (33%) remain 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 44 of 112 
06 November 2017  
on therapy. Four patients experienced 5 total grade 3-5 drug-related adverse events: peripheral 
sensory neuropathy, fatigue, decreased appetite, hypoxia, and pneumonitis (n = 1 each). There 
was 1 drug-related death (hypoxia). ORR was 22% (95% CI 10-39) by central review and 33% 
(95% CI 19-50) by Investigator review. Median time to response was 8 weeks (range 7-16), with 
a median response duration of 24 weeks (range 8+ to 33+). PD-L1 expression level was 
associated with ORR (1-sided P = 0.10). The 6-month PFS rate was 24%. The 6-month OS rate 
was 69%.  
In conclusion, pembrolizumab demonstrated manageable toxicity and promising antitumor 
activity in advanced gastric cancer patients selected for PD-L1 expression using a prototype 
immunohistochemistry assay. These results support the ongoing development of pembrolizumab 
for gastric cancer (Muro 2015). 
The safety and efficacy of nivolumab, another anti-PD-1 antibody was assessed in 7 patients 
with advanced gastric cancer, unselected for PD-L1 expression, in a multicenter phase 1 trial. No 
objective responses were observed in the gastric cancer patients (Brahmer 2012). 
4.6.3. 
Use of PEGPH20 in HA-high Tumors 
The degradation of tumor-associated HA is hypothesized to increase the ability of anti-cancer 
agents to penetrate tumor tissue and, therefore increase cytotoxic activity in tumors. In tumors 
that are rich in HA, as is the case for NSCLC and gastric cancer, tumor tissue may be especially 
sensitive to the HA-degradation by PEGPH20 and thus responsive to an increase in the 
immunotherapeutic effects of pembrolizumab. Modifying the extracellular environment to 
increase the penetration and efficacy of immunotherapeutics represents a novel approach to 
treating NSCLC and gastric adenocarcinoma in a setting that has demonstrated preliminary 
therapeutic efficacy. 
In addition to increasing tumor perfusion, and subsequently increasing the accumulation of 
therapeutics, PEGPH20-mediated HA removal alone has been shown in preclinical models to 
significantly inhibit tumor growth; the magnitude of the PEGPH20 antitumor activity correlating 
with the magnitude of tumor HA accumulation (Thompson 2010; Jiang 2012). Further, HA 
removal appears to be associated with sustained changes in tumor vascular architecture and a 
reduction of EMT tumor markers (Provenzano 2012; Jacobetz 2013; Kultti 2014). 
In an investigation of the HA accumulation profile in human lung cancer using commercially 
available human tissue microarray (n=117, US Biomax), high levels of HA accumulation were 
found in 29% of NSCLC cancer tissues with the highest levels of (41%) of HA in squamous 
tumor type (HA high accumulation [HA-high] was found in 33% of large cell carcinomas and 
11% of adenocarcinomas; Jiang 2011). In an investigation of human tissue microarray of gastric 
adenocarcinoma, high levels of HA accumulation were found in 42% of the gastric 
adenocarcinoma tissues (Jacobetz 2013). 
In an investigation of the antitumor activity of PEGPH20 (single-agent and in combination with 
therapeutically relevant drug regimens) in NSCLC HA-high expressing human tumor explant 
models, the antitumor activity of PEGPH20 corresponded to the extent of HA in the tumor, and 
tumor growth inhibition responses were 97% for HA-high tumors, 44% for medium-HA tumors, 
and 16% for low-HA tumors (Jiang 2012). 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 45 of 112 
06 November 2017  
In an animal study combining PEGPH20 with cisplatin and GEM (indicated for the first-line 
treatment of patients with inoperable, locally advanced [Stage IIIA or IIIB], or metastatic 
[Stage IV] NSCLC (GEMZAR® Product Insert), in HA-high patient-derived xenograft models of 
NSCLC, PEGPH20 administered 24 hours before combination chemotherapy inhibited tumor 
growth by 76.6% (ΔT/ΔC=23.4%, p < 0.01), whereas the combination of cisplatin and GEM 
alone was not significant. In an animal study combining PEGPH20 with Doc (indicated for 
patients with locally advanced or metastatic NSCLC after failure of prior platinum-based 
chemotherapy (Joshi 2014; TAXOTERE® Product Insert), co-administration of PEGPH20 with 
Doc increased Doc growth inhibition from 52% (p < 0.01) to 116% (p < 0.0001), and increased 
the median survival time 2-fold (35 days with Doc alone compared with 70 days with Doc plus 
PEGPH20). Further details of these studies are provided in the PEGPH20 Investigator’s 
Brochure. 
4.6.4. 
Rationale for Dose Selection 
Rationale for PEGPH20 Dose Selection  
A dose of 3.0 μg/kg was identified as the MTD for PEGPH20 as either a single agent or in 
combination with GEM in 3 separate trials (2 Phase 1 and 1 Phase 1b clinical study). In the 
phase 1 trial Study HALO-109-101, PEGPH20 was administered once every 21 days. In the 
phase 1 trial, Study HALO-109-102, PEGPH20 was administered twice per week for the first 
4 weeks followed by once a week for the following 4-week cycles (no washout in week 4). In the 
phase 1b trial, Study HALO-109-201, PEGPH20 was administered twice weekly for the first 
4 weeks, then once weekly for 3 of every 4 weeks for the duration of subject participation. 
In an ongoing randomized Phase 2 study in subjects with advanced PDA, PEGPH20 is being 
administered at 3.0 µg/kg twice weekly for 3 weeks during the 1st 4-week cycle, then weekly for 
3 of 4 weeks in subsequent cycles in combination with nab-paclitaxel at 125 mg/m2/week for 
3 of 4 weeks and GEM at 1000 mg/m2 weekly for 3 of 4 weeks. 
Since PEGPH20 has not been evaluated in clinical studies in combination with pembrolizumab, 
this study will have a Dose Escalation portion in which PEGPH20 will be administered to 
consecutive cohorts in increasing doses (1.6, 2.2, 2.6, 3.0, and 4.0 µg/kg) selected based on 
clinical judgment, to evaluate the safety and tolerability of PEGPEM treatment before the Dose 
Expansion portion is initiated. The Dose Escalation portion will also be used to determine the 
dose of PEGPH20 to be evaluated in the Dose Expansion portion. 
Rationale for Pembrolizumab Dose Selection in Dose Escalation 
Standard dosing of pembrolizumab (2 mg/kg) will be administered every 3 weeks in the Dose 
Escalation portion per the Pembrolizumab Prescribing Information (Keytruda® US Prescribing 
Information 2015) (Protocol Amendment 2).  
Rationale for Pembrolizumab Dose Selection in Dose Expansion 
A dose of 200 mg pembrolizumab will be administered every 3 weeks to NSCLC subjects in the 
Dose Expansion portion, per the Pembrolizumab Prescribing Information (Keytruda® US 
Prescribing Information 2017). The same dosage of pembrolizumab (200 mg every 3 weeks) will 
also be administered to gastric adenocarcinoma subjects as it is being used in Phase 2 and Phase 
3 gastric adenocarcinoma trials evaluating pembrolizumab as a single agent or in combination 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 46 of 112 
06 November 2017  
with other chemotherapeutics (KEYNOTE-59 [Clinicaltrials.gov identifier NCT02335411], 
KEYNOTE-061 [Clinicaltrials.gov identifier NCT02370498]). 
5. 
STUDY OBJECTIVES AND ENDPOINTS 
5.1. 
Study Objectives 
5.1.1. 
Dose Escalation 
Primary Objectives 
• To assess the safety and tolerability of PEGPEM in subjects with relapsed/refractory 
NSCLC and relapsed/refractory gastric adenocarcinoma. 
• To determine the RP2D of PEGPH20 when administered with pembrolizumab in 
subjects with relapsed/refractory NSCLC and relapsed/refractory gastric 
adenocarcinoma. 
Secondary Objectives 
• To assess the PK of PEGPH20 when given in combination with pembrolizumab in 
subjects with relapsed/refractory NSCLC or relapsed/refractory gastric 
adenocarcinoma. 
• To obtain an early assessment of the antitumor activity of PEGPEM, as assessed by 
ORR, DOR, disease control rate (DCR) and PFS based on RECIST v1.1, and OS in 
subjects with relapsed/refractory NSCLC or relapsed/refractory gastric 
adenocarcinoma. 
 Exploratory Objective: 
• To assess the PK of pembrolizumab when given in combination with PEGPH20 in 
subjects with relapsed/refractory NSCLC or relapsed/refractory gastric 
adenocarcinoma. 
5.1.2. 
Dose Expansion 
Note: The objectives described below will be evaluated in HA-high subjects with 
relapsed/refractory NSCLC and HA-high subjects with relapsed/refractory gastric 
adenocarcinoma. 
Primary Objective  
• To evaluate the efficacy of PEGPEM as assessed by ORR based on RECIST v1.1 
Secondary Objectives  
• To evaluate the efficacy of PEGPEM as assessed by DOR, DCR and PFS based on 
RECIST v1.1, and OS  
• To evaluate the efficacy of PEGPEM as assessed by ORR, DOR, DCR and PFS based 
on immune-response related criteria (irRC)  


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 47 of 112 
06 November 2017  
• To characterize the PK of PEGPH20 when given in combination with pembrolizumab  
• To evaluate the safety and tolerability profile of PEGPEM 
Exploratory Objectives 
• To evaluate the efficacy of PEGPEM, as assessed by ORR, DOR, DCR, and PFS 
based on RECIST v1.1 criteria and irRC, by PD-L1 expression levels 
• To assess the treatment effect of PEGPEM as follows: 
− Based on HA levels in plasma and tumors, or other potential biomarkers. 
− Based on tumor blood flow and metabolic activity as assessed by dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron 
emission tomography (PET)/computed tomography (CT) scans, respectively. 
• To assess the PK of pembrolizumab when given in combination with PEGPH20 
5.2. 
Study Endpoints 
5.2.1. 
Dose Escalation 
Primary Endpoint 
• Dose-limiting toxicity, MTD, and RP2D. 
Secondary Endpoints 
• PK parameters of PEGPH20: maximum observed concentration (Cmax), minimum 
observed concentration (Cmin), terminal elimination half-life (T1/2), area-under 
the-concentration-time curve (AUC), volume of distribution (VD) and clearance (CL). 
• ORR, DOR, DCR and PFS based on RECIST v1.1. 
• OS. 
Exploratory Endpoint 
• PK parameters of pembrolizumab: Cmax, Cmin, T1/2, AUC, VD and CL. 
5.2.2. 
Dose Expansion 
Primary Endpoint 
• ORR based on RECIST v1.1. 
Secondary Endpoints 
• DOR, DCR and PFS based on RECIST v1.1, and OS. 
• ORR, DOR, DCR and PFS based on irRC. 
• PK parameters of PEGPH20: Cmax, Cmin, T1/2, AUC, VD and CL. 
• Incidence of AEs. 
• Changes in clinical safety laboratory values.  


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 48 of 112 
06 November 2017  
• Changes in cardiovascular parameters (electrocardiogram [ECG]) and vital signs. 
Exploratory Endpoints 
• ORR, DOR, DCR, and PFS based on RECIST v1.1 criteria and irRC by PD-L1 
expression levels. 
• Changes from pre-treatment in plasma HA and tumor HA (when available). 
• Correlation between plasma HA levels pre-dose, post-dose and any 
pharmacodynamic response. 
• Changes in tumor blood flow as measured by DCE-MRI. 
• Changes in tumor metabolism as measured by PET/CT. 
• Correlation of biomarkers in plasma and tumor biopsy to study endpoints. 
• PK parameters of pembrolizumab: Cmax, Cmin, T1/2, AUC, VD and CL. 
6. 
INVESTIGATIONAL PLAN 
6.1. 
Overall Study Design and Plan: Description 
This Phase 1b study of PEGPEM will consist of 2 portions: 
• A Dose Escalation portion in subjects with relapsed/refractory Stage IIIB or IV 
NSCLC after failing at least 1 previous platinum-based chemotherapy regimen (refer 
to Inclusion Criterion #2) and subjects with relapsed/refractory locally advanced or 
metastatic gastric adenocarcinoma after failing at least 1 previous chemotherapy 
regimen for locally advanced or metastatic disease. 
• Followed by a Dose Expansion portion in: 
− Previously untreated or treated HA-high subjects with Stage IIIB or IV NSCLC. 
Previously treated subjects must have failed no more than 1 previous  
platinum-based chemotherapy regimen for locally advanced or metastatic disease 
(refer to Inclusion Criterion #3).  
− HA-high subjects with relapsed/refractory locally advanced or metastatic gastric 
adenocarcinoma having failed no more than 2 previous chemotherapy regimens 
for locally advanced or metastatic disease. 
Note: In Dose Expansion, subjects will be selected for enrollment whose tumors are HA-high, 
using a co-developed investigational diagnostic assay (details in Section 8.2.17.1.3). Subjects 
will be tested retrospectively for PD-L1 expression levels. 
The study design is depicted in Figure 1. 
Since PEGPH20 has not been evaluated in clinical studies in combination with pembrolizumab, 
this study will have a Dose Escalation portion to evaluate the safety and tolerability of PEGPEM 
treatment before the Dose Expansion portion is initiated. The Dose Escalation portion will also 
be used to determine the dose of PEGPH20 to be evaluated in the Dose Expansion portion. 
The treatment period will consist of 21-day cycles.  


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 49 of 112 
06 November 2017  
In Dose Escalation, PEGPH20 will be administered on Day 1, Day 8 and Day 15 of each 21-day 
cycle (i.e. 3 doses/cycle) and pembrolizumab (2 mg/kg every 21 days) on Day 1 of each cycle 
(i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration.  
In Dose Expansion, 200 mg of pembrolizumab will be administered every 21 days (per Protocol 
Amendment 3 [see Section 4.6.4 for additional details]) and the dosing schedule will be as 
follows: 
• PEGPH20 will be administered on Day 1, Day 8 and Day 15 of each 21-day cycle 
(i.e. 3 doses/cycle) and pembrolizumab (200 mg every 21 days) on Day 1 of each 
cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration.  
In Dose Expansion, an independent DMC will review all available safety data from the first 3 
NSCLC subjects and first 3 gastric adenocarcinoma subjects who have completed Cycle 1, to 
determine if the safety and tolerability profile of the PEGPEM combination is acceptable (refer 
to the DMC charter for additional details). The DMC will also continue to periodically review 
safety data to protect subject welfare and identify potential safety signals. 
Treatment in both portions of the study will continue until death, withdrawal of consent from the 
study, disease progression, or unacceptable toxicity; however, subjects with asymptomatic 
disease progression will be allowed to continue study treatment at the Investigator’s discretion 
despite evidence of increasing tumor burden or appearance of new lesions for up to 6 weeks if 
the subject is “clinically stable.” Clinically stable is defined as: 
• Absence of symptoms and signs indicating clinically significant PD (including 
worsening of laboratory values) indicating disease progression; 
• No decline in Eastern Cooperative Oncology Group (ECOG) performance status; and 
• Absence of rapid progression of disease or of progressive tumor at critical anatomical 
sites (e.g., cord compression) requiring urgent alternative medical intervention. 
Dose interruptions and modifications of study treatment are permitted. 
In the single-agent studies of PEGPH20 and the combination study with GEM, the DLTs were 
MSEs of myalgia and muscle cramping. In clinical studies HALO-109-102, HALO-109-201 and 
HALO-109-202, dexamethasone was administered per protocol to attenuate the severity of 
MSEs. Since this study uses an immunotherapeutic agent, and dexamethasone may suppress an 
immune response, it should only be used when prescribed by the Investigator and following a 
discussion with the Sponsor (Section 10.12.4). 
Piroxicam and toradol have been investigated in an animal model of MSEs and may be helpful in 
decreasing the severity of MSEs in subjects (internal unpublished Halozyme report). Piroxicam 
(20 mg) will be administered at least 1-2 hours prior to PEGPH20 administration on the day of 
dosing (timing will be at the Investigator’s discretion based on the piroxicam manufacturer’s 
Prescribing Information and subject’s convenience), to minimize the severity of MSEs. The 
prophylactic use of a proton pump inhibitor is mandated for all subjects while receiving 
PEGPH20 (e.g. 20 mg omeprazole daily or over-the-counter [OTC] equivalent). 
Toradol may be given for severe pain as recommended in the Toradol Prescribing Information 
(Section 10.12.1). Toradol should not be administered concurrently with piroxicam as it is 
contraindicated in the Prescribing Information to administer toradol simultaneously with other 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 50 of 112 
06 November 2017  
nonsteroidal anti-inflammatory drugs (NSAIDs) because of the cumulative risk of inducing 
serious NSAID-related side effects. 
To help minimize MSEs, prescribed medication such as narcotics, muscle relaxants and other 
analgesics (with the exceptions of steroids), OTC drugs and physical therapy can be used at the 
Investigator’s discretion. 
All NSCLC subjects will be given enteric-coated 81 mg of prophylactic aspirin/day and all 
gastric adenocarcinoma subjects will be given prophylactic enoxaparin 40 mg/day (pre-filled 
syringes of enoxaparin are allowed), for prophylaxis of TE events, given the high incidence seen 
in these tumor types (Section 10.12.2). PEGPH20 will be discontinued for subjects who 
experience any TE requiring full-dose anticoagulation while on study. Treatment with 
pembrolizumab, however, may continue as deemed appropriate by the Investigator. 
In gastric adenocarcinoma subjects, if enoxaparin is discontinued for any reason, PEGPH20 will 
also be discontinued. Treatment with pembrolizumab, however, may continue as deemed 
appropriate by the Investigator. 
After discontinuing study treatment (PEGPH20 and pembrolizumab), subjects will have an End 
of Treatment Visit and will enter the long-term follow-up for survival. 
Subjects will be assessed for AEs and clinical laboratory evaluations as graded by the 
CTCAE v 4.03. 
In both portions of the study, tumor response and progression based on RECIST v 1.1 criteria 
(Eisenhauer 2009; Appendix C) and irRC (Nishino 2013; Nishino 2014; Appendix E) will be 
assessed by the Investigator at the end of Cycle 2, Cycle 4 and then at the end of every fourth 
treatment cycle thereafter (i.e., Week 3 of Cycles 2, 4, 8, 12, 16 and beyond). Scans may be 
obtained any time on or after Day 15 (of Cycles 2, 4, 8, 12, 16 and every fourth treatment cycle 
thereafter) to allow enough time for the scan to be reviewed locally prior to the subject’s next 
scheduled dosing visit. A confirmatory scan must be performed no sooner than 28 days after the 
initial scan that showed a response (PR or CR) based on RECIST v1.1 (to determine the best 
overall response) and irRC. A confirmatory scan should also be performed to confirm disease 
progression based on irRC no sooner than 28 days after the initial scan that showed progression. 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 51 of 112 
06 November 2017  
Figure 1: 
Study Design - Phase 1b Dose Escalation and Dose Expansion (HALO-107-101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: NSCLC = Non-Small Cell Lung Cancer; PEGPH20 = PEGylated Recombinant Human Hyaluronidase; DLT = dose-limiting toxicity;  
MTD = maximum tolerated dose; RP2D = recommended Phase 2 dose; PK = pharmacokinetic; ORR = objective response rate; HA = hyaluronan; 
DOR = duration of response; PFS = progression-free survival; OS = overall survival 
a In Dose Expansion, subjects will be selected for enrollment whose tumors are HA-high, using a co-developed investigational diagnostic assay. Subjects will be 
tested retrospectively for PD-L1 expression levels 
PEGPH20 (at the 
RP2D determined in 
the Dose Escalation 
portion) will be 
administered on Day 
1, Day 8 and Day 15 
of each cycle and 
pembrolizumab (200 
mg) will be 
administered on Day 
Approximately 
51 subjects 
(approximately 
30 subjects with 
Stage IIIB or Stage 
IV NSCLC and 
approximately 
21 subjects with 
relapsed/refractory 
gastric 
adenocarcinoma) 
will be enrolled
Dose escalation, 3+3 design, 
PEGPH20 will be 
administered to consecutive 
cohorts in increasing doses 
(1.6, 2.2, 2.6, 3.0,  
4.0 ug/kg) on Day 1, Day 8 
and Day 15 of each cycle 
(i.e. 3 doses/cycle), 4-6 
hours before the dose of 
pembrolizumab (2 mg/kg) 
administered on Day 1 of 
each cycle only (i.e. 1 
dose/cycle).  
Note: If ≥2 subjects 
experience a DLT at the 
1.6 µg/kg dose level within 
the first 21 days of 
Phase 1b Dose Escalation Portion (subjects 
with relapsed/refractory Stage IIIb or IV NSCLC 
and subjects with relapsed/refractory locally 
advanced or metastatic gastric 
adenocarcinoma) 
Phase 1b Dose Expansion Portion (HA-High, previously untreated or treated 
subjects with Stage IIIB or IV NSCLC and HA-High subjects with relapsed/refractory 
locally advanced or metastatic gastric adenocarcinomaa) 
Determine 
DLT, MTD, 
RP2D 
PEGPH20 
PK 
parameters, 
ORR, DOR, 
PFS, and OS 
21-Day Cycles 
21-Day Cycles 
Determine 
ORR, DOR, 
PFS, OS, 
PEGPH20 
PK 
parameters
, and safety 
and 
tolerability
Survival 
Follow-up 
(every


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 52 of 112 
06 November 2017  
6.1.1. 
Phase 1b Dose Escalation 
This portion of the study is a single-arm, dose escalation study of PEGPH20 in combination with 
pembrolizumab subjects with relapsed/refractory NSCLC after failing at least 1 previous 
platinum-based therapy (refer to Inclusion Criterion #2) and subjects with relapsed/refractory 
gastric adenocarcinoma after failing at least 1 previous chemotherapy regimen. Using a standard 
3+3 dose escalation design, approximately 3 to 6 subjects in each cohort will receive PEGPH20 
+ pembrolizumab. PEGPH20 will be administered on Day 1, Day 8 and Day 15 of each 21-day 
cycle to consecutive cohorts in increasing dose levels (1.6, 2.2, 2.6, 3.0, and 4.0 µg/kg). 
Pembrolizumab will be administered on Day 1 of each cycle, 4-6 hours after the dose of 
PEGPH20. If the MTD is not reached at 4.0 µg/kg, higher doses may be evaluated. If ≥2 subjects 
experience a DLT at the 1.6 µg/kg dose level, Cohort -1 will be opened and subjects will be 
dosed at 1.0 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle. The RP2D of PEGPH20 
will be the MTD determined in Dose Escalation or the Sponsor may decide to choose a dose 
lower than the MTD and which has completed evaluation in Dose Escalation and is found to be 
safe and tolerable to evaluate in Dose Expansion. 
The number of cohorts studied and number of subjects exposed to a given dose level will depend 
on the doses tested. It is anticipated that up to 5 dose levels will be studied for a total of 
approximately 30 subjects exposed to study medication. The dose allocation for 5 cohorts of 
subjects assigned to the 5 preselected dose levels and 1 cohort assigned to the preselected dose of 
1.0 µg/kg (if ≥2 subjects experience a DLT at 1.6 µg/kg dose level) is shown as an example in 
Table 4. The study medication dosing and treatment schedule are shown in Table 5. 
Safety data from all subjects dosed will be reviewed to determine the RP2D. Dose escalation will 
be guided by safety data from each subject during the 21 days following their first dose of 
PEGPH20. Intra-subject dose escalation to the next PEGPH20 dose studied may be allowed if 
the Investigator deems it in the best interest of the subject and after discussion with the Sponsor 
and provided the next PEGPH20 dose studied has been determined not to have exceeded the 
MTD. 
• If none of 3 subjects in a given cohort experience a DLT within 21 days of starting 
treatment, enrollment and dosing may proceed at the next planned dose level. 
• If 1 of 3 subjects at a given dose level experiences a DLT within the first 21 days of 
treatment, 3 additional subjects will be enrolled and dosed at the dose level at which 
the DLT occurred. If ≤1 of 6 subjects experience a DLT, dose escalation will continue 
to the next planned higher dose. 
• If ≥2 subjects at a given dose level experience a DLT within the first 21 days of 
treatment, that dose level will be considered to have exceeded the MTD and dose 
escalation will be stopped. If the previous dose level did not already have 6 subjects 
treated with ≤1 DLT, enrollment and dosing will then resume in the previous dose 
level with additional subjects up to a total of 6 subjects. The highest dose level at 
which no more than 1 of 6 evaluable subjects has experienced a DLT in the first 
3 weeks of treatment will be considered the MTD for the PEGPEM combination. The 
RP2D will be based on the overall safety profile. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 53 of 112 
06 November 2017  
• If ≥2 subjects at the 1.6 µg/kg dose level experience a DLT within the first 21 days of 
treatment, Cohort -1 will be opened at a lower dose level of 1.0 µg/kg. 
Note: Additional subjects may be enrolled in each cohort to further assess the tolerability of 
PEGPEM and determine an acceptable safety profile prior to the enrollment in the next dose 
level and expansion portion of the study.  
Definition of DLT 
DLTs will be assessed for each subject during the 21 days following their first PEGPH20 dose 
and will be defined as any of the following: 
• Any treatment-emergent Grade ≥3 toxicity that is considered related to either 
PEGPH20 or pembrolizumab or the combination of PEGPH20 and pembrolizumab 
(nausea, vomiting, musculoskeletal events and diarrhea will be considered DLTs only 
if they reach ≥ Grade 3 despite adequate supportive care measures). 
• Grade 3 MSEs are considered DLTs only if they do not reduce to ≤ Grade 2 within 
48 hours despite therapeutic intervention. 
• Hypersensitivity/infusion reactions related to PEGPH20 or pembrolizumab dosing 
will not be considered DLTs (hypersensitivity reactions are generally not related to 
the dose level of a drug since they can occur even upon a low level of exposure). 
To be considered evaluable for DLT assessment, subjects must receive 1 of the 3 full planned 
doses of PEGPH20 and 1 complete dose of pembrolizumab in Cycle 1. Subjects who experience 
a DLT within the first 21 days of treatment and withdraw from the study will be considered 
evaluable for DLT and will not be replaced. Subjects who withdraw within the first 21 days for 
reasons other than a DLT will be considered not evaluable and will be replaced. Any PEGPH20 
treatment-related AE that results in interruption or reduction of either drug (PEGPH20 or 
pembrolizumab) may be considered a DLT at the Investigator’s discretion. 
The Sponsor and the participating Investigators will meet as soon as practical, post completion of 
a cohort, and no more than 10 business days after the end of the last cohort to determine an 
acceptable dose for the Dose Expansion portion after reviewing all available safety data from 
Cycle 1 from all subjects in the Dose Escalation portion. 
Table 4: 
Dose Allocation and Cohort Schedule - Dose Escalation Portion 
Dose Level 
PEGPH20 µg/kg 
Pembrolizumab mg/kg 
-1 
1.0 
2 
1 
1.6 
2 
2 
2.2 
2 
3 
2.6 
2 
4 
3.0 
2 
5 
 4.0a 
2 
Abbreviations: PEGPH20 = PEGylated Recombinant Human Hyaluronidase. 
Note: Each treatment cycle is 21 days. Dose interruption and modifications are permitted. 
a If the MTD is not reached at 4.0 µg/kg, higher doses may be evaluated. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 54 of 112 
06 November 2017  
6.1.2. 
Phase 1b Dose Expansion 
Approximately 51 HA-high subjects will be studied in the Dose Expansion portion at the RP2D 
identified in the Dose Escalation portion: 
• Approximately 30 subjects with Stage IIIB or IV NSCLC, previously untreated or 
treated and having failed no more than 1 previous platinum-based chemotherapy 
(refer to Inclusion Criterion #3) 
• Approximately 21 subjects with relapsed/refractory gastric adenocarcinoma having 
failed no more than 2 previous chemotherapy regimens. 
The study medication dosing and treatment schedule are shown in Table 5. 
Table 5: 
Study Medication Dosing and Treatment Schedule - Dose Escalation and 
Dose Expansion 
Time point 
PEGPEM Treatment  
Subjects with NSCLC or Gastric Adenocarcinoma 
Cycle 1 and Beyond (Each Cycle 21 Days) 
Week 1 
Day 1 
PEGPH20 
Pembrolizumab (4-6 hours after PEGPH20) 
Week 2 
Day 8 
PEGPH20 
Week 3 
Day 15 
PEGPH20 
Abbreviations: PEGPEM = PEGPH20 in combination with pembrolizumab; PEGPH20 = PEGylated Recombinant 
Human Hyaluronidase; NSCLC = non-small cell lung cancer. 
Notes: Dose interruption and modifications are permitted; refer to Section 8.3 for further guidance. 
Visit window is ±2 days of the specified times. 
6.1.3. 
Study Duration 
The study will consist of a Screening period of up to 28 days, a treatment period (21-day cycles), 
a 30-day post-treatment period (after last dose) for collection of AEs and a long-term follow-up. 
Subjects will be allowed to continue treatment on study until disease progression (as defined in 
Section 6.1.4) or unacceptable toxicity. Subjects with asymptomatic disease progression 
however, will be allowed to continue the study treatment at the Investigator’s discretion despite 
evidence of increasing tumor burden or appearance of new lesions for up to 6 weeks if the 
subject is clinically stable. 
Investigators may also discontinue study treatment if it is no longer in the best interest of the 
subject. Subjects who discontinue treatment with PEGPH20 and pembrolizumab will be 
followed every 12 weeks for survival until death, withdrawal of consent, or lost to follow-up. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 55 of 112 
06 November 2017  
6.1.4. 
Disease Progression 
Disease progression will be defined as presence of 1 or both of the following: 
Disease progression documented by CT scan/MRI scan based on RECIST v1.1 
(Eisenhauer 2009; Appendix C) as determined by the Investigator. 
Clinical tumor-related progression that is well documented in the absence of scans demonstrating 
radiographic disease progression. 
Radiographic disease progression is based on the analysis of CT/MRI scans by the Investigator. 
Investigators should continue study treatment until disease progression (not including 
asymptomatic disease progression in clinically stable subjects [see Section 6.1 for definition of 
clinically stable]) has occurred, but may discontinue study treatment if there is documented 
clinical disease progression and/or unacceptable toxicity and/or study treatment is no longer in 
the best interest of the subject. Subjects who discontinue treatment with PEGPH20 and 
pembrolizumab will be followed every 12 weeks for survival until death, withdrawal of consent, 
or lost to follow-up. 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS AND STUDY 
TERMINATION 
The Dose Escalation portion of the study will enroll subjects with relapsed/refractory Stage IIIB 
or IV NSCLC after failing at least 1 previous platinum-based chemotherapy regimen (refer to 
Inclusion Criterion #2) and subjects with relapsed/refractory locally advanced or metastatic 
gastric adenocarcinoma after failing at least 1 previous chemotherapy regimen for locally 
advanced or metastatic disease. 
The Dose Expansion portion of the study will enroll:  
• HA-high subjects with Stage IIIB or IV NSCLC, previously untreated or treated and 
having failed no more than 1 previous platinum-based chemotherapy (refer to Inclusion 
Criterion #3), who have tissue available for HA-selection and PD-L1 testing 
and 
• HA-high subjects with relapsed/refractory locally advanced or metastatic gastric 
adenocarcinoma having failed no more than 2 previous chemotherapy regimens for locally 
advanced or metastatic disease, who have tissue available for HA-selection and PD-L1 
testing. 
7.1. 
Inclusion Criteria 
For both portions of the study (unless otherwise specified), subjects must satisfy all of the 
following inclusion criteria to be enrolled in the study: 
1. Written Institutional Review Board (IRB)/Ethics Committee (EC) -approved Informed 
Consent form (ICF), signed by subject or legally authorized representative. 
2. Dose Escalation portion - Histologically confirmed and documented, previously treated 
stage IIIB or IV NSCLC having failed at least 1 previous platinum-based chemotherapy 
regimen for locally advanced or metastatic disease, or relapsed/refractory locally 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 56 of 112 
06 November 2017  
advanced or metastatic gastric adenocarcinoma having failed at least 1 previous 
chemotherapy regimen for locally advanced or metastatic disease. Subjects with NSCLC 
who are known to be epidermal growth factor receptor (EGFR)-mutation positive must 
have received an EGFR inhibitor and subjects known to be anaplastic lymphoma kinase 
(ALK)-mutation positive must have received an ALK inhibitor (subject’s documented 
EGFR/ALK mutation status and/or confirmation reports/molecular pathology/analysis 
reports should be included in the subject’s medical records and made available for 
Sponsor/Sponsor representative[s] review).  
a. Subjects with gastroesophageal junction (GEJ) tumors are eligible. 
b. For subjects with either NSCLC or gastric cancer, prior treatment administered in the 
adjuvant setting is permitted provided it was administered at least 6 months prior to 
first-line therapy for metastatic disease. 
c. For subjects with NSCLC, prior first-line treatment with bevacizumab (AVASTIN®) 
or biosimilars is allowed. 
d. For subjects with NSCLC, prior maintenance treatment with bevacizumab, 
pemetrexed (ALIMTA®), or erlotinib (TARCEVA®) is allowed. 
e. For subjects with human epidermal growth factor receptor 2 positive (HER2+) gastric 
cancer, prior treatment with trastuzumab (HERCEPTIN®) is required (subject’s 
documented HER2 status and/or confirmation reports/molecular pathology/analysis 
reports should be included in the subject’s medical records and made available for 
Sponsor/Sponsor representative[s] review). 
3. Dose Expansion portion - NSCLC subjects: Histologically confirmed and documented, 
previously untreated or treated stage IIIB or IV NSCLC. Previously treated subjects must 
have failed no more than 1 previous platinum-based chemotherapy regimen for locally 
advanced or metastatic disease. Previously treated subjects with NSCLC who are known 
to be EGFR-mutation positive must have received an EGFR inhibitor and subjects who 
are known to be ALK-mutation positive must have received an ALK inhibitor (subject’s 
documented EGFR/ALK mutation status and/or confirmation reports/molecular 
pathology/analysis reports should be included in the subject’s medical records and made 
available for Sponsor/Sponsor representative[s] review). Gastric adenocarcinoma 
subjects: histologically confirmed and documented previously treated relapsed/refractory 
locally advanced or metastatic gastric adenocarcinoma having failed no more than 2 
previous chemotherapy regimens for locally advanced or metastatic disease.  
a. Subjects with GEJ tumors are eligible. 
b. For subjects with either NSCLC or gastric cancer, prior treatment administered in the 
adjuvant setting is permitted provided it was administered at least 6 months prior to 
first-line therapy for metastatic disease. 
c. For previously treated subjects with NSCLC, prior treatment with or without 
bevacizumab (AVASTIN®) or bevacizumab biosimilars is allowed. 
d. For previously treated subjects with NSCLC, prior maintenance treatment with 
bevacizumab, pemetrexed (ALIMTA®), or erlotinib (TARCEVA®) is allowed.  
e. For subjects with HER2+ gastric cancer, prior treatment with trastuzumab 
(HERCEPTIN®) is required (subject’s documented HER2 status and/or confirmation 
reports/molecular pathology/analysis reports should be included in the subject’s 
medical records and made available for Sponsor/Sponsor representative[s] review). 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 57 of 112 
06 November 2017  
4. Prior to enrollment, confirmation of the following must be obtained: 
a. Dose Escalation portion - Available tumor tissue in a formalin-fixed  
paraffin-embedded (FFPE) block or 5-10 unstained consecutive core biopsy slides 
from 1 tumor tissue block that meet specific tissue sample requirements are preferred 
but not mandatory for enrollment in this portion of the study. Note: Fine needle 
aspirates or brushing biopsies will not be acceptable. 
b. Dose Expansion portion - Available tumor tissue in FFPE block or 10-15 unstained 
consecutive tumor tissue slides from 1 tumor tissue block that meet specific tissue 
sample requirements are mandatory. Note: Fine needle aspirates or brushing biopsies 
will not be acceptable. Archived resection specimens from the primary tumor without 
radiologic evidence of metastasis at the time of resection are not suitable to establish 
histological confirmation and require new tumor tissue of a metastatic site. 
5. To be eligible for the Dose Escalation portion, subjects need only have evaluable disease 
(details in Section 8.2.15); to be eligible for the Dose Expansion portion, subjects must 
have measurable disease per RECIST v1.1. Previously irradiated tumors may be eligible 
if they have clearly progressed in size. 
6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 
(Appendix B). 
7. Life expectancy ≥3 months. 
8. Males and females aged ≥18 years. 
9. Resolution of all acute toxic effects of prior therapy or surgery to baseline. 
10. Screening clinical laboratory values are as follows: 
a. Total and indirect bilirubin ≤1.5 × upper limit of normal (ULN), except for Gilbert’s 
syndrome 
b. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase (ALP) ≤2.5 × ULN (<5 × ULN is allowed if liver metastases are present) 
c. Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥40 mL/min 
d. Serum albumin ≥3.0 g/dL 
e. Hemoglobin ≥10 g/dL (transfusion and erythropoietic agents allowed) 
f. Absolute neutrophil count ≥1500 cells/mm3 
g. Platelet count ≥100,000/mm3 
11. Female participants of childbearing potential (WOCBP) must have a negative urine or 
serum pregnancy test within 7 days before Day 1 (first dose of study medication). 
12. For WOCBP and for men, agreement to use an effective contraceptive method from the 
time of screening throughout the study until 4 months (WOCBP) or 3 months (men) after 
administration of the last dose of any study medication. Highly effective contraceptive 
methods consist of prior sterilization, intrauterine device (IUD), intrauterine hormone 
releasing system (IUS), oral or injectable contraceptives, and/or barrier methods. 
Abstinence alone is not considered an adequate contraceptive measure for the purposes of 
this study. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 58 of 112 
06 November 2017  
13. Subjects must also satisfy the following inclusion criterion to be enrolled in the Dose 
Expansion portion of the study: 
a. Subjects (NSCLC and gastric adenocarcinoma) must be determined to have HA-high 
levels from their tumor biopsies. Tumor samples must meet the requirements noted in 
the Inclusion Criterion #4. 
b. NSCLC and gastric adenocarcinoma subjects must have tissue available for  
HA-selection and PD-L1 testing. Tumor samples must meet the requirements noted in 
the Inclusion Criterion #4. 
7.2. 
Exclusion Criteria 
Subjects are ineligible for enrollment if they meet any of the following exclusion criteria.  
1. Previous treatment with pembrolizumab, nivolumab, or other anti-PD-1 or anti-PD-L1 
agents. 
2. New York Heart Association Class III or IV (Appendix D) cardiac disease or myocardial 
infarction within the past 12 months before screening, or preexisting atrial fibrillation. 
3. History of cerebrovascular accident or transient ischemic attack. 
4. NSCLC subjects with known brain metastases (exception below) 
a. Subjects with treated brain metastases who meet all of the following criteria are 
eligible: 
i. Stable brain metastases for at least 1 month,  
ii. No evidence of progression or hemorrhage after treatment, 
iii. No ongoing requirement for corticosteroids. 
5. Gastric adenocarcinoma subjects with brain metastases. 
6. History of active bleeding within the last 3 months requiring transfusion. 
7. Anti-angiogenic therapy within the last month. 
8. Subjects with known interstitial fibrosis or interstitial lung disease. 
9. History of pulmonary embolism or pulmonary embolism found on screening exam. 
10. Pre-existing carotid artery disease. 
11. History of DVT with contraindications to pharmacologic anticoagulation. 
12. History of: 
a. Pneumonitis that requires oral or IV steroids; 
b. Or known cases of hepatobiliary diseases (e.g., primary biliary cholangitis, primary 
sclerosing cholangitis, history of immune-mediated cholangitis); 
i. Subjects with cholangitis attributed to infectious etiology (e.g., ascending 
cholangitis, bacterial cholangitis) are eligible if the infection has been fully 
resolved prior to the screening visit. 
c. Or known cases of drug-induced hepatobiliary toxicities. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 59 of 112 
06 November 2017  
13. NSCLC subjects with hypersensitivity to aspirin. 
14. Gastric adenocarcinoma subjects with contraindications to enoxaparin. 
15. Autoimmune diseases: 
a. Active autoimmune disease requiring systemic treatment within the past 3 months  
b. Documented history of clinically severe autoimmune disease (e.g., colitis, Crohn’s 
disease)* 
16. Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. 
17. Known infection with human immunodeficiency virus, active infection with hepatitis B, 
or hepatitis C. 
18. Known allergy to hyaluronidase. 
19. Hypersensitivity to the active substance or ingredients of PEGPH20 and pembrolizumab. 
20. Known allergy to piroxicam or other NSAIDs. 
21. Current use of megestrol acetate (within 10 days of Day 1). 
22. Chronic use of steroids for pain or emesis management. 
23. Women currently pregnant or breastfeeding. 
24. History of another primary cancer within the last 3 years that required treatment, with the 
exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated 
cervical carcinoma in situ. 
25. Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that lead to reasonable suspicion of a disease or condition that 
contraindicates the use of an investigational drug, may affect the interpretation of the 
results, or may render the subject at high risk for treatment complications. 
26. Subject inability to comply with study and follow-up procedures, as judged by the 
Investigator. 
*Any relevant diseases that are not listed as examples of exclusionary diseases are to be 
discussed with the Sponsor. 
7.3. 
Subject Withdrawal Criteria 
7.3.1. 
Discontinuation of Treatment 
The Investigator must guard the subject’s welfare and may discontinue study drug treatment at 
any time when this action appears to be in the subject’s best interest. The reason for the subject’s 
withdrawal must be recorded in the subject’s electronic case report form (eCRF). Possible 
reasons for such actions may include, but are not limited to, the following: 
• Disease progression (defined in Section 6.1.4). 
• AE. 
• Any significant protocol violation (e.g., demonstrated lack of treatment compliance, 
subject starts taking any concomitant anti-cancer therapy). 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 60 of 112 
06 November 2017  
• Withdrawal of consent by an enrolled subject, either for study treatment itself (and 
subsequent follow-up) or for participation in follow-up. 
• Other reasons as determined by the Investigator or Sponsor: a subject may have study 
treatment discontinued if, in the opinion of the Investigator or Sponsor, it is not in the 
subject’s best interest to continue. 
• The subject becomes pregnant (treatment must be discontinued immediately). 
• Treatment delay ≥21 days. 
• Subjects experiencing any TE event that requires full-dose anticoagulation while on 
study (PEGPH20 will be discontinued; treatment with pembrolizumab may continue 
as deemed appropriate by the Investigator). 
• Gastric adenocarcinoma subjects for whom enoxaparin is discontinued for any reason 
(PEGPH20 will be discontinued; treatment with pembrolizumab may continue as 
deemed appropriate by the Investigator). 
Subjects who discontinue treatment with PEGPH20 and pembrolizumab should enter long-term 
follow-up unless they withdraw consent, die, or are lost to follow-up. 
7.3.2. 
Discontinuation from Study 
After discontinuing study treatment (PEGPH20 and pembrolizumab treatment), the subject will 
enter long-term follow-up for assessment of survival and subsequent anti-cancer therapies 
(Section 8.1.2.4). Long-term follow-up will continue until the subject discontinues from the 
study. The reason for the subject’s discontinuation from the study should be documented in the 
subject’s eCRF. Possible reasons for study discontinuation include the following: 
• Death. 
• Withdrawal of consent. 
• Lost to follow-up. 
• Sponsor termination of the study. 
• Other. 
7.4. 
Sponsor Study Stopping Rules 
Halozyme may terminate this study after informing Investigators at any time. Investigators will 
be notified by Halozyme (or designee) if the study is placed on hold, completed, or closed. 
Conditions that may warrant termination of the study include but are not limited to the following: 
• The discovery of unexpected, serious, or unacceptable risk to the subjects in the 
study. 
• A decision on the part of the Sponsor to suspend or discontinue testing, evaluation, or 
development of the product. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 61 of 112 
06 November 2017  
8. 
STUDY PROCEDURES AND ASSESSMENTS 
Study procedures for each portion of the study are provided in the tables in Section 3. This 
section describes evaluations to be done before, during, and after treatment. Section 8.2 provides 
information on individual study assessments. 
When duplicate evaluations are performed before study commencement, the data from the 
evaluation closest in time to study entry will be recorded. When duplicate evaluations are 
performed in a given time window, the worst case value will be recorded for safety evaluations, 
unless otherwise stipulated. Unless otherwise specified, clinical laboratory tests may be 
performed 1 day earlier than specified in the relevant Study Schedule of Events. 
Scheduled clinic attendance should occur within ±2 days of the specified dates, as long as doses 
are separated by the appropriate amount of time. Where this is not possible because of 
extenuating circumstances (e.g., holidays), the reason should be noted and the doses should be 
separated by at least 45 hours. 
8.1. 
Study Procedures by Visit 
8.1.1. 
Screening  
If the following procedures were done as per the standard of care prior to the subject signing the 
ICF, the results may be used for this study provided they were within the screening window 
(≤28 days before Day 1): physical examination, vital sign measurements, height, weight and 
CT/MRI scan. 
Note: Plasma samples are required for PEGPH20 PK, hyaluronan, biomarker, and PEGPH20 
immunogenicity analysis; serum samples are required for pembrolizumab PK analysis. All 
subjects will be monitored for study procedure-associated serious adverse events (SAEs) starting 
from the time of ICF signature as described in Section 10.2. 
8.1.1.1. 
Within 28 Days Prior to Day 1 (Unless Otherwise Indicated) 
• Sign and date prescreening ICF for HA testing in Dose Expansion (if applicable, [See 
Section 8.2.1.1]). 
• Sign and date ICF. 
• Register subjects into an Interactive Web Response System [IWRS] for screening/ 
prescreening (if conducted in Dose Expansion). 
• Confirm availability of and retrieve tumor tissue (refer to Inclusion Criterion #4 for 
more details). Tumor tissue must be sent to central laboratory to assess HA status for 
eligibility into the Dose Expansion portion of the study. 
• Obtain CT/MRI scan for disease assessment and eligibility review and send to Central 
Imaging Vendor (CIV) for storage. 
• Obtain CT/MRI brain scan to assess potential CNS disease and/or metastases. 
• Review inclusion/exclusion criteria. 
• Collect medical and prior medication history. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 62 of 112 
06 November 2017  
• Optional (at selected sites only): Perform PET/CT scan and DCE-MRI. DCE-MRI 
scans must be obtained within 14 days prior to Day 1 (first dose of study medication). 
• Perform the following assessments: 12-lead ECG, physical examination, vital signs, 
ECOG Performance Status, height, weight, and urine or serum pregnancy test within 
7 days before Day 1 (first dose of study medication) (WOCBP; local laboratory). 
• Obtain samples for the following tests and send to the central laboratory: plasma 
samples for HA level and exploratory biomarkers, thyroid hormones, hematology, 
blood chemistry (including glucose), urinalysis, coagulation. 
8.1.2. 
Treatment Period 
AEs and concomitant medications will be obtained throughout the study and at every visit. 
8.1.2.1. 
Treatment Cycle 1 
8.1.2.1.1. Cycle 1 Day 1 
Before PEGPH20 and Pembrolizumab Infusion 
• Confirm subjects’ eligibility based on inclusion and exclusion criteria. 
• Perform the following assessments: vital signs, ECOG Performance Status and 
weight. 
• Obtain blood samples for the following tests and send to the central laboratory: 
− Hematology, blood chemistry (including glucose) and coagulation. NOTE: 
Measurements of total bilirubin, ALP, AST, and ALT (as part of blood chemistry) 
must be obtained prior to dosing (within 48 hours is acceptable). Local 
laboratories may be used for these measurements. Dosing can only take place if 
total bilirubin, ALP, AST and ALT values are within the ranges specified in the 
Inclusion Criteria.  
− Immunogenicity. 
− PEGPH20 PK, plasma HA, and exploratory biomarkers within 2 hours prior to 
PEGPH20 dosing (as specified in Table 3) (actual collection times to be 
recorded). 
− Pembrolizumab PK within 2 hours prior to dosing (as specified in Table 3) (actual 
collection times to be recorded). 
• Administer piroxicam (20 mg) at least 1-2 hours prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information and subject’s convenience) to 
minimize the severity of MSEs. Prophylactic use of a proton pump inhibitor is 
mandated for all subjects while receiving PEGPH20 (e.g. 20 mg omeprazole daily or 
OTC equivalent). 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 63 of 112 
06 November 2017  
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 
PEGPH20 and Pembrolizumab Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
• Pembrolizumab IV infusion over 30 minutes, 4-6 hours after completion of PEGPH20 
infusion. 
After PEGPH20 and Pembrolizumab Infusion 
• Obtain blood samples for the following tests and send to the central laboratory: 
− PEGPH20 PK 15 minutes (±5 minutes), 1 hour (±15 minutes), 2-4 hours and  
6-8 hours after PEGPH20 infusion (as specified in Table 3) (actual collection 
times to be recorded). 
− Plasma HA and exploratory biomarkers 2-4 hours and 6-8 hours after PEGPH20 
infusion (as specified in Table 3) (actual collection times to be recorded). 
− Pembrolizumab PK after 2 hours of dosing (as specified in Table 3) (actual 
collection times to be recorded). 
8.1.2.1.2. Cycle 1 Day 2 
• Optional at selected sites only: Perform DCE-MRI 24 hours after PEGPH20 infusion. 
• Obtain blood samples for the following tests and send to the central laboratory: 
− PEGPH20 PK, Plasma HA, and exploratory biomarkers 24-26 hours after 
PEGPH20 infusion (as specified in Table 3) (actual collection times to be 
recorded). 
− PEGPH20 PK 28-32 hours after PEGPH20 infusion (as specified in Table 3) 
(actual collection times to be recorded). 
− Pembrolizumab PK 24-28 hours after pembrolizumab infusion (as specified in 
Table 3) (actual collection times to be recorded). 
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 
8.1.2.1.3. Cycle 1 Day 8 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain a hematology blood sample and send to the central laboratory. 
• Obtain a blood sample for blood chemistry and send to the central laboratory. NOTE: 
Measurements of total bilirubin, ALP, AST, and ALT (as part of blood chemistry) 
must be obtained prior to dosing (within 48 hours is acceptable). Local laboratories 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 64 of 112 
06 November 2017  
may be used for these measurements. Dosing can only take place if total bilirubin, 
ALP, AST and ALT values are within the ranges specified in the Inclusion Criteria. 
• Administer piroxicam (20 mg) within at least 1-2 hours prior to the start of the 
PEGPH20 infusion on the day of dosing (timing will be at the Investigator’s 
discretion based on the piroxicam manufacturer’s Prescribing Information and 
subject’s convenience) to minimize the severity of MSEs. The prophylactic use of a 
proton pump inhibitor is mandated for all subjects while receiving PEGPH20 (e.g. 
20 mg omeprazole daily or OTC equivalent). 
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 
PEGPH20 Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.1.4. Cycle 1 Day 15 
Before PEGPH20 Infusion 
• Assess vital signs.  
• Obtain a hematology blood sample and send to the central laboratory.  
• Obtain a blood sample for blood chemistry and send to the central laboratory. NOTE: 
Measurements of total bilirubin, ALP, AST, and ALT (as part of blood chemistry) 
must be obtained prior to dosing (within 48 hours is acceptable). Local laboratories 
may be used for these measurements. Dosing can only take place if total bilirubin, 
ALP, AST and ALT values are within the ranges specified in the Inclusion Criteria. 
• Administer piroxicam (20 mg) at least 1-2 hours prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information and subject’s convenience) to 
minimize the severity of MSEs. The prophylactic use of a proton pump inhibitor is 
mandated for all subjects while receiving PEGPH20 (e.g. 20 mg omeprazole daily or 
OTC equivalent). 
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 
PEGPH20 Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.1.5. Cycle 1 Day 18 
• Optional selected sites only: Perform DCE-MRI and PET/CT scan. 
• Perform optional post-dose tumor biopsy at the end of Cycle 1 (on or after Day 18 
PEGPH20 dose) but prior to 1st PEGPH20 dose in Cycle 2. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 65 of 112 
06 November 2017  
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 
8.1.2.2. 
Treatment Cycle 2 and Beyond (Repeats Every 3 weeks)  
8.1.2.2.1. Cycle 2 and Beyond, Day 1 
Before PEGPH20 and Pembrolizumab Infusion 
• Perform the following assessments: vital signs, ECOG Performance Status and 
weight.  
• Obtain blood samples for the following tests and send to the central laboratory: 
− Hematology, blood chemistry (including glucose), coagulation. NOTE for Cycle 2 
only: Measurements of total bilirubin, ALP, AST, and ALT (as part of blood 
chemistry) must be obtained prior to dosing (within 48 hours is acceptable). Local 
laboratories may be used for these measurements. Dosing can only take place if 
total bilirubin, ALP, AST and ALT values are within the ranges specified in the 
Inclusion Criteria. If a subject has any of these values outside the specified ranges 
on Day 1 of Cycle 2, the Investigator should discuss further dosing plans for the 
subject with the Sponsor. 
− Immunogenicity. 
− Thyroid hormones (to be collected every third cycle thereafter (i.e., Day 1 of 
Cycles 2, 5, 8, 11, 14, 17, 20, etc.). 
− Plasma HA and exploratory biomarkers within 2 hours prior to PEGPH20 dosing 
(as specified in Table 3) (actual collection times to be recorded). 
− Pembrolizumab PK within 2 hours prior to dosing (as specified in Table 3) (actual 
collection times to be recorded). 
• Urine/serum pregnancy test (WOCBP; local laboratory). 
• Administer piroxicam (20 mg) at least 1-2 hours prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information and subject’s convenience) to 
minimize the severity of MSEs. The prophylactic use of a proton pump inhibitor is 
mandated for all subjects while receiving PEGPH20 (e.g. 20 mg omeprazole daily or 
OTC equivalent). 
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 66 of 112 
06 November 2017  
PEGPH20 and Pembrolizumab Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
• Pembrolizumab IV infusion over 30 minutes, 4-6 hours after completion of PEGPH20 
infusion. 
After PEGPH20 and Pembrolizumab Infusion 
• Obtain blood samples for the following tests and send to the central laboratory: 
− PEGPH20 PK 15 minutes (±5 minutes), 6-8 hours after PEGPH20 infusion (as 
specified in Table 3) (actual collection times to be recorded). 
− Pembrolizumab PK 0-2 hours after PEM dose (as specified in Table 3) (actual 
collection times to be recorded). 
8.1.2.2.2. Cycle 2 and Beyond, Day 2 
• Obtain blood samples for the following tests and send to the central laboratory: 
− PEGPH20 PK samples 24-26 hours after PEGPH20 infusion (as specified in 
Table 3) (actual collection times to be recorded). 
− PEGPH20 PK samples 28-32 hours after PEGPH20 infusion (as specified in 
Table 3) (actual collection times to be recorded). 
− Pembrolizumab PK samples 24-28 hours after PEGPH20 infusion (as specified in 
Table 3) (actual collection times to be recorded). 
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 
8.1.2.2.3. Cycle 2 and Beyond Day 8 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain blood sample for testing of glucose and send to the central laboratory. 
• Obtain a hematology blood sample and send to the central laboratory. 
• Administer piroxicam (20 mg) at least 1-2 hours prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information and subject’s convenience) to 
minimize the severity of MSEs. The prophylactic use of a proton pump inhibitor is 
mandated for all subjects while receiving PEGPH20 (e.g. 20 mg omeprazole daily or 
OTC equivalent). 
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 67 of 112 
06 November 2017  
8.1.2.2.4. Cycle 2 and Beyond Day 15 
Before PEGPH20 Infusion 
• Assess vital signs.  
• Obtain a blood sample for testing of glucose and send to the central laboratory. 
• Obtain a hematology blood sample and send to the central laboratory. 
• Administer piroxicam (20 mg) at least 1-2 hours prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information and subject’s convenience) to 
minimize the severity of MSEs. The prophylactic use of a proton pump inhibitor is 
mandated for all subjects while receiving PEGPH20 (e.g. 20 mg omeprazole daily or 
OTC equivalent). 
• Administer enteric-coated 81 mg of aspirin to all NSCLC subjects and 40 mg of 
enoxaparin (pre-filled syringes of enoxaparin are allowed) to all gastric 
adenocarcinoma subjects. 
PEGPH20 Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
After PEGPH20 Infusion 
• Optional at selected sites in Cycle 2 only: Perform PET/CT. The CIV will analyze 
PET/CT scans if they are conducted. 
PEGPH20 Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.5. Selected Cycles from Cycle 2 Onwards, Day 15 
• Obtain CT/MRI scans for tumor assessment (based on RECIST v1.1 and irRC) at the 
end of Cycles 2, 4, and then at the end of every fourth cycle thereafter (i.e., Week 3 of 
Cycles 2, 4, 8, 12, 16 and beyond). Scans may be obtained any time on or after 
Day 15 (of Cycles 2, 4, 8, 12, 16 and every fourth treatment cycle thereafter) to allow 
enough time for the scan to be reviewed locally prior to the subject’s next scheduled 
dosing visit. The results should be interpreted before dosing in the next cycle begins. 
For subjects who are withdrawn from the study due to clinical disease progression, a 
CT/MRI scan should be requested as soon as possible after clinical progression is 
determined. 
Note: A confirmatory scan should be performed no sooner than 28 days if the initial 
scan showed a response (PR or CR) based on RECIST v1.1 and irRC. A confirmatory 
scan should also be performed to confirm disease progression based on irRC no 
sooner than 28 days after the initial scan that showed progression. 
• For the duration of the study, post-baseline, CT/MRI of the brain will be performed if 
clinically indicated, and within a target of 1 week after a subject achieves a CR. For 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 68 of 112 
06 November 2017  
NSCLC subjects with a history of treated brain metastases, brain scans will be 
performed at tumor assessment time points. 
8.1.2.3. 
End of Treatment Visit 
The End of Treatment Visit procedures described below will be the same for all subjects, 
regardless of phase. Subjects should return to the study site for an End of Treatment Visit within 
approximately 7 days after determination of disease progression or within 7 days after treatment 
discontinuation of PEGPH20 and pembrolizumab for other reasons. AEs and concomitant 
medications will be obtained and the following procedures should be performed: 
• Perform the following assessments: physical examination including vital signs, 
ECOG Performance Status and 12-lead ECG. 
• Obtain CT/MRI scan and send to CIV for storage (CT/MRI should only be done if 
radiographic disease progression was not documented in the previous CT/MRI scan). 
• Obtain samples for the following tests and send to the central laboratory: hematology, 
blood chemistry and coagulation. 
• Obtain sample for immunogenicity testing and send to the central laboratory. 
8.1.2.4. 
Long-Term Follow-Up 
After the End of Treatment Visit, all subjects will enter long-term follow-up during which 
information on the subject’s survival status and subsequent anti-cancer therapies (i.e., therapies 
received, responses) will be obtained by the site once every 12 weeks. Long-term follow-up will 
continue until the subject dies, is lost to follow-up, or withdraws consent. 
8.1.3. 
Procedures for Study Treatment Discontinuation 
In the event of study treatment discontinuation, the subject should be instructed to report to the 
clinic as early as possible after the decision to discontinue study treatment has been made or for 
the next scheduled clinic visit. When the subject returns to the clinic, all End of Treatment 
procedures should be conducted (see Section 8.1.2.3). The Investigator will make his or her best 
efforts to perform these procedures. 
8.2. 
Study Assessments 
8.2.1. 
Informed Consent 
The Investigator or designee must present and explain the study protocol to prospective study 
subjects before screening. The Investigator or designee must be available to answer any 
questions the subject may have regarding the study protocol and procedures. The Investigator or 
designee must explain that the subject is not obliged to enter the study and is free to withdraw 
from it at any time for any reason. If new safety information becomes available and results in 
significant changes in risk/benefit assessment, the ICF should be reviewed and updated if 
necessary. Under this circumstance, all subjects, including those already being treated, should be 
given the new information, given a copy of the revised ICF, and allowed to re-evaluate their 
consent to continue in the study. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 69 of 112 
06 November 2017  
A copy of the signed and dated ICF will be provided to the subject. The original ICF will be 
retained by the Investigator. 
8.2.1.1. 
Prescreening Informed Consent in Dose Expansion  
In accordance with local policies and institutional guidelines, subjects may provide consent for 
their tumor tissue to undergo HA testing on a separate, prescreening ICF. Note: If the subject 
provides consent to participate in the study and undergoes the remaining screening procedures, 
the 28-day screening window will begin when the subject signs the study ICF (i.e., signature on a 
prescreening ICF does not initiate the screening window). 
8.2.2. 
Inclusion/Exclusion Criteria 
The inclusion/exclusion criteria (Sections 7.1 and 7.2) must be reviewed at screening to ensure 
that the subject qualifies for the study. Subjects may be enrolled into the study if all selection 
criteria are met.  
8.2.3. 
Medical History  
A complete medical history (significant past and ongoing conditions), tobacco/nicotine usage 
history and demographic information will be obtained at screening. Previous history of 
allergies/allergic reactions (e.g., allergy to bee stings, anaphylaxis, etc.) should also be captured 
on the Medical History eCRF page. 
8.2.4. 
Concomitant Medications 
Information regarding collection of concomitant medications is provided in Section 10.12. 
8.2.5. 
Adverse Events 
AEs will be collected as defined in Section 10. 
8.2.6. 
Physical Examination 
Physical examination, including head/ears/eyes/nose/throat, respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, central and peripheral nervous system, and dermatologic 
assessments, will be performed when required by protocol. 
8.2.7. 
Height and Weight 
Height will be recorded in cm, and weight will be recorded in kg. 
8.2.8. 
ECOG Performance Status 
The subject’s ECOG Performance Status will be assessed (see Appendix B). 
8.2.9. 
Vital Signs 
Assessment of vital signs includes the measurement of blood pressure (systolic and diastolic), 
pulse, respiratory rate, and body temperature. Blood pressure and pulse will be measured with 
the subject at rest and in a sitting position for at least 5 minutes. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 70 of 112 
06 November 2017  
8.2.10. 
12-lead ECG 
ECGs including clinical significance will be evaluated by the Investigator and recorded in the 
eCRF. 
8.2.11. 
Hematology, Blood Chemistry, Glucose, Thyroid Hormones, Coagulation 
Parameters, and Urinalysis 
Hematology, blood chemistry, blood glucose, thyroid hormones, coagulation parameters, and 
urinalysis will all be analyzed by the central laboratory. In addition, local laboratories may be 
used if immediate clinical decision making is required (e.g., for measurement of liver function, 
including total bilirubin, ALP, AST and ALT prior to dosing [within 48 hours is acceptable] 
during Cycle 1 through Day 1 of Cycle 2 [Table 2 and Section 8.1.2]). For study analysis and 
reporting purposes, only values derived from the central laboratories will be utilized. The 
Investigator must evaluate all results outside the reference range and determine the clinical 
significance (clinically significant or not clinically significant). 
• Hematology: hemoglobin, hematocrit, red blood cell count, white blood cell (WBC) 
count, neutrophils (ANC), lymphocytes (absolute), monocytes (absolute), eosinophils 
(absolute), basophils (absolute), granulocytes (absolute), mean corpuscular 
hemoglobin, mean corpuscular volume, and platelet count. 
• Blood chemistry: glucose, blood urea nitrogen (BUN), albumin, total bilirubin, 
alkaline phosphatase, AST, ALT, electrolytes (including sodium, potassium, calcium, 
magnesium, chloride, and bicarbonate), and creatinine. 
• Since the pembrolizumab Prescribing Information (Keytruda® US Prescribing 
Information 2017) advises monitoring of patients for hyperglycemia or other signs 
and symptoms of diabetes, blood glucose will be monitored throughout the study as 
either part of the chemistry panel or as a single assessment (see Schedule of Events 
Table 1 and Table 2). 
• Since the pembrolizumab Prescribing Information (Keytruda® US Prescribing 
Information 2017) advises monitoring of patients for changes in thyroid function at 
the start of treatment and periodically during treatment, the thyroid hormones free 
triiodothyronine (T3); free total thyroxine (T4), and thyroid stimulating hormone 
(TSH) will be monitored throughout the study (see Schedule of Events Table 1 and 
Table 2). 
• Coagulation: international normalized ratio (INR), prothrombin time (PT), and partial 
thromboplastin time (PTT). 
• Urinalysis: protein, glucose, ketones, blood, specific gravity, nitrite, pH, and 
leukocytes. 
8.2.12. 
Pregnancy Test 
A serum or urine human chorionic gonadotropin test to determine whether a female subject is 
pregnant should be collected for all WOCBP. A woman is considered of childbearing potential, 
i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. 
A postmenopausal state is defined as no menses for 12 months without an alternative medical 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 71 of 112 
06 November 2017  
cause. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and 
bilateral oophorectomy. The pregnancy test will be done by the local laboratory within 7 days 
before Day 1 (first dose of study medication). Pregnancy tests will be performed approximately 
every month at the beginning of each treatment cycle (Cycles 2 and beyond) during the study. 
8.2.13. 
Contraception 
Highly effective methods of contraception for participating WOCBP should be used during the 
study treatment and up to 4 months following the last dose of any study medication, and include 
the following:  
• Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (oral, intravaginal, transdermal) 
• Progestogen-only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable)  
• Intrauterine device  
• Intrauterine hormone-releasing system  
• Bilateral tubal occlusion 
• Vasectomized partner  
Participating men can be fertile or vasectomized. Fertile men are advised to use effective 
methods of contraception during the study and until 3 months after administration of the last 
dose of any study medication. 
8.2.14. 
Immunogenicity 
A blood sample will be collected from all subjects who receive PEGPH20 and analyzed to 
determine if PEGPH20 is eliciting a humoral immune response. Initial anti-drug antibodies 
(ADA) testing will be done using a multi-tiered approach per the Guidance, and 
immunocompetition will be performed to confirm an initial positive response in the screening 
assay. Any samples confirmed as positive in the ADA assay will then be assayed for neutralizing 
antibodies.  
Refer to the Prescribing information of pembrolizumab for information related to 
immunogenicity of pembrolizumab (Keytruda® US Prescribing Information 2017). 
8.2.15. 
Imaging/Radiologic Evaluation 
CT/MRI with contrast evaluations will be performed for all subjects in accordance with each 
site’s Standard of Care Lung or Gastric Adenocarcinoma CT/MRI imaging protocols (include 
chest, abdomen, pelvis contrast-enhanced CT/MRI). CT/MRI scans of other areas of known or 
newly suspected disease must also be obtained. In the event that the subject is intolerant to any 
contrast agents needed for imaging, local/institutional guidelines should be followed for imaging 
evaluation. 
All scans will be evaluated locally for disease assessment using RECIST v1.1 and irRC, and sent 
to the CIV for storage and possible analysis at the end of the study.  


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 72 of 112 
06 November 2017  
For study eligibility, the Investigator must determine the presence of 1 or more tumors based on 
CT/MRI scans performed within 28 days of Day 1. For subject eligibility in the Dose Escalation 
portion subjects need only have evaluable disease (evaluable disease may include measurable 
lesions, although not required, but also may include such lesions as bone metastasis or pleural 
effusions that can’t be measured but can be evaluated). For subject eligibility in the Dose 
Expansion portion measurable disease must be determined using RECIST v1.1 
(Eisenhauer 2009; Appendix C). 
During the study, CT/MRI scans for objective tumor assessment (based on RECIST v1.1 and 
irRC) will be performed at the end of Cycle 2, at the end of Cycle 4, and at the end of every 
fourth treatment cycle thereafter (i.e., Week 3 of Cycles 2, 4, 8, 12, 16 and beyond). CT/MRI 
scans should be performed after the last dose in each cycle to allow time for reading of the scans 
by the Investigator prior to start of subsequent cycles. For subjects who are withdrawn from the 
study due to clinical disease progression, a CT/MRI scan should be requested as soon as 
possible. At the End of Treatment Visit, a CT/MRI scan is only required if radiographic disease 
progression was not documented in the previous CT/MRI scan. 
Note: For disease assessment, if a CT/MRI scan is taken at screening then the same modality of 
scanning must be used for the subject throughout the course of the study. 
A CT/MRI brain scan must also be performed at Screening (within 28 days prior to first dose of 
study drugs), to assess potential CNS disease and/or metastases. 
For the duration of the study (i.e., post-baseline), CT/MRI of the brain will be performed if 
clinically indicated, and within a target of 1 week after a subject achieves a complete response 
(CR). For NSCLC subjects with a history of treated brain metastases, brain scans will be 
performed at tumor assessment time points. 
Additional optional imaging using PET/CT and DCE-MRI will be performed at selected sites 
only to assess treatment effects of pembrolizumab based on tumor blood flow and metabolic 
activity. Details about the conduct of these assessments are provided in a separate manual. 
8.2.16. 
Pharmacokinetic Assessments 
Plasma samples will be collected to assess the potential effects of pembrolizumab on the PK of 
PEGPH20 (as specified in Table 3). Additionally, serum samples will be collected to potentially 
assess the PK of pembrolizumab as an exploratory endpoint. Post-dose PK time points should be 
relative to the stop time of the PEGPH20 infusion. If samples are collected from a central line, 
the line should be flushed with saline prior to collecting the PK samples. Samples should not be 
collected from the same line used to administer PEGPH20. Actual sampling times must be 
recorded. Initial testing will be done during the study; however, samples will be stored for 
possible re-analysis if deemed necessary and for potential future testing of other biomarkers that 
may be found to be relevant. 
If a subject discontinues PEGPH20 therapy, PEGPH20 PK samples will not be collected from 
that subject. However, if that subject continues on pembrolizumab therapy at the discretion of the 
Investigator, pembrolizumab PK samples must be collected. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 73 of 112 
06 November 2017  
8.2.17. 
Biomarker Assessments  
This study will collect samples for biomarker assessments in all subjects (where not prohibited 
by local regulations). Sample types collected include tumor samples and plasma samples. Any 
sample or derivatives (such as deoxyribonucleic acid [DNA], ribonucleic acid [RNA], and 
protein) may be stored for up to 15 years after study completion to assist in any research related 
to PEGPH20 or cancer, and for potential diagnostic development. 
In addition, biomarkers identified in other clinical studies may also be assessed in the biomarker 
samples collected from subjects enrolled in this study. The decision to perform other biomarker 
assessments may be based on the clinical outcome of this study and/or the signals observed in 
other clinical studies or other information available at that time.  
Refer to the Laboratory Manual for detailed instructions on the processing, storage, and shipping 
of samples. 
8.2.17.1.1. Tumor Biopsies 
Tumor tissue needs to meet specific tissue sample requirements as follows (see Laboratory 
Manual):  
• A tumor tissue in FFPE block or 5-10 unstained, consecutive core biopsy slides from 
1 tumor tissue block are preferred but not mandatory for subjects eligible for the Dose 
Escalation portion. 
• A tumor tissue in FFPE block or 10-15 unstained, consecutive tumor tissue slides 
from 1 tumor tissue block are mandatory for subjects eligible for the Dose Expansion 
portion, that meet specific tissue sample requirements (see Laboratory Manual). 
Archived resection specimens from the primary tumor without radiologic evidence of 
metastasis at the time of resection are not suitable to establish histological 
confirmation and require new tumor tissue of a metastatic site. 
• Fine needle aspiration and/or brushing biopsy are not acceptable.  
The pathology report as well as any molecular pathology reports (e.g., for ALK or EGFR 
mutational status in NSCLC and HER2 status in gastric cancer) must be provided. Specific 
sampling and processing instructions will be outlined in a separate laboratory manual. The tumor 
biopsy, whether a block or unstained slides, must be sent to the appropriate laboratory as soon as 
possible after it is obtained; however, it should not be sent prior to the subject signing the ICF (or 
prescreening ICF if used in Dose Expansion). Tumor biopsy samples will be utilized for analysis 
of HA, PD-L1 expression levels (retrospectively), and other exploratory biomarkers. 
An optional post-dose biopsy will be collected at the end of Cycle 1 for all subjects who provide 
separate informed consent. The sample will be analyzed for tumor HA, PD-L1 expression, and 
other exploratory biomarkers in comparison with the pre-dose sample to evaluate PEGPH20 
and/or pembrolizumab effects. 
8.2.17.1.2. Plasma Hyaluronan and Exploratory Biomarkers  
Plasma HA is an indicator of PEGPH20 pharmacological activity. Baseline and post-dose HA 
levels in plasma samples will be analyzed to evaluate the PEGPH20 treatment effect, and assess 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 74 of 112 
06 November 2017  
drug exposure. In addition, plasma samples may be analyzed for exploratory biomarkers of 
PEGPH20 and/or pembrolizumab activity.  
8.2.17.1.3. Tumor-Associated Hyaluronan and Tissue-Based Biomarkers 
Tumor tissue available at Screening and collected optionally during the study will be sent to a 
central laboratory and tested for HA levels using a co-developed investigational diagnostic assay 
(VENTANA RxDx). This assay uses an affinity-histochemistry-based staining method to 
evaluate HA levels in tumor biopsies.  
Expression of exploratory biomarkers will also be assessed. 
For screening purposes, the result for each subject screened (i.e., eligible/ineligible based on HA 
level) will be sent to the sites to determine eligibility of subjects to enter the study. 
8.2.17.1.4. Tumor-Associated PD-L1 Expression in Gastric Adenocarcinoma 
Tumor tissue available from gastric adenocarcinoma subjects at screening and collected 
optionally during the study will be tested for PD-L1 expression levels retrospectively. 
8.2.17.1.5. Tumor-Associated PD-L1 expression in NSCLC 
Tumor tissue available from NSCLC subjects at screening and collected optionally during the 
study will be tested retrospectively for PD-L1 expression levels. 
8.3. 
Study Drug Administration 
Each treatment cycle is 21 days (3 weeks). 
In Dose Escalation, PEGPH20 will be administered on Day 1, Day 8 and Day 15 of each 21-day 
cycle (i.e. 3 doses/cycle) and pembrolizumab (2 mg/kg every 21 days) on Day 1 of each cycle 
(i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration.  
 
In Dose Expansion, PEGPH20 will be administered on Day 1, Day 8 and Day 15 of each 21-day 
cycle (i.e. 3 doses/cycle) and pembrolizumab (200 mg every 21 days) on Day 1 of each cycle 
(i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration.  
Treatment in both portions of the study will continue until disease progression or unacceptable 
toxicity, death, or withdrawal of consent from the study. 
If a dose of PEGPH20 is missed on Day 1 of cycle 2 or beyond, the cycle will continue as 
scheduled. If it is known that pembrolizumab will be missed or held on Day 1, PEGPH20 should 
also be held and the cycle will not start until the first dose of pembrolizumab is administered. 
This will require planning such that the dose of PEGPH20 can be given before the 
pembrolizumab dose is set to resume. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 75 of 112 
06 November 2017  
8.3.1. 
PEGPH20 
8.3.1.1. 
PEGPH20 Administration 
The PEGPH20 dose will be individually calculated for all dosing visits according to the subject’s 
screening weight. In calculating the dose, there will be no downward adjustment to “ideal” body 
weight. Doses should be re-adjusted if the subject’s weight changes by >10%. If the subject’s 
weight changes by ≤10%, no adjustment is necessary unless the site has a standard procedure to 
adjust doses based upon current weight. The dispensing pharmacist will verify the dose accuracy 
with a qualified study staff member. The appropriate dose will be diluted as per the instructions 
provided in a separate pharmacy manual. 
After completion of pre-dose activities, PEGPH20 will be administered as an IV infusion over 
10 minutes, approximately 1 mL/minute (a window of +2 minutes is allowed, i.e., infusion can 
be 10 to 12 minutes), under observation by qualified clinic staff. The volume and/or duration of 
PEGPH20 administration may change at the discretion of the Sponsor, based upon safety 
information. The study nurse or alternate designee by the Investigator will record the time the 
infusion was started and stopped. A saline flush should follow IV delivery of the complete 
PEGPH20 dose as per standard of care for flushing IV lines. Only a peripheral line should be 
used for the administration of PEGPH20 (heparin flushes should not be used on the same line as 
PEGPH20), but heparin flushes may be used for central lines as per standard of care. In the event 
that peripheral venous access cannot be obtained, the central line may be used. If this happens, 
ensure the line is flushed with saline (minimum of 10 mL) prior to administering PEGPH20 and 
after administering PEGPH20. Ensure the PEGPH20 administration is not done immediately 
before or after the central line has been flushed with a heparin flush (i.e., ensure the line is 
flushed with a heparin flush no earlier than 1 hour before or after the PEGPH20 administration).  
8.3.1.2. 
Hypersensitivity to PEGPH20 
In the event of a hypersensitivity reaction, the PEGPH20 infusion should be stopped and the 
symptoms should be treated as necessary. Halozyme should be contacted immediately (see study 
manual for contact information). 
At the Investigator’s discretion and after discussion with the Sponsor, a re-challenge for the next 
visit may be done if the reaction is not considered anaphylaxis and is ≤ Grade 2. Any subject 
with anaphylaxis or a ≥Grade 3 hypersensitivity reaction/infusion reaction should be 
discontinued from the study. In the event of a ≤Grade 2 hypersensitivity/infusion reaction, the 
Sponsor and Investigator will agree on how subsequent injections will be administered. In 
general, a re-challenge should be done after pre-medication with a combination of IV 
diphenhydramine, IV H2 blockers (such as famotidine), and IV dexamethasone. If the 
hypersensitivity reactions are experienced at the re-challenge, the subject should be discontinued 
from the study. 
8.3.1.3. 
PEGPH20 Dose Modification Guidelines 
PEGPH20 dose adjustments are allowed based on toxicities that are deemed related, possibly 
related, or probably related to PEGPH20. See Table 6 for guidelines. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 76 of 112 
06 November 2017  
Table 6: 
PEGPH20 Dose Adjustment and Toxicity Management Guidelines 
Event 
Management/Action 
Musculoskeletal  
Any Grade 1 MSEs 
• No change in PEGPH20 dose or frequency. Prescribed 
medication such as narcotics, muscle relaxants and other 
analgesics (with the exceptions of steroids), OTC drugs 
and physical therapy can be used at the Investigator’s 
discretion. 
Any Grade 2 MSEs 
• Based on Investigator’s discretion use prescribed 
medication such as narcotics, muscle relaxants and other 
analgesics (with the exceptions of steroids), OTC drugs 
and physical therapy. 
• If the MSEs resolve or decrease to Grade 1 with 
administration of prescribed medication such as 
narcotics, muscle relaxants and other analgesics (with the 
exceptions of steroids), OTC drugs and physical therapy, 
PEGPH20 can be continued. 
• If the MSEs persist at Grade 2 despite administration of 
prescribed medication such as narcotics, muscle relaxants 
and other analgesics (with the exceptions of steroids), 
OTC drugs and physical therapy, the Investigator must 
discuss any further PEGPH20 treatment with the 
Sponsor’s Medical Monitor. 
Any Grade 3 or 4 MSEs  
• Hold PEGPH20 treatment. 
• Based on Investigator’s discretion use prescribed 
medication such as narcotics, muscle relaxants and other 
analgesics (with the exceptions of steroids), OTC drugs 
and physical therapy. 
• If the MSEs decrease to ≤ Grade 2, the Investigator must 
discuss any PEGPH20 treatment reinitiation with the 
Sponsor’s Medical Monitor.  
• If the MSEs persist at Grade 3 or 4 levels, PEGPH20 
should not be resumed. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 77 of 112 
06 November 2017  
Table 6: 
PEGPH20 Dose Adjustment and Toxicity Management Guidelines 
(Continued) 
Event 
Management/Action 
All non-MSE Events (Except TE Events) Potentially Related to PEGPH20 
Grade 1 or 2 
• No change in PEGPH20 treatment. 
Grade 3 
• Hold PEGPH20 treatment.  
• If toxicity is resolved to baseline within 14 days, 
treatment may resume at the same dose level.  
• If toxicity is reduced to ≤ Grade 2 within 14 days, 
treatment may resume but at next lower dose but must be 
discussed and decided upon mutual agreement with the 
Sponsor’s Medical Monitor.  
• If toxicity persists at Grade 3, any consideration to 
resume PEGPH20 treatment must be discussed with the 
Sponsor’s Medical Monitor. 
Grade 4 
• Hold PEGPH20 treatment.  
• If toxicity is resolved or reduced to ≤ Grade 2, any 
PEGPH20 treatment reinitiation must be discussed with 
the Sponsor’s Medical Monitor. 
Thromboembolic Events (Regardless of Relatedness to PEGPH20) 
Any Grade TE event 
• Discontinue PEGPH20 treatment for subjects who 
experience any TE requiring full dose anticoagulation 
while on study. Treatment with pembrolizumab may 
continue as deemed appropriate by the Investigator. 
Abbreviations: MSE = musculoskeletal event; NSAIDs = non-steroidal anti-inflammatory drugs; 
PEGPH20 = PEGylated recombinant human hyaluronidase. 
If PEGPH20 is held on Day 1 of treatment cycles 2+, pembrolizumab must still be given. 
For details on administration of piroxicam and toradol for the management of MSEs, refer to 
Section 10.12.1; for information on administration of prophylactic enoxaparin and aspirin for 
management of TE events, refer to Section 10.12.2 and Section 10.12.3, respectively. 
8.3.2. 
Pembrolizumab  
8.3.2.1. 
Pembrolizumab Administration 
Pembrolizumab will be administered by IV infusion at a dose of  
2 mg/kg (in Dose Escalation) or 200 mg (in Dose Expansion) over 30 minutes once every 
21 days on Day 1 of each cycle, 4-6 hours after the PEGPH20 dose. 
The pembrolizumab dose will be individually calculated for all infusion visits in Dose Escalation 
according to the subject’s screening weight. In calculating the dose, there will be no downward 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 78 of 112 
06 November 2017  
adjustment to “ideal” body weight unless institution policy requires it. Doses should be re-
adjusted if the subject’s weight changes by >10%. If the subject’s weight changes by ≤10%, no 
adjustment is necessary unless the site has a standard procedure to adjust doses based upon 
current weight. 
All Cycle Day 1 administrations of pembrolizumab should occur 4-6 hours after PEGPH20 
administration. 
8.3.2.2. 
Identified Risks of Pembrolizumab Treatment 
Refer to the current Keytruda® US Prescribing Information for the identified risks associated 
with pembrolizumab treatment. 
8.3.2.3. 
Pembrolizumab Dose Adjustment and Toxicity Management 
Dose adjustments (reduction, interruption, and discontinuation) and toxicity management should 
be undertaken per the current Keytruda® US Prescribing Information. 
8.4. 
Excluded Concomitant Medications and Study Restrictions 
Concurrent chronic use of IV heparin is prohibited; however, for acute TEs, IV heparin may be 
used. PEGPH20 administration must be stopped during this period. Use of megestrol acetate is 
prohibited. 
Any other anti-cancer agents or investigational agents are prohibited while the subject is on 
study. After treatment is discontinued and a subject enters long-term follow-up, the subject will 
not have any restrictions (i.e., when being followed every 12 weeks to collect survival and anti-
cancer therapy data). 
The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab 
should be avoided because of their potential interference with the pharmacodynamic activity and 
efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can 
be used after starting pembrolizumab to treat immune-related adverse reactions (see 
Section 8.3.2.2). 
8.5. 
Treatment Compliance 
Trained medical personnel are to administer the IV study treatments. Treatment compliance will 
be monitored by the review of drug accountability records and study treatment administration 
data, which will be recorded in the subject’s medical record and eCRFs. 
8.6. 
Randomization and Blinding 
This is an open-label, non-randomized study.  
A subject will be registered in the centralized IWRS and will be assigned a unique subject 
identification number. The subject’s identification number will be used on all of that subject’s 
eCRFs and SAE forms (if applicable). Any subject identification numbers that are assigned will 
not be reused even if the subject does not receive treatment. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 79 of 112 
06 November 2017  
9. 
STUDY DRUG AND MATERIALS  
9.1. 
Study Drug Description 
9.1.1. 
PEGPH20 
The investigational material in PEGPH20 is a PEGylated, neutral-pH-active human 
hyaluronidase PH20 produced by recombinant DNA technology. rHuPH20 degrades HA under 
physiologic conditions and acts as a spreading factor in vivo. 
PEGPH20 is a multi-site PEGylated enzyme generated by conjugating N-hydroxysuccinimidyl 
ester of methoxypoly(ethylene glycol)-butanoic acid (MSBA30K or PEG) and PH20. 
Chemical Name 
PEGPH20 (PEGylated recombinant human hyaluronidase: 36-482-hyaluronoglucosaminidase 
PH20 [human]) 
Structural Formula 
The structure of PEGPH20 is represented in Figure 2. 
Figure 2: 
Structure of PEGPH20 
 
The empirical formula for P is rHuPH20: C2327H3565N589O667S20 and PEG: C1371H2737NO686. 
PEGPH20 is a multi-site PEGylated enzyme. Its measured molecular weight is generally 
between 100,000 and 270,000 Da. 
9.1.2. 
Pembrolizumab 
Pembrolizumab is a human programmed death receptor-1-blocking antibody indicated for the 
treatment of patients with unresectable or metastatic melanoma; patients with metastatic NSCLC 
whose tumors express PD-L1 as determined by an FDA-approved test and who have disease 
progression on or after platinum-based chemotherapy (patients with EGFR or ALK genomic 
tumor aberrations should have disease progression on FDA-approved therapy for these 
aberrations prior to receiving pembrolizumab); and patients with recurrent or metastatic head and 
neck squamous cell carcinomas with disease progression on or after platinum-based 
chemotherapy. 
Pembrolizumab will be considered investigational for the purpose of this study since the 
combination of pembrolizumab with PEGPH20 has not been indicated as yet for the treatment of 
the populations studied in this trial. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 80 of 112 
06 November 2017  
Refer to the Keytruda Prescribing Information for a thorough description and diagram of the 
structure of pembrolizumab (Keytruda® US Prescribing Information 2017). 
9.2. 
Study Drug Packaging and Labeling 
9.2.1. 
PEGPH20 
PEGPH20 drug product is supplied as a refrigerated, sterile, single-use, injectable liquid. The 
PEGPH20 drug product is an aqueous solution containing 0.3 mg/mL PEGPH20 with 10 mM 
succinic acid, 130 mM NaCl, and 10 mM methionine at a pH of 6.2. Each vial contains 1.2 mL 
(0.36 mg) of PEGPH20 drug product. PEGPH20 drug product will be packaged in clear, Type 1 
borosilicate glass vials with a 13 mm FLUROTEC®-coated chlorobutyl rubber stopper and a 
13 mm aluminum overseal with white plastic flip-off cap. 
PEGPH20 mixing instructions will be provided to sites in the pharmacy binder. PEGPH20 will 
be administered as an IV infusion over 10 minutes, approximately 1 mL/minute (a window of 
+2 minutes is allowed, i.e., infusion can be 10 to 12 minutes). In the Dose Escalation portion, the 
dose will depend on the escalation process. In the Dose Expansion portion, the dose selected in 
the escalation portion will be used. 
Label information is provided in the Pharmacy Manual. 
9.2.2. 
Pembrolizumab 
Pembrolizumab will be administered as an IV infusion over 30 minutes every 21 days on Day 1 
of each cycle at a dose of 2 mg/kg in Dose Escalation and 200 mg in Dose Expansion. 
9.3. 
Study Drug Storage 
9.3.1. 
PEGPH20 
PEGPH20 drug product, supplied at a concentration of 0.3 mg/mL, is a liquid formulation and 
should be stored at 2°C to 8°C before use. Stability testing of this PEGPH20 drug product was 
initiated following general International Conference on Harmonisation (ICH) guidelines at 
5°C ±3°C, and concurrent stability evaluation is ongoing. The Sponsor will monitor drug 
stability and provide updates on an ongoing basis. 
9.3.2. 
Pembrolizumab 
The reconstituted and diluted solutions of pembrolizumab will be stored either: 
• At room temperature for no more than 4 hours from the time of reconstitution. This 
will includes room temperature storage of reconstituted vials, storage of the infusion 
solution in the IV bag, and the duration of infusion. 
• Or under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 24 hours from 
the time of reconstitution. If refrigerated, the diluted solution will be allowed to come 
to room temperature prior to administration. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 81 of 112 
06 November 2017  
9.4. 
Study Drug Preparation 
9.4.1. 
PEGPH20 
Instructions for preparing PEGPH20 can be found in the pharmacy manual. 
9.4.2. 
Pembrolizumab 
Pembrolizumab will be prepared and administered according to local site standard of care and 
the appropriate package insert. 
9.5. 
Study Drug Accountability 
The Investigator, pharmacist, or qualified designee is responsible for making an inventory of 
study drug(s) upon their receipt. All used and unused study drug supplies should be retained until 
final reconciliation or as indicated by Halozyme, or as per Institution policy. The study drug is to 
be administered/prescribed by the Principal Investigator (PI) or appropriately qualified site 
personnel named on the delegation of authority log. Under no circumstances will the Investigator 
allow the study drug to be used other than as directed by this protocol. Although appropriate 
personnel may be designated to administer/dispense drug and maintain drug accountability 
records, the PI is ultimately responsible for all drug accountability. 
The Investigator or designee must maintain accurate records of the receipt and disposition of 
study drug supplies. Documentation of drug disposition should identify the subject receiving the 
drug, the amount and date of the dose, and any unused drug. This documentation is required in 
addition to drug accountability information recorded on eCRFs. A copy of the reconciled drug 
inventory record will be provided to Halozyme or its designee, and the study site will retain the 
original record. 
After study drug is reconciled by the study monitor, drug may be destroyed as per Institutional 
Policy, or returned to the country specific drug depot as per country regulations. If used study 
medications cannot be stored until drug accountability has been performed as per clinic/institution 
policy, the Sponsor should be notified in advance, and reconciliation procedures will be agreed 
upon. 
10. 
SAFETY ASSESSMENTS 
Safety parameters monitored and recorded during this study include AEs; medical history; 
concomitant medications; immunogenicity, hematology, blood chemistry (including glucose), 
thyroid hormone levels, coagulation, and urinalysis results; physical examination findings; vital 
signs; ECG results; pregnancy test results; and ECOG Performance Status. 
10.1. 
Management of Thromboembolic Events 
TE events have been identified in the pancreatic cancer clinical studies with PEGPH20. While 
pancreatic cancer is considered to be one of the most thrombogenic malignancies, it is necessary 
to manage any potential risks in subjects with NSCLC and gastric adenocarcinoma. All NSCLC 
subjects will be given enteric-coated 81 mg of aspirin/day and all gastric adenocarcinoma 
subjects will be given enoxaparin 40 mg/day in this study, for prophylaxis of TE events, given 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 82 of 112 
06 November 2017  
the high incidence seen in these tumor types. PEGPH20 will be discontinued for subjects who 
experience any TE requiring full-dose anticoagulation while on study. Treatment with 
pembrolizumab, however, may continue as deemed appropriate by the Investigator. If in gastric 
adenocarcinoma subjects, enoxaparin is discontinued for any reason, PEGPH20 will be 
discontinued. Treatment with pembrolizumab, however, may continue as deemed appropriate by 
the Investigator. Subjects who discontinue PEGPH20 and pembrolizumab treatment will have an 
End of Treatment Visit and enter long-term follow-up for survival. 
Any anticoagulation therapy received by the subjects must be documented in the applicable 
eCRF pages. 
10.2. 
Adverse Event Definitions 
An AE is any unfavorable or unintended sign, symptom, or disease temporally associated with 
the use of a pharmaceutical product (i.e., study drug), whether or not considered related to the 
pharmaceutical product. 
The recording of AEs (except for procedure-associated SAEs) will begin at the start of the 
administration of the first dose of a study drug and continue until 30 days after the last dose of 
study drug. Procedure-associated SAEs, will be recorded starting after the subject signs the 
informed consent for the study. AEs should include the development or increased severity of an 
undesirable medical condition or the worsening of a pre-existing medical condition during or 
following exposure to study drug, regardless of relationship to study drug. Only the highest 
severity will be recorded for a single AE in the eCRF. 
An SAE is any AE that: 
• Results in death. 
• Is life-threatening. 
A life-threatening SAE is any AE that places the subject at immediate risk of death 
from the reaction as it occurred, as assessed by the Investigator. This definition does 
not include a reaction that might have caused death if it occurred in a more severe 
form. 
• Requires inpatient hospitalization or prolongs existing hospitalization. 
• For the purposes of this protocol, any hospital admission will be considered inpatient 
hospitalization, regardless of duration. An emergency room visit without hospital 
admission will not be recorded as a SAE under this criterion, nor will cases of 
elective hospitalization for administration of chemotherapy, hospitalization for social 
admissions, or hospitalization for a procedure scheduled before study enrollment. 
However, unexpected complications that occur during elective surgery should be 
recorded as AEs and assessed for seriousness. 
• Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions. 
• Results in a congenital anomaly or birth defect. 
• Is any other important medical event, 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 83 of 112 
06 November 2017  
Other medical events may be considered SAEs when, based on appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the other outcomes in the SAE definition. Examples 
include allergic bronchospasm requiring intensive treatment in an emergency room or 
at home, blood dyscrasias or convulsions that do not result in hospitalization of the 
subject, or the development of drug dependency or drug abuse. 
10.3. 
Reporting Serious Adverse Events 
Report all SAEs to the designated safety contact IMMEDIATELY AND NO LATER THAN 
24 HOURS OF AWARENESS, i.e., knowledge, discovery or notification of the SAE. Enter the 
study-specific SAE/AE of special interest information into the EDC and send any other available 
pertinent information (e.g., hospital records, laboratory results, etc.) to the designated safety 
contact (contact information is provided in the study reference binder). 
If additional follow-up information is required or becomes available for a previously reported 
SAE/AE of special interest, entry of the new information into the EDC should be completed and 
submitted IMMEDIATELY AND NO LATER THAN 24 HOURS OF AWARENESS. For 
hospitalizations, all attempts to obtain the hospital record should be documented in the study file. 
10.4. 
Reporting Adverse Events of Special Interest 
10.4.1. 
Thromboembolic Events 
TE events are considered AEs of special interest in the current trial. All TE events, regardless of 
type of event, severity, or seriousness, must be reported to the Sponsor IMMEDIATELY AND 
NO LATER THAN 24 HOURS OF AWARENESS. Details regarding timelines for the 
reporting of such events are available on the AE of Special Interest form (guidance regarding 
completion of associated eCRF pages will be provided to the study sites). Complete the study-
specific AE of Special Interest form and send to the designated safety contact (contact 
information is provided in the study reference binder). 
The current version of the NCI CTCAE (i.e. Version 4.03 [14 June 2010]) should be utilized 
when grading TE events. Table 7 denotes the most commonly reported TE events and the 
associated grading scale per CTCAE Version 4.03 (14 June 2010). If the CTCAE is updated 
during the study, the current version of the CTCAE (i.e. Version 4.03 [14 June 2010]) should be 
used. 
 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 84 of 112 
06 November 2017  
Table 7: 
CTCAE Version 4.03 Grading for Thromboembolic Events 
Grade 
Adverse Event 
1 
2 
3 
4 
5 
Acute coronary 
syndrome 
- 
Symptomatic, 
progressive 
angina; cardiac 
enzymes normal; 
hemodynamically 
stable 
Symptomatic, 
unstable angina 
and/or acute 
myocardial 
infarction, 
cardiac enzymes 
abnormal, 
hemodynamically 
stable 
Symptomatic, 
unstable angina 
and/or acute 
myocardial 
infarction, 
cardiac enzymes 
abnormal, 
hemodynamically 
unstable 
Death 
Definition: A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary 
to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to 
myocardial infarction. 
Ischemia 
cerebrovascular 
Asymptomatic; 
clinical or 
diagnostic 
observations 
only; 
intervention not 
indicated 
Moderate 
symptoms 
- 
- 
- 
Definition: A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction 
(thrombosis or embolism) of an artery resulting in neurological damage. 
Myocardial 
infarction 
- 
Asymptomatic 
and cardiac 
enzymes 
minimally 
abnormal and no 
evidence of 
ischemic ECG 
changes 
Severe 
symptoms; 
cardiac enzymes 
abnormal; 
hemodynamically 
stable; ECG 
changes 
consistent with 
infarction 
Life-threatening 
consequences; 
hemodynamically 
unstable 
Death 
Definition: A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood 
supply to the area. 
Portal Vein 
Thrombosis 
- 
Intervention not 
indicated 
Medical 
intervention 
indicated 
Life-threatening 
consequences; 
urgent 
intervention 
indicated 
Death 
Definition: A disorder characterized by the formation of a thrombus (blood clot) in the portal vein. 
Superficial 
thrombophlebitis 
- 
Present 
- 
- 
- 
Definition: A disorder characterized by a blood clot and inflammation involving a superficial vein of the 
extremities. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 85 of 112 
06 November 2017  
Table 7: 
CTCAE Version 4.03 Grading for Thromboembolic Events (Continued) 
Grade 
Adverse Event 
1 
2 
3 
4 
5 
Thromboembolic 
event 
Venous 
thrombosis 
(e.g., superficial 
thrombosis) 
Venous 
thrombosis (e.g., 
uncomplicated 
deep vein 
thrombosis), 
medical 
intervention 
indicated 
Thrombosis (e.g., 
uncomplicated 
pulmonary 
embolism 
[venous], non-
embolic cardiac 
mural [arterial] 
thrombus), 
medical 
intervention 
indicated 
Life-threatening 
(e.g., pulmonary 
embolism, 
cerebrovascular 
event, arterial 
insufficiency); 
hemodynamic or 
neurologic 
instability; urgent 
intervention 
indicated 
Death 
Definition: A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via 
the blood stream. 
Vascular access 
complication 
- 
Device 
dislodgement, 
blockage, leak, or 
malposition; 
device 
replacement 
indicated 
Deep vein or 
cardiac 
thrombosis; 
intervention 
indicated (e.g., 
anticoagulation, 
lysis, filter, 
invasive 
procedure) 
Embolic event 
including 
pulmonary 
embolism or life 
threatening 
thrombus 
Death 
Definition: A finding of a previously undocumented problem related to the vascular access site. 
Source: NCI CTCAE 4.03 June 14, 2010. 
10.4.2. 
Disease-Related Events That Are Endpoints 
For the purposes of this study in subjects with NSCLC and gastric adenocarcinoma, progression 
of the subject’s underlying disease (“disease progression”) is an efficacy assessment and should 
generally not be reported as an AE or SAE. However, if the Investigator determines that there is 
evidence suggesting a causal relationship between the event and the study medication, 
immediately report the event to the safety contact and record as an AE or SAE. 
Death resulting from disease progression is a study endpoint, and generally should not be 
reported as a SAE. This event must be recorded in the eCRF and will be reviewed by the 
Sponsor periodically for increased frequency in the treatment group. However, if the Investigator 
determines that there is evidence suggesting a causal relationship between the event and the 
study medication, immediately report the event as an SAE. 
10.5. 
Adverse Events 
Events that occur before the first administration of study drug are not considered AEs, by 
definition (Section 10.2); record these events on the Medical History eCRF. However, as noted 
in Section 10.2, any study procedure-associated events occurring after the subject’s signing of 
the informed consent for the study (including prior to the administration of study drug) should be 
recorded if the event is considered serious. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 86 of 112 
06 November 2017  
The Investigator or a qualified designee will question and examine subjects for evidence of AEs. 
Subjects should not be asked about specific AEs. Instead, they should be asked general questions 
(e.g., “How have you been feeling since your last visit?”). Record all AEs in the eCRF.  
For an event to be recorded as an AE, the onset must occur during or after the subject’s first 
exposure to study drug (except for study procedure-associated SAEs), and no later than 30 days 
after the last study drug dose. However, there is no limit on reporting SAEs considered 
reasonably related to study drugs (i.e., assessed as “Yes, Related,” “Probably Related,” or 
“Possibly Related,” Section 10.5.2); these should be submitted as SAEs per Section 10.3, even if 
they are first identified during the long-term follow-up period. The Investigator should follow all 
AEs that are considered reasonably related to study drug until resolution or stabilization. All 
other AEs should be followed until resolution or stabilization or until the End of Treatment Visit, 
whichever occurs first. 
Wherever possible, record syndromes rather than individual signs or symptoms to avoid 
duplication and to facilitate meaningful interpretation of data. For example, a subject presenting 
with rhinitis, fever, and headache should be reported as having “flu-like symptoms,” without 
independently recording each accompanying sign. When no clearly recognizable clinical 
syndrome can be described, record individual clinical signs and symptoms. In addition, “disease 
progression” or “death” should not be reported as an AE or SAE term; instead the underlying 
cause of the disease progression or death should be reported. 
All AEs that occur during the study should be treated appropriately to protect and ensure the 
subject’s well-being. If such treatment constitutes a deviation from this protocol, Halozyme must 
be notified and the Investigator should comply with applicable IRB/EC reporting requirements. 
The Investigator is responsible for determining whether or not an AE is severe enough to require 
the subject’s removal from treatment. A subject may also voluntarily withdraw from treatment 
because of an AE. If either occurs, the subject must receive appropriate medical care, and the 
Investigator must strongly encourage the subject to return to the study site for the final protocol-
specified visit and assessments, and to continue returning to the study site for follow-up 
evaluations until the AE resolves or stabilizes. All AEs, serious or not, that result in permanent 
withdrawal from study treatment should be immediately reported to Halozyme (Section 10.3). 
Halozyme will conduct reviews of all available AEs to determine dose escalation steps, to 
determine the optimal pembrolizumab schedule at the end of Dose Escalation, and at a minimum 
of once every 3 months during Dose Expansion. 
10.5.1. 
Classification of Adverse Events by Severity 
The Investigator must categorize the severity of each AE using the NCI CTCAE v4.03 (Table 6). 
It is important to distinguish between AE seriousness and severity; these terms are not 
interchangeable. Severity is a measure of intensity, whereas seriousness is defined by the criteria 
in Section 10.2. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 87 of 112 
06 November 2017  
10.5.2. 
Classification of Adverse Events by Relationship to Study Drug 
For each AE, the Investigator must document whether there is a reasonable possibility that the 
event was caused by administration of PEGPH20 or pembrolizumab. The Investigator should 
make this decision after careful consideration of the following questions: 
• Does the AE follow a reasonable temporal sequence from administration of study 
drug? 
• Can the AE be reasonably explained by the known characteristics of the subject’s 
clinical state, environmental or toxic factors, or other therapy? 
• Do the AE symptoms disappear or decrease on cessation of study drug or reduction in 
study drug dose? (There are exceptions when an AE does not disappear on 
discontinuation of the drug, yet drug relatedness clearly exists [e.g., bone marrow 
depression, fixed drug eruptions, tardive dyskinesia, etc.]) 
• Does the AE reappear or worsen when the study drug is re-administered? 
• Does the AE follow an expected response pattern based on the established 
pharmacologic and toxicologic effects of the study drug? 
• Does the AE follow an expected response pattern based on the known effects of other 
products in the same class? 
For this assessment, the Investigator will classify each AE as one of the following: 
• Yes, Related: The AE is definitely related to study drug administration.  
• Probably Related: There is a high degree of certainty that the AE is related to study 
drug administration. 
• Possibly Related: The AE could be related either to study drug administration or to 
concurrent disease/medication. 
• Unlikely Related: There is a high degree of certainty that the AE is NOT related to 
study drug administration. 
• Not Related: The AE is clearly due to other causes (e.g. concurrent medication, 
underlying disease, etc.). 
For the purposes of expedited reporting to regulatory authorities, AEs assessed as “Yes, 
Related,” “Probably Related,” or “Possibly Related” will be considered suspected adverse 
reactions. 
10.6. 
Abnormal Laboratory Results  
Abnormal laboratory results may occur in the context of an AE that is a clinical syndrome (e.g., 
elevated BUN and creatinine in the setting of an AE of renal failure, or elevated AST/ALT in the 
setting of an AE of hepatitis). In these cases, do not record the abnormality itself as an AE. 
However, in the absence of an AE that encompasses an observed abnormal laboratory result, 
report the abnormality as an AE if the Investigator judges it to be clinically significant for the 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 88 of 112 
06 November 2017  
subject. Changes in trial dosing or study discontinuation resulting from an abnormal laboratory 
value not associated with an AE should also be captured as an AE. 
If test results lead to a change in trial dosing or discontinuation from the trial, significant 
additional concomitant drug treatment, or other therapy, and/or requires medical/surgical 
intervention and/or is considered to be an AE by the Investigator or Sponsor as an abnormal 
objective test finding, it should be reported as an AE. 
10.7. 
Pregnancy 
Pregnancy itself is not regarded as an AE unless there is suspicion that the study drug may have 
interfered with the effectiveness of the contraceptive medication. Refer to the pembrolizumab 
Prescribing Information for the summary of risks in this specific population. Based on its 
mechanism of action, pembrolizumab can cause fetal harm when administered to a pregnant 
woman. Women of childbearing potential should therefore use highly effective contraception 
during treatment with pembrolizumab and refrain from breast feeding for 4 months after the last 
dose of pembrolizumab. Pregnancy within 120 days of study drug discontinuation in a subject 
must be reported to the designated safety contact (contact information is provided in the study 
reference binder) IMMEDIATELY AND NO LATER THAN 24 HOURS OF 
AWARENESS. Complete the study-specific Pregnancy Report Form with all available 
information and submit the form with pregnancy test results and any other pertinent information. 
Also, within 24 hours, complete the eCRF with all available AE, demographic, medical history, 
concomitant medication, and study drug administration information. As additional information 
on a previously reported pregnancy becomes available, a follow-up Pregnancy Report Form 
should be prepared with the new information and submitted to the safety contact. 
Subjects who become pregnant during the study will not receive any additional study drug and 
will be withdrawn from the study. The Investigator must strongly encourage these subjects to 
return to the study site for the final protocol-specified visit and assessments. In addition, the 
Investigator will monitor the pregnancies of subjects exposed to study drug or the partner of a 
male subject who may become pregnant while that subject is on study until final resolution 
(delivery, miscarriage, or early termination). Follow-up should occur monthly and should be 
documented in the study file. A follow-up Pregnancy Report Form must be completed for each 
follow-up contact with the subject or the partner of a male subject who became pregnant while 
that subject is on study and submitted to the Sponsor’s designated safety contact. Report a 
spontaneous miscarriage, therapeutic abortion, stillbirth, or congenital anomaly as an SAE 
(Section 10.3). 
10.8. 
Overdose 
PEGPH20 and pembrolizumab will be administered by IV infusion at a qualified and 
experienced clinical study site. The potential for drug overdose is therefore minimal. However, 
should an overdose occur, the infusion should be stopped immediately. A blood PK plasma 
sample should be taken as soon as possible, with a notation of the time of sampling relative to 
the time of cessation of the infusion. The Investigator should also monitor the subject with 
appropriate blood counts and blood chemistry tests, and should also provide supportive therapy, 
as necessary. Contact the Halozyme Medical Monitor, or designee, WITHIN 24 HOURS. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 89 of 112 
06 November 2017  
There are no data regarding PEGPH20 overdose in humans. However, the likelihood of 
significant MSEs (such as pain, spasms, and weakness) increases with increasing PEGPH20 
dose. An overdose and AEs should be treated as per standard medical practice. There is no 
known antidote for PEGPH20. 
Overdose of pembrolizumab should be managed per the Prescribing Information. 
Dosing details should be captured in the eCRF. If the subject receives a dose of a study drug that 
exceeds protocol specifications and the subject is symptomatic, then the symptom(s) should be 
documented as AEs in the eCRF and, if serious, submitted to the Sponsor’s designated safety 
contact on an SAE Report Form. Do not record the overdose as an AE if the subject is not 
symptomatic. 
10.9. 
Data Monitoring Committee 
An independent DMC will review all available safety data from the first 3 NSCLC subjects and 
first 3 gastric adenocarcinoma subjects who have completed Cycle 1 in Dose Expansion to 
determine if the safety and tolerability profile of the PEGPEM combination is acceptable (refer 
to the DMC charter for additional details). The DMC will also continue to periodically review 
safety data to protect subject welfare and identify potential safety signals. 
10.10. 
Unblinding 
No part of the study is blinded. 
10.11. 
Reporting Safety Information to the Regulatory Authorities and to 
the Institutional Review Board 
The Sponsor will determine if SAEs are suspected unexpected serious adverse reactions 
(SUSARs), and if so will expedite reporting to Regulatory Authorities according to applicable 
Clinical Trials Regulations. 
The Sponsor and/or a designated agent may provide written safety reports or other safety-related 
communications to the Investigator. The Investigator will ensure that these reports are reviewed 
and processed in accordance with regulatory and IRB/EC requirements and archived in the site’s 
study file. 
At the completion or early termination of the study, the Investigator will submit a final report to 
the IRB/EC within the applicable time frame. 
10.12. 
Concomitant Medications 
Any medication received during the study, other than a designated study drug (PEGPH20 or 
pembrolizumab), is regarded as concomitant medication. Record concomitant medications taken 
after the subject signs the ICF during the Screening period (≤28 days prior to Study Day 1) 
through 30 days after the End of Treatment Visit on the Concomitant Medications eCRF. 
Update information on concomitant medications, including medication used to treat an AE, at 
each visit according to the study schedule of events. At each visit, ask subjects if there have been 
any changes in their prescription or non-prescription medications since their last visit. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 90 of 112 
06 November 2017  
Subjects may receive medications during the study including, but not limited to, antibiotics, 
analgesics, antipyretics, etc., when clinically indicated. Prohibited medications are identified in 
Section 8.4. 
Piroxicam and toradol used to decrease the severity of musculoskeletal symptoms should be 
documented and recorded in the eCRF. Prescribed medication such as narcotics, muscle 
relaxants and other analgesics (with the exceptions of steroids), OTC drugs and physical therapy 
can also be used at the Investigator’s discretion and should be documented and recorded in the 
eCRF. Dexamethasone may be used at the Investigator’s discretion and following a discussion 
with the Sponsor, and should be documented and recorded in the eCRF. For additional details, 
refer to Table 6. 
Enoxaparin and any other anticoagulants should also be documented and recorded in the eCRF. 
10.12.1. 
Piroxicam and Toradol 
Refer to the current piroxicam and toradol Prescribing Information for prescribing information 
and toxicity profile. 
Piroxicam and toradol have been investigated in an animal model of MS events and may be 
helpful in decreasing the severity of MSEs in subjects. Piroxicam (20 mg) will be administered at 
least 1-2 hours prior to PEGPH20 administration on the day of dosing (timing will be at the 
Investigator’s discretion based on the piroxicam manufacturer’s Prescribing Information and 
subject’s convenience) to minimize the severity of MSEs. The prophylactic use of a proton pump 
inhibitor is mandated for all subjects while receiving the study drug (e.g. 20 mg omeprazole 
daily or OTC equivalent). 
Toradol should not be administered concurrently with piroxicam as it is contraindicated in the 
Toradol Prescribing Information to administer toradol simultaneously with other NSAIDs 
because of the cumulative risk of inducing serious NSAID-related side effects. If piroxicam is 
used chronically, consideration should be given to begin an H2 blocker to decrease the risk of 
gastric irritation. 
If side effects are observed following administration of NSAIDs, the dosing of piroxicam may be 
adjusted at the Investigator’s discretion upon discussion with the Sponsor. 
10.12.2. 
Enoxaparin  
Refer to the current enoxaparin Prescribing Information for prescribing information and toxicity 
profile.  
All gastric adenocarcinoma subjects with or without a history of DVT will be given enoxaparin 
40 mg/day (pre-filled syringes of enoxaparin are allowed), for prophylaxis of TE events, given 
the high incidence seen in this tumor type. PEGPH20 will be discontinued for subjects who 
experience any TE requiring full-dose anticoagulation while on study. Treatment with 
pembrolizumab, however, may continue as deemed appropriate by the Investigator.  
If in gastric adenocarcinoma subjects, enoxaparin is discontinued for any reason, PEGPH20 will 
also be discontinued. Treatment with pembrolizumab, however, may continue as deemed 
appropriate by the Investigator. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 91 of 112 
06 November 2017  
10.12.3. 
Aspirin 
All NSCLC subjects will be given enteric-coated 81 mg of aspirin/day for prophylaxis of TE 
events, given the high incidence seen in this tumor type. 
10.12.4. 
Dexamethasone 
As this study uses an immunotherapeutic agent and dexamethasone may suppress an immune 
response, it should only be used when prescribed by the Investigator and following a discussion 
with the Sponsor. Dexamethasone may be used to attenuate musculoskeletal symptoms that may 
occur in subjects treated with PEGPH20 and/or pembrolizumab if prescribed by the Investigator 
(and following a discussion with the Sponsor). In this situation dexamethasone may be given 
orally, intramuscularly, or intravenously. 
Refer to a current dexamethasone Prescribing Information for prescribing information and 
toxicity profile. 
11. 
STATISTICS 
11.1. 
Statistical Methods 
In general, continuous variables will be summarized using descriptive statistics (N, mean, 
standard deviation, median, minimum, and maximum). Categorical variables will be presented 
using frequencies and percentages. Dose escalation data summaries will be presented by 
PEGPH20 dose level. All statistical analyses and data listings will be performed using SAS 
version 9.3 or higher (Cary, NC). 
11.1.1. 
Randomization and Blinding 
This is a multicenter, open-label, non-randomized study. 
11.1.2. 
Sample Size 
In the dose escalating portion, there may be up to 5 dose levels for a total of approximately 
30 subjects. 
In the Dose Expansion portion, approximately 51 subjects with HA-high tumors will be enrolled 
(30 with HA-high tumors in NSCLC cohort and 21 with HA-high tumors in the gastric 
adenocarcinoma cohort). 
KEYNOTE-001 study data presented at the American Society of Clinical Oncology 2016 
(Hui 2016) showed that when treated with pembrolizumab alone, treatment naïve subjects who 
had evaluable PD-L1 Tumor Proportion Score [TPS] levels had an ORR of 29% and previously 
treated subjects who had evaluable PD-L1 TPS levels had an ORR of 21%. Under the assumption 
that no more than 40% of the subjects enrolled in this study will be treatment naïve, ORR in the 
combined NSCLC population is expected to be approximately 24% when treated with 
pembrolizumab alone. A 20% improvement in ORR is considered clinically meaningful when 
PEGPH20 is added to pembrolizumab. Under these conditions, 30 NSCLC subjects would 
provide approximately 80% power at the hypothesized ORR of 44% when the null hypothesis 
H0: ORR ≤24% is tested against H1: ORR >24% using an exact one-sided binomial test at a 10% 
significance level. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 92 of 112 
06 November 2017  
KEYNOTE-012 study data showed that the ORR in PD-L1 positive gastric cancer subjects is 
about 22% (Muro 2016). Since subjects will not be selected based on PD-L1 expression levels 
prospectively in this study, in order to accommodate all subjects (irrespective of PD-L1 
expression levels), a conservative ORR of 15% is assumed with pembrolizumab treatment alone 
and it is further assumed that the addition of PEGPH20 to pembrolizumab will lead to a 
clinically meaningful improvement of 20% in ORR to 35%.Under these assumptions, 21 subjects 
will provide approximately 80% power at the hypothesized ORR of 35% when the null hypothesis 
H0: ORR ≤15% tested against H1: ORR >15% using an exact one sided binomial test at a 10% 
significance level. 
11.1.3. 
Analysis Populations 
11.1.3.1. Safety Population  
All subjects who receive any study medication. The Safety Population will be used for subject 
disposition, demographics and safety analyses. 
11.1.3.2. DLT Evaluable Population  
All subjects who receive at least 1 of the 3 full planned doses of PEGPH20 and 1 complete dose 
of pembrolizumab in Cycle 1 and have been followed for the first 21 days of treatment or have 
experienced a DLT during the initial 21 days (Cycle 1) of the study. The DLT Evaluable 
Population will be used for DLT analysis.  
11.1.3.3. PK Analysis Population  
All subjects who receive any PEGPH20 and have measurable PEGPH20 concentrations in at 
least 1 sample collected for PK analysis. PK Analysis Population will be used for PK analysis. 
11.1.3.4. Efficacy Evaluable Population  
All HA-high subjects who receive at least 1 dose of the RP2D of PEGPH20 and at least 1 dose of 
pembrolizumab. The efficacy evaluable population will be used for all efficacy analyses. 
11.1.3.5. Tumor Response Evaluable Population 
Subjects in the Efficacy Evaluable Population who have at least one post-baseline tumor 
assessment. Tumor Response Evaluable Population will also be used for overall tumor response 
analysis. 
11.1.4. 
Subject Disposition 
Subject disposition data (including analysis populations) will be summarized. 
Subject disposition will be tabulated with number of subjects enrolled, receiving study treatment, 
on study treatment, discontinuation from treatment, and reasons for discontinuing treatment. 
Enrollment by center, major protocol deviations will also be summarized. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 93 of 112 
06 November 2017  
11.1.5. 
Analysis of Demographics and Baseline Characteristics 
Demographics and baseline characteristics will be summarized using safety population by dose 
level for subjects in the Dose Escalation portion and separately for all subjects in the Dose 
Expansion portion. The following demographic and baseline characteristics will be summarized: 
age, race, height, weight, medical history, disease characteristics, and treatment history.  
11.1.6. 
Efficacy Analyses 
All efficacy analyses will be conducted using the Efficacy Evaluable Population. ORR and DOR 
will also be analyzed using Tumor Response Evaluable population.  
11.1.6.1. Analyses of the Primary ORR Efficacy Endpoint 
The primary efficacy endpoint of the study is PEGPEM treatment effect on ORR (based on 
RECIST v1.1). The statistical hypothesis tests for the primary endpoint are as follows: 
• NSCLC cohort: H0: ORR ≤23%; H1: ORR >23% 
• Gastric adenocarcinoma cohort: H0: ORR ≤15%; H1: ORR >15% 
The hypothesis tests will be conducted using the one-sided exact binomial test at the significance 
level of 0.1.  
ORR will be calculated as the number of subjects with a confirmed CR or PR divided by the 
number of subjects in the analysis population multiplied by 100. The exact 80% confidence 
interval of ORR will also be constructed.  
11.1.6.2. Analyses of Secondary Efficacy Endpoints 
Median DOR, PFS and OS will be estimated using the Kaplan-Meier method. 
• DOR is defined as the time from the date on which objective response (CR or PR) is first 
determined until the first date on which radiographic disease progression is determined, 
and will only be calculated for subjects with a confirmed objective response. Subjects 
achieving a confirmed objective response who do not have radiographic disease 
progression will be censored at the date of the last available post-baseline evaluable 
tumor assessment. DOR will be analyzed using Kaplan-Meier methods. 
• PFS, defined as the time from first dose date until the first occurrence of either 
radiographic or clinical disease progression as determined by the Investigator or death 
from any cause before discontinuation from treatment. PFS for surviving subjects without 
disease progression will be censored at the date of the last available post-baseline 
evaluable tumor assessment. Surviving subjects without any post-baseline disease 
assessment will be censored on Day 1. 
• OS is defined as the time from first dose date until death from any cause. OS data from 
surviving subjects will be censored at time of the last contact. 
• DCR is defined as the proportion of subjects who achieve CR, PR, or stable disease, and 
will be analyzed using the same method as ORR. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 94 of 112 
06 November 2017  
Descriptive summaries will be provided for estimation of ORR, DOR, DCR and PFS based on 
RECIST v1.1 and irRC. 
11.1.7. 
Analysis of Treatment Exposure 
The study medication exposure will be summarized using the Safety Population by dose level. 
Study medication exposure will include exposure duration, dosing cycles, dosing information for 
study medication, such as number of doses, relative dose intensity, and dose changes. 
11.1.7.1. Pharmacokinetic Analyses 
For PEGPH20 noncompartmental and compartmental PK modeling will be performed. The 
AUC, the Cmax, and T1/2 will be summarized from noncompartmental analysis along with 
descriptive statistics. Other PK analyses may be performed and population PK parameters 
including T1/2, VD, and CL will be evaluated and reported if the data are sufficient. 
11.1.7.2. Plasma Hyaluronan 
Descriptive statistics will be used to summarize measured plasma concentrations of HA. 
11.1.7.3. Exploratory Analyses 
Descriptive summaries will be provided for all exploratory analysis data, which include 
estimation of ORR, DOR, DCR, and PFS based on RECIST v1.1 and irRC, by PD-L1 expression 
levels, changes in tumor blood flow as measured by DCE-MRI and changes in tumor metabolism 
as measured by PET/CT, and changes in potential biomarkers in plasma and tumor biopsy and 
their correlation to study endpoints. For pembrolizumab, noncompartmental and compartmental 
PK modeling will be performed. The AUC, Cmax, and T1/2 will be summarized from the 
noncompartmental analysis along with descriptive statistics. 
11.1.8. 
Safety Analyses 
All safety parameters will be summarized using the Safety Population by dose level will be 
descriptive in nature. No inferential statistical tests will be conducted for safety parameters. 
All AEs will be presented in incidence tables coded by the Medical Dictionary for Regulatory 
Activities (MedDRA) Preferred Term and System Organ Class. 
Additionally, separate AE incidence tables, coded by MedDRA term, will be presented by: 
1) toxicity grade (severity) graded by the CTCAE and 2) relationship to study medication 
(PEGPH20 and pembrolizumab). 
All AEs, SAEs, AEs leading to treatment discontinuation, and deaths occurring during the study 
will be summarized. 
In addition, subjects who experienced TE will be summarized by SMQ term and MedDRA 
preferred term by grade. 
Laboratory parameters and vital signs and the corresponding change from baseline over time will 
be summarized using descriptive statistics. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 95 of 112 
06 November 2017  
11.1.9. 
Interim Analysis 
No interim analysis will be performed for this study.  
12. 
SPONSOR AND INVESTIGATOR RESPONSIBILITIES  
12.1. 
Protocol Compliance 
Except for a change intended to eliminate an apparent immediate hazard to a study subject, the 
study must be conducted as specified. Any such change must be reported immediately to 
Halozyme and to the IRB/EC according to the applicable IRB/EC policy. 
12.1.1. 
Protocol Waivers 
Halozyme, or its designee, will not prospectively authorize any protocol waivers to study 
inclusion/exclusion criteria.  
12.1.2. 
Protocol Deviations 
Written documentation of all major protocol deviations must be kept in the study site file and 
provided to Halozyme. Examples of possible major protocol deviations include, but are not 
limited to: 
• Failure to obtain/maintain IRB/EC approval for the study. 
• Failure to obtain subject’s informed consent. 
• Failure to collect, submit, or file AE reports. 
• Performance of an unapproved study procedure. 
• Performance of the study at an unapproved location.  
• Failure to adhere to the approved protocol. 
The Investigator must notify the IRB/EC of all protocol deviations according to applicable 
IRB/EC policy. Halozyme will not authorize any protocol deviations. 
12.2. 
Study Monitoring 
Site visits will be conducted by an authorized Halozyme representative, who will inspect study 
data, subject medical records, and eCRFs according to Good Clinical Practice (GCP) and FDA 
and ICH guidelines. 
In addition to monitoring by Halozyme or its designees, the study may be audited by 
representatives of the FDA, who will also be allowed access to study documents. The 
Investigator should immediately notify Halozyme’s Department of Clinical Development and 
Medical Affairs of any proposed or scheduled audits by regulatory authorities. 
The Investigator will permit authorized representatives of Halozyme and national or local health 
authorities to inspect facilities and records relevant to this study. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 96 of 112 
06 November 2017  
12.3. 
Data Collection and Electronic Case Report Forms 
eCRFs must be completed for each subject enrolled in the study according to GCP and FDA 
guidelines. Data collected for each study subject will be recorded on eCRFs provided or 
approved by Halozyme. 
eCRF completion is the Investigator’s responsibility. eCRF completion may be delegated to 
other study personnel and documented on the log for delegation of authority. The Investigator is 
responsible for ensuring the accuracy, completeness, legibility, and timeliness of all data 
reported on CRFs and all required reports for each study subject. The Investigator is also 
responsible for maintaining any source documentation related to the study (e.g., operative 
reports, laboratory results, radiographic films, tracings, and computer discs or files). 
12.4. 
Financial Disclosure 
The Investigator is required to provide a financial disclosure statement or certification to 
Halozyme before study initiation. In accordance with 21 Code of Federal Regulations (CFR) 54, 
Investigators and all sub-Investigators are required to disclose all financial interests to the study 
Sponsor (Halozyme), to permit complete and accurate certification statements in an application 
for marketing authorization. This disclosure includes compensation affected by the outcome of a 
clinical study, significant equity interest in Halozyme’s parent entity, Halozyme Therapeutics, 
Inc., and proprietary interest in the tested product. Investigators must promptly update this 
information if any relevant changes occur during the study and for 1 year following study 
completion (21 CFR 312.64(d)). 
12.5. 
Investigator’s Final Report 
After completion of the Investigator’s participation in the study, the Investigator will submit a 
written report to Halozyme. This report may be a copy of the Investigator’s end-of-study report 
to the IRB/EC. The report to the IRB/EC will be consistent with applicable IRB/EC regulations 
and time frames. 
12.6. 
Data Disclosure and Publication 
All information concerning this study and which was not previously published is considered 
confidential information. This confidential information shall remain the sole property of 
Halozyme; it shall not be disclosed to others without written consent of Halozyme; and shall not 
be used except in the performance of this study. 
The information compiled during the conduct of this study is also considered confidential and 
may be disclosed and/or used only by Halozyme as it deems necessary. To allow the use of the 
information derived from this study and to ensure compliance to current federal regulations, the 
Investigator is obliged to furnish Halozyme with the complete test results and all data compiled 
in this study. 
This section of the protocol is intended to be a brief, high-level summary of the requirements for 
data disclosure and publication. The Clinical Study Agreement between Halozyme and the 
Investigator/Institution details the specific disclosure and publication requirements. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 97 of 112 
06 November 2017  
13. 
QUALITY CONTROL AND QUALITY ASSURANCE 
In addition to routine monitoring procedures, audits of clinical research activities may be 
performed to evaluate compliance with the principles of GCP. A regulatory authority may also 
wish to conduct an inspection during the study or after its completion. If an audit of this or any 
other study is requested by any regulatory authority, the Investigator must inform Halozyme 
immediately of the request (Section 12.2). The study site will permit access to all necessary 
records. 
The study protocol, each step of the data recording process, and data handling, as well as any 
study report or publication, will be subject to independent review by Halozyme or its 
representatives. 
14. 
ETHICS 
This study will be conducted under a US Investigational New Drug Application according to the 
provisions of the US CFR, FDA regulations and guidelines, GCP guidelines, and the Declaration 
of Helsinki, revised version of Seoul, October, 2008. All applicable US regulations governing 
human subject protection must be followed. All ethical and regulatory requirements are 
necessary to comply with the principles of GCP. This includes inspection by the Sponsor, its 
representatives, health authority representatives, or IRB/EC representatives at any time. The 
Investigator must agree to the inspection of study-related records by the health authority, the 
Sponsor, and/or the Sponsor's representatives. 
To ensure ethical conduct of this study, the Investigator will be expected to adhere to basic 
principles provided by generally recognized guidelines such as the Belmont Report and the 
International Ethical Guidelines for Biomedical Research Involving Human Subjects. 
14.1. 
Institutional Review Board and Approval 
In accordance with 21 CFR Parts 50 and 56, the Investigator agrees to obtain IRB/EC approval 
of all appropriate material, including a copy of the protocol, ICF, Investigator’s Brochure, and 
any proposed advertisement/study material prior to the start of the study and/or prior to its use on 
the study. 
Halozyme must also agree to the proposed ICF and any proposed study advertisements. A copy 
of the IRB/EC approval letter(s) for the protocol and ICF must be supplied to Halozyme before 
subjects are screened. 
The Investigator will supply Halozyme with the names, professions, and affiliations of IRB/EC 
member, to demonstrate compliance with membership requirements. If the Investigator or a 
sub-investigator is a routine voting member of the IRB/EC, Halozyme will be provided with a 
statement from the IRB/EC that the Investigator /sub-investigator did not vote on this study. 
During the study, the Investigator is responsible for satisfying all IRB/EC regulations for 
reporting study progress. Copies of all reports to and correspondence with the IRB/EC must be 
provided to Halozyme. Furthermore, at the completion or early termination of the study, the 
Investigator should make a final report to the IRB/EC. A copy of this report should be provided 
to Halozyme (Section 12.5). 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 98 of 112 
06 November 2017  
The Investigator must maintain an IRB/EC correspondence file and make this file available for 
review by Halozyme or its designated representatives as part of the study monitoring process. 
14.2. 
Written Informed Consent 
A copy of the proposed ICF must be submitted to Halozyme for review and comment before 
submission to the IRB/EC. The ICF must be approved by the IRB/EC and contain all elements 
required by all applicable federal, state, local, and institutional regulations or policies including 
subject compensation information (if applicable), before it is used to obtain a subject’s informed 
consent. Authorization to use or disclose personal health information in accordance with 
requirements of the Health Insurance Portability and Accountability Act of 1996 should be 
provided in the ICF, or in a separate document to be signed by the subject. 
Each subject found eligible for the study must have voluntarily provided written informed 
consent, using the IRB/EC-approved ICF, before study screening (i.e., before any protocol-
specified procedures that are not part of normal subject care). 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 99 of 112 
06 November 2017  
15. 
DATA HANDLING AND RECORD KEEPING 
15.1. 
Record Inspection  
An audit may be performed at any time after completion of the study by Halozyme personnel or 
their designees, FDA, or other regulatory agencies. All study-related documentation must be 
made available to the designated auditors. 
15.2. 
Study Documentation and Record Retention 
The Investigator must retain all records of this study, including but not limited to, the following. 
• Protocol and all protocol amendments. 
• All signed versions of the Statement of Investigator, Form FDA 1572. 
• All drug accountability records. 
• All IRB/EC approvals, correspondence and reports. 
• Signed and dated ICFs for each subject. 
• Completed eCRFs for each subject. 
• Copies of any other material distributed to subjects. 
• Any advertisements for this study. 
• The Investigator’s final report to the IRB/EC. 
• Source documents pertaining to the study, including but not limited to, any operative 
reports, laboratory results, radiographic films, tracings, and computer discs or files. 
The period for which these documents must be retained is governed by US law and, when 
applicable, non-US regulations. The Investigator must retain all records for at least 2 years after 
the FDA has approved the New Drug Application, or until 2 years after all studies of the drug 
and indication have been discontinued. However, because of international regulatory 
requirements, Halozyme may request retention for a longer period. Halozyme or its designee will 
inform the Investigator when these documents may be destroyed. Halozyme or its designee must 
be notified in writing at least 30 days before the intended date of disposal of study records. The 
Investigator must obtain written approval from Halozyme before destruction of records. 
The Investigator must advise Halozyme in writing if records are to be moved to a location other 
than the study site’s archives. If the Investigator leaves the study site, the records will be 
transferred to an appropriate designee at the site, who will assume responsibility for record 
retention. Notice of this transfer will be documented in writing and provided to Halozyme. 
If any study records are accidentally lost or destroyed, the Investigator will immediately notify 
Halozyme in writing. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 100 of 112 
06 November 2017  
16. 
REFERENCES 
1. American Cancer Society. Cancer Facts and Figures 2015. Atlanta: American Cancer 
Society, 2015.  
2. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, Kosma V-M. High 
levels of stroma hyaluronan predict poor disease outcome in epithelial ovarian cancer. 
Cancer Res 2000; 60:150-155. 
3. Auvinen P, Tammi R, Parkkinen J, Tammi M, Ågren U, Johansson R. Hyaluronan in 
peritumoral stroma and malignant cells associates with breast cancer spreading and 
predicts survival. Am J Pathol 2000; 156:529-536. 
4. Bapat B, Bhurke S, Rosen E, Stokes M, Bhagnani T, Nordstrom B, et al. Risks of 
thromboembolic events among patients diagnosed with metastatic pancreatic ductal 
adenocarcinoma treated with chemotherapy. 2016 Gastrointestinal Cancers Symposium, 
Poster Abstract 380. J Clin Oncol 34, 2016 (suppl 4S; abstr 380). 
5. Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. 
Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 
513(7517):202–209. 
6. Baumgartner G, Gomar-Hoss C, Sakr, L, Ulsperger E, Wogritsch C. The impact of 
extracellular matrix on the chemoresistance of solid tumors – experimental and clinical 
results of hylauronidase as additive to cytostatic chemotherapy. Cancer Lett 1998; 
131:85-99. 
7. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA. 
Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis 
and processing. Am J Pathol 2009 Mar; 174(3):1027-36. 
8. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, et al. Clinical activity 
and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. JCO, 
2014 ASCO Annual Meeting Abstracts. Vol 32, No 15_suppl (May 20 Supplement), 
2014: 8021 © 2014 American Society of Clinical Oncology 
9. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, et al. Safety and Activity 
of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012; 
366:2455-65. 
10. Brekken C, de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in 
solid tumors in a non-linear concentration-dependent manner. Cancer Lett 1998;  
131:65-70. 
11. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous 
thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;  
6: 601-8. 
12. Chow G, Tauler J, Mulchine JL. Cytokines and growth factors stimulate hyaluronan 
production: role of hyaluronan in epithelia to mesenchymal-like transition in non-small 
cell lung cancer. Journal of Biomedicine and Biotechnology 2010; Article ID 485468, 
11 pages. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 101 of 112 
06 November 2017  
13. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM. Gastric 
Adenocarcinoma Review and Considerations for Future Directions. Ann Surg 2005; 
241:27-39 
14. Eikenes L, Tari M, Tufto I, Bruland OS, de Lange Davies C. Hyaluronidase induces a 
transcapillary pressure gradient and improves the distribution and uptake of liposomal 
doxorubicin (Caelyx™) in human osteosarcoma xenografts. Br J Cancer 2005; 93:81-88. 
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
Eur J Cancer 2009; 45:228-247. 
16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, et al. 
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N Engl J Med 
2015:1-11. 
17. GEMZAR® (gemcitabine hydrochloride injection, powder, lyophilized, for solution) 
Package Insert. Eli Lilly and Company. 2014. 
18. Gupta SK. Role of crizotinib in previously treated non-small-cell lung cancer. South 
Asian J Cancer 2014 Apr-Jun; 3(2):138-40. 
19. Halozyme Report 13036. In vivo efficacy and safety evaluation of PEGPH20 as single 
agent or combination with Taxotere in the treatment of LU0697 Huprime® Non-small 
cell lung cancer(NSCLC) xenograft model in nude mice. 
20. Hingorani S, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotskyet EM, et al. 
Final Results of a Phase 1b Study of Gemcitabine Plus PEGPH20 in Patients With Stage 
IV Previously Untreated Pancreatic Cancer. ASCO 2015 Gastrointestinal Cancers 
Symposium, Poster Abstract 359. 
21. Hingorani S, Harris W, Hendifar A, Bullock A, Wu W, Huang Y, et al. High Response 
Rate and PFS with PEGPH20 added to Nab-Paclitaxel/Gemcitabine in Stage IV 
Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results 
of a Randomized Phase 2 Study. ASCO 2015 Gastrointestinal Cancers Symposium, 
Poster Abstract 4006. 
22. Hui R, Gandhi L, Costa EC, Felip E, Ahn M-J, Eder JP. Long-Term Overall Survival for 
Patients with Advanced NSCLC Enrolled in KEYNOTE-001 Study of Pembrolizumab 
ASCO 2016 Annual Meeting, Poster Abstract 9026. 
23. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan 
impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 
2013; 62(1):112-20. 
24. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 
61(2):69-90. 
25. Jiang P, Ramanathan R, Infante J. Hyaluronan accumulation in tumors correlates with 
response to pegylated rHuPH20 hyaluronidase in human tumors: a biomarker strategy. In: 
Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and 
Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; 
Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B35. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 102 of 112 
06 November 2017  
26. Jiang P, Li X, Thompson CB, Huang Z, Araiza F, Osgood R, et al. Effective targeting of 
the tumor microenvironment for cancer therapy. Anticancer Res 2012; 32(4):1203-12. 
27. Joshi M, Liu X, Belani CP. Taxanes, past, present, and future impact on non-small cell 
lung cancer. Anticancer Drugs 2014; 25(4):571-83. 
28. Keytruda® US Prescribing Information, revised October 2015.  
29. Keytruda® US Prescribing Information, revised September 2017. 
30. Kim H-R, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, et al. Hyaluronan 
facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer 
Res 2004; 64:4569-4576. 
31. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 
2004; 5:655-663. 
32. Khorana AA, O’Connell C, Agnelli G, Liebman HA, Lee AYY. Incidental venous 
thromboembolism in oncology patients. J Thromb Haemost 2012; 10(12): 2602-2604. 
33. Klocker J, Sabitzer H, Raunik W, Wieser S, Schumer J. Hyaluronidase as additive to 
induction chemotherapy in advanced squamous cell carcinoma of the head and neck. 
Cancer Lett 1998; 131:113-115. 
34. Kultti A, Li X, Jiang P, Thompson CB, Frost GI, Shepard HM. Therapeutic targeting of 
hyaluronan in the tumor stroma. Cancers 2012; 4(3):873-903. 
35. Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R et al. Accumulation 
of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and 
modulates the pancreatic cancer microenvironment. Biomed Res Int 2014; 2014:817613.  
36. Li Y, Li L, Brown TJ, Heldin P. Silencing of hyaluronan synthase 2 suppresses the 
malignant phenotype of invasive breast cancer cells. Int J Cancer 2007; 120:2557-2567. 
37. Manuel ER, Lampa MG, Kim J, Chung V, D'Apuzzo M, Thompson CB, et al. Control of 
PDAC Tumor Progression by RNA Interference Targeting Indoleamine 2,3-Dioxygenase 
using Salmonella as a Delivery Vehicle Facilitated by PEGPH20. Abstract B86 presented 
at May 2014 AACR Pancreatic Cancer: Innovations in Research and Treatment Meeting, 
New Orleans. 
38. Matsueda S and Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol 
2014; 20(7):1657-1666 
39. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug resistance in 
cancer cells by hyaluronan. J Biol Chem 2003 Jul 11; 278(28):25285-8. 
40. Muro K, Bang Y, Shankaran V, Geva R, Catenacci D, Gupta S, Eder J, et al. 
Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with 
advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab 
(Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol 33, 2015 (suppl 3; abstr 3) 
41. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab 
for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a 
multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717–26 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 103 of 112 
06 November 2017  
42. NCCN Guidelines Version 2.2013: Venous Thromboembolic Disease. 
43. Nishida Y, Knudson W, Knudson CB, Ishiguro N. Antisense inhibition of hyaluronan 
synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. 
Exp Cell Res 2005; 307:194-203. 
44. Nishino M, Gargano M, Suda M, et al. Optimizing immune-related tumor response 
assessment: does reducing the number of lesions impact response assessment in 
melanoma patients treated with ipilimumab?. J Immunother Cancer. 2014;2:17.  
45. Nishino M, Hurder AG, Gargano M, et al. Developing a Common Language for Tumor 
Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional 
Measurements. Clin Cancer Res 2013;19:3936-3943.  
46. Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of 
Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced 
Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol 2015; 1-8. 
47. Pillwein K, Fuiko R, Slavc I, Czech T, Hawliczek G, Bernhardt G, et al. Hyaluronidase 
additional to standard chemotherapy improves outcome for children with malignant brain 
tumors. Cancer Lett 1998; 131:101-108. 
48. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. 
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic 
ductal carcinoma. Cancer Cell 2012; 21:418-29. 
49. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in 
pancreas cancer. Br J Cancer 2013; 108:1-8. 
50. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, et al. Tumor 
cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. 
Cancer Res 1998; 58:342-347. 
51. Sculier JP, Moro-Sibilot D. First- and second-line therapy for advanced nonsmall cell 
lung cancer. Eur Respir J. 2009 Apr; 33(4):915-30. 
52. Setälä LP, Tammi MI, Tammi RH, Eskelinen MJ, Lipponen PK, Agren UM, et al. 
Hyaluronan expression in gastric cancer cells is associated with local and nodal spread 
and reduced survival rate. Br J Cancer 1999; 79:1133-1138. 
53. Shuster S, Frost GI, Csoka AB, Formby B, Stern R. Hyaluronidase reduces human breast 
cancer xenografts in SCID mice. Int J Cancer 2002; 102:192-197. 
54. Singha NC, Nekoroski T, Zhao C, Symons R, Jiang P, Frost GI. Tumor-Associated 
Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy. Mol Cancer Ther 2015; 
14:523-532 
55. Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan 
synthesis impairs subcutaneous growth and vascularization in immunocompromised 
mice. Amer J Path 2002; 161:849-857. 
56. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in 
human malignancies. Exp Cell Res 2011; 317:383-391. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 104 of 112 
06 November 2017  
57. Spruss T, Bernhardt G, Schonenberger H, Schiess, W. Hyaluronidase significantly 
enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J 
Cancer Res Clin Oncol 1995; 121:193-202. 
58. Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. 
Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical 
animal models. Mol Cancer Ther 2010; 9:3052-3064.  
59. Tetzlaff ED, Cheng JD and Ajani JA. Thromboembolism in Gastrointestinal Cancers. 
Gastrointest Cancer Res 2008; 2:267-272. 
60. TAXOTERE® (docetaxel) Package Insert. Sanofi-Aventis US LLC. 2014. 
61. Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and 
malignancy in cancer cells. Semin Cancer Biol 2008 Aug; 18(4):244-50. 
62. Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, et al. Antisense-
mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and 
progression of breast cancer. Cancer Res 2005; 65:6139-6150. 
63. Wang J, Binder KR, Khatri R, Jaffee E and Laheru D. Immune Therapy in GI 
Malignancies: A Review. J Clin Oncol 2015; 1-9. 
64. Whatcott CJ, Jiang P, Watanabe A, Hostetter G, Hu C, Shepard HM, et al. Hyaluronan 
deposition correlates with poor survival in pancreatic cancer Abstract LB-307, AACR 
National Meeting. Cancer Res 2011; 71 Suppl. 1. 
65. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the 
Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response 
Criteria. Clin Cancer Res 2009; 15(23): 7412-7420. 
66. Wolf RA, Chaung LY, O'Hara D, Smith TW, Muller JE.The serum kinetics of bovine 
testicular hyaluronidase in dogs, rats and humans. J Pharmacol Exp Ther 1982; 
Aug;222(2):331-7. 
67. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, et al. Survival of metastatic 
gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011; 2: 
77-84. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 105 of 112 
06 November 2017  
17. 
APPENDICES 
APPENDIX A. ABBREVIATIONS 
The following abbreviations are used in this study protocol. 
Abbreviation 
Term 
ADA 
anti-drug antibodies 
AE 
adverse event 
AG 
nab-paclitaxel plus gemcitabine 
ALK 
anaplastic lymphoma kinase 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase  
ANC 
absolute neutrophil count 
AP 
Asia Pacific 
AST 
aspartate aminotransferase  
AUC 
area-under-the-concentration time curve 
BUN 
blood urea nitrogen 
CFR 
Code of Federal Regulations 
CIV 
Central Imaging Vendor 
CL 
clearance 
Cmax 
maximum observed concentration 
Cmin 
minimum observed concentration 
CR 
complete response 
CT 
computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
CTLA-4 
cytotoxic T-lymphocyte-associated protein 4 
DCE-MRI 
dynamic-contrast enhanced magnetic resonance imaging 
DCR 
disease control rate 
DLT 
dose limiting toxicity 
Doc 
docetaxel alone  
DOR 
duration of response 
DVT 
deep vein thrombosis 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 106 of 112 
06 November 2017  
Abbreviation 
Term 
EC 
Ethics Committee 
ECG 
electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
electronic case report form 
EE 
efficacy evaluable 
EGFR 
epidermal growth factor receptor 
EMT 
epithelial-mesenchymal transition 
FDA 
Food and Drug Administration 
FNA 
Fine Needle Aspirates 
GCP 
Good Clinical Practice 
GEM 
Gemcitabine 
HA 
Hyaluronan 
HER2+ 
human epidermal growth factor receptor 2 positive 
High-HA 
high expression of HA 
ICF 
Informed Consent Form  
ICH 
International Conference on Harmonisation  
IgE 
immunoglobulin E 
IgG 
immunoglobulin G 
INR 
international normalized ratio 
IRB 
Institutional Review Board  
irRC 
Immune-response related criteria 
ITT 
Intent-to-treat 
IWRS 
Interactive Web Response System 
MedDRA 
Medical Dictionary of Regulatory Activities 
MRI 
Magnetic Resonance Imaging 
MSE 
Musculoskeletal Event 
MTD 
Maximum Tolerated Dose 
NCCN 
National Comprehensive Cancer Network 
NCI  
National Cancer Institute  
NK 
Natural Killer Cells 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 107 of 112 
06 November 2017  
Abbreviation 
Term 
NSAID 
nonsteroidal anti-inflammatory drugs 
NSCLC 
Non-Small Cell Lung Cancer 
ORR 
Objective Response Rate 
OS 
Overall Survival 
OTC 
over-the-counter  
PAG 
PEGPH20 combined with nab-paclitaxel plus gemcitabine 
PDoc 
PEGPH20 plus docetaxel 
PD-1 
programmed cell death-1 
PDA 
pancreatic ductal adenocarcinoma 
PD-L1 
PD-1 ligand 1 
PEG 
Polyethylene glycol 
PEGPH20 
PEGylated recombinant human hyaluronidase 
PEGPEM 
PEGylated recombinant human hyaluronidase (PEGPH20) combined with 
pembrolizumab (Keytruda®) 
PET 
positron emission tomography 
PFS 
progression-free survival 
PK 
pharmacokinetic(s) 
PRO 
patient reported outcome 
PT 
prothrombin time 
PTT 
partial thromboplastin time 
RECIST 
Response Evaluation Criteria in Solid Tumors 
rHuPH20 
PH20 recombinant human hyaluronidase enzyme 
ROW 
Rest Of The World  
RP2D 
recommended Phase 2 dose 
rHuPH20  
recombinant human hyaluronidase PH20 
SAE  
serious adverse event  
SD 
stable disease 
t1/2 
terminal half-life 
TB 
total bilirubin  
TE 
thromboembolic event 
tmax 
time to maximum concentration 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 108 of 112 
06 November 2017  
Abbreviation 
Term 
TME 
tumor microenvironment 
TPS 
Tumor Proportion Score 
ULN 
upper limit of normal 
US 
United States 
Vd 
volume of distribution 
WBC 
white blood cell 
WOCBP 
women of childbearing potential 
 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 109 of 112 
06 November 2017  
APPENDIX B. EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCES STATUS 
Activity Status 
Description 
0 
Asymptomatic, fully active, and able to carry on all predisease performance 
without restrictions. 
1 
Symptomatic, fully ambulatory but restricted in physical strenuous activity and 
able to carry out performance of a light or sedentary nature, e.g., light 
housework, office work. 
2 
Symptomatic, ambulatory and capable of self-care but unable to carry out any 
work activities. Up and about more than 50% of waking hours, but not 
bedridden. 
3 
Symptomatic, capable of only limited self-care, confined to a bed/chair more 
than 50% of waking hours, but not bedridden. 
4 
Completely disabled. Cannot carry on self-care. Totally bedridden. 
5 
Dead 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 110 of 112 
06 November 2017  
APPENDIX C. RESPONSE EVALUATION CRITERIA IN SOLID 
TUMORS (RECIST 1.1) 
Target Lesion Response Evaluation: 
Complete Response (CR) 
Disappearance of all target lesions. Any pathological lymph nodes (whether 
target or non-target) must have reduction in short axis to <10 mm. 
Partial Response (PR) 
At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters. 
Progressive Disease (PD) 
At least a 20% increase in the sum of diameters of target lesions, taking as 
reference the smallest sum on study thus far, nadir (this includes the baseline 
sum if that is the smallest on study). In addition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least 5 mm. 
The appearance of one or more new lesions is also considered progression. 
Stable Disease (SD) 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study 
Non-Target Lesion Response Evaluation: 
Complete Response (CR) 
Disappearance of all non-target lesions and normalization of tumor marker 
level. All lymph nodes must be non-pathological in size (<10 mm short axis). 
Non-CR/Non-PD 
Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits. 
Progressive Disease (PD) 
Unequivocal progression of existing non-target lesions. 
Overall Response Evaluation: 
Target Lesion Response 
Non-Target Lesion 
Response 
New Lesions 
Overall 
Response 
CR 
CR or NA 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all evaluated or NA 
No 
PR 
SD 
Non-PD or not all evaluated or NA 
No 
SD 
Not all evaluated 
Non-PD or NA 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
NA=Not Applicable (i.e., no non-target lesions identified at baseline); NE=Not Evaluable. 
Source: Eisenhauer 2009 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 111 of 112 
06 November 2017  
APPENDIX D. NEW YORK HEART ASSOCIATION CLASSIFICATIONS 
1994 Revisions to Classification of Functional Capacity and Objective Assessment of Patients 
with Diseases of the Heart 
Functional Capacity 
Objective Assessment 
Class I. Patients with cardiac disease but without 
resulting limitation of physical activity. Ordinary 
physical activity does not cause undue fatigue, 
palpitation, dyspnea, or anginal pain. 
A. No objective evidence of cardiovascular 
disease. 
Class II. Patients with cardiac disease resulting in 
slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal 
pain. 
B. Objective evidence of minimal cardiovascular 
disease. 
Class III. Patients with cardiac disease resulting in 
marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity 
causes fatigue, palpitation, dyspnea, or anginal 
pain. 
C. Objective evidence of moderately severe 
cardiovascular disease. 
Class IV. Patients with cardiac disease resulting in 
inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the 
anginal syndrome may be present even at rest. If 
any physical activity is undertaken, discomfort is 
increased. 
D. Objective evidence of severe cardiovascular 
disease. 


Halozyme, Inc. 
Protocol HALO-107-101 Amendment 4 
CONFIDENTIAL 
Page 112 of 112 
06 November 2017  
APPENDIX E. IMMUNE-RESPONSE RELATED CRITERIA 
Immune-response related criteria (irRC) based on bidimensional measurements of measurable 
lesions were first introduced by Wolchok et al in 2009. This protocol will adopt a modified 
version of the criteria based on unidimensional measurements of measurable lesions, as 
described by Nishino et al in 2013 and 2014, as follows: 
At the baseline tumor assessment, the sum of the longest diameters (SLD) of all identified index 
lesions (2 per organ, up to 5 in total) will be calculated. At each subsequent tumor assessment, 
the SLD of the index lesions and of new measurable lesions (2 per organ, up to 5 in total) are 
added together to provide the total tumor burden = SLDindex lesions + SLDnew, measurable lesions. Total 
tumor burden will be used to assess the immune related response as described in the table below. 
Immune-Response Related Criteria 
Index Lesions (Baseline 
Measurable Lesions)  
Up to 2 per organ, up to 5 in total 
(see RECIST 1.1 for guidelines on measurable lesions) 
• 
≥10 mm in the longest diameter for all except for lymph nodes 
• 
≥15 mm in short axis for lymph nodes 
New Lesions (Measurable) 
 
Up to 2 per organ, up to 5 in total 
• 
≥10 mm in the longest diameter for all except for lymph nodes 
• 
≥15 mm in short axis for lymph nodes 
Tumor Burden 
SLDindex lesions + SLDnew, measurable lesions 
If a lymph node qualifies and chosen as a new measurable lesion for 
tumor burden calculations, its short axis length is included in the sum  
(SLDnew, measurable lesions) 
Immune Related Response 
Assessment 
PD: ≥20% increase in tumor burden from nadir 
PR: ≥30% decrease in tumor burden from baseline  
SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD 
CR: Disappearance of all lesions including non-index lesions and new 
non-measurable lesions, lymph nodes must be <10 mm in short axis) 
Confirmation 
Confirmation is required for CR, PR and PD by a consecutive 
observation not less than 4 weeks apart  
Source: Wolchok 2009; Nishino 2013; Nishino 2014. 

SAP_001.pdf: 
Page 1 of 31 
STATISTICAL ANALYSIS PLAN 
A Phase 1b Open-Label Study of PEGylated Recombinant 
Human Hyaluronidase (PEGPH20) Combined with 
Pembrolizumab in Subjects with Selected 
Hyaluronan-High Solid Tumors 
Investigational Product: PEGPH20 
Protocol Number: HALO-107-101 
Sponsor: 
Halozyme, Inc. 
11388 Sorrento Valley Road 
San Diego, CA 92121 
Office: 
 
Version Number: 1.0 
Date: 19 April, 2019 
CONFIDENTIAL 
This document and the information it contains are the property of Halozyme, Inc. and are provided for the sole and 
exclusive use of Investigators in this clinical study. The information in this document may not be disclosed unless 
such disclosure is required by Federal or applicable State Law or Regulations, or unless there is prior written consent 
from Halozyme, Inc. Subject to the foregoing, this information may be disclosed only to those persons involved in 
the clinical investigation who need it, and who share the obligation not to disseminate this information further. 
NCT #: NCT02563548


Page 2 of 31 
 
 
 
 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Nu mber: HAL0-107-101 
  
V_e_rs_i_on_Dat<:.: 19 April 2019 
 
SIGNATURE PAGE 
 
 
Protocol Title and Protocol Number 
 
 
We, the undersigned, have reviewed and approve this Statistical Analysis Plan. 
 
 
Signature 
Date 
 
 
 
 
Medpace, Inc. 
 
.   
Medpace, Inc. 
 
Halozyme, Inc. 
 
 
 
 
 
 
 
 
 
 
 
 
Digitally signed by
 
DN: cn=
, o=Halozyme, ou, 
ema.il=
,   c=US 
Date: 2019.05.06 09:25:57 -07'00' --· 
 
 
 
Halozyme, Inc. 
 
 
 


Page 2 of 31 
 
{ 


Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
Page 3 of 31 
 
 
VERSION HISTORY 
 
Version 
Date 
Description 
1.0 
19 April 2019 
Original final version 


Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
Page 4 of 31 
 
 
TABLE OF CONTENTS 
1 
Introduction ........................................................................................................................... 9 
2 
Study Objectives .................................................................................................................... 9 
2.1 Dose Escalation ................................................................................................................ 9 
2.2 Dose Expansion ................................................................................................................ 9 
3 
Study Overview ................................................................................................................... 10 
3.1 Study Design .................................................................................................................. 10 
3.1.1 Phase 1b Dose Escalation Portion ........................................................................ 11 
3.1.2 Phase 1b Dose Expansion Portion ........................................................................ 12 
3.2 Discontinuation of Treatment ......................................................................................... 13 
3.3 Study Centers.................................................................................................................. 14 
3.4 Randomization and Blinding .......................................................................................... 14 
3.5 Study Duration................................................................................................................ 14 
3.6 Tumor Response and Disease Progression Assessment ................................................. 14 
3.7 Disease Progression Criteria ........................................................................................... 15 
4 
Statistical Methods .............................................................................................................. 15 
4.1 General Considerations................................................................................................... 15 
4.2 Missing Data .................................................................................................................. 15 
4.3 Study Endpoints ............................................................................................................. 17 
4.3.1 Dose Escalation .................................................................................................... 17 
4.3.2 Dose Expansion .................................................................................................... 17 
4.4 Analysis Populations ...................................................................................................... 18 
4.4.1 Enrolled Population .............................................................................................. 18 
4.4.2 Safety Population .................................................................................................. 18 
4.4.3 DLT Evaluable Population ................................................................................... 18 
4.4.4 PK Analysis Population ........................................................................................ 18 
4.4.5 Efficacy Evaluable Population ............................................................................. 18 
4.4.6 Tumor Response Evaluable Population ................................................................ 18 
4.5 Subject Enrollment and Disposition ............................................................................... 19 
4.6 Demographics and Other Baseline Data ......................................................................... 19 
4.6.1 Demographics ....................................................................................................... 19 
4.6.2 Baseline Disease Characteristics ........................................................................... 19 


Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
Page 5 of 31 
 
 
4.6.3 Medical History and Prior Cancer Treatments ..................................................... 20 
4.6.4 Prior and Concomitant Medications ..................................................................... 20 
4.7 Efficacy Evaluations ....................................................................................................... 21 
4.7.1 Definitions ............................................................................................................ 21 
4.7.2 Analysis of Unconfirmed/Confirmed ORR, DCR and DOR ................................ 24 
4.7.3 Analysis of PFS and OS ....................................................................................... 24 
4.7.4 Exploratory Analyses ........................................................................................... 25 
4.7.5 Adjustment for Covariates .................................................................................... 25 
4.7.6 Multicenter Studies ............................................................................................... 25 
4.7.7 Multiple Comparisons/Multiplicity ...................................................................... 25 
4.8 Subgroup Analysis .......................................................................................................... 25 
4.9 Safety Evaluations .......................................................................................................... 25 
4.9.1 Definitions ............................................................................................................ 25 
4.9.2 Extent of Exposure ............................................................................................... 25 
4.9.3 Analysis of DLTs .................................................................................................. 28 
4.9.4 Analysis of AEs .................................................................................................... 28 
4.9.5 Vital Signs and Body Weight ............................................................................... 29 
4.9.6 Clinical Laboratory Evaluation ............................................................................. 29 
4.9.7 12-Lead Electrocardiogram (ECG) ....................................................................... 30 
4.10 ECOG Performance Status ............................................................................................. 30 
4.11 Immunogenicity Assessments ........................................................................................ 30 
4.12 Sample Size Determination ............................................................................................ 30 
4.13 Interim Analysis and Early Stopping Rules ................................................................... 31 
5 
Changes from the Protocol Specified Statistical Analysis ..................................................... 31 
6 
References .............................................................................................................................. 31 


Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
Page 6 of 31 
 
 
LIST OF ABBREVIATIONS 
 
AE 
adverse event 
ALT 
alanine transferase 
ANC 
absolute neutrophil count 
AST 
aspartate aminotransferase 
AUC 
area-under-the-concentration time curve 
BUN 
blood urea nitrogen 
CIV 
central imaging vendor 
Cmax 
maximum observed concentration 
Cmin 
minimum observed concentration 
CR 
complete response 
CRF 
case report form 
CT 
computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
DCE-MRI 
dynamic contrast-enhanced magnetic resonance imaging 
DCR 
disease control rate 
DLT 
dose limiting toxicity 
DOR 
duration of response 
ECG 
electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
HA 
Hyaluronan 
HA-high 
hyaluronan high 
irRC 
immune-related response criteria 
INR 
international normalized ratio 


Page 7 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
 
MedDRA 
Medical Dictionary of Regulatory Activities 
MRI 
Magnetic Resonance Imaging 
MTD 
maximum tolerated dose 
NSCLC 
non-small cell lung cancer 
ORR 
objective response rate 
OS 
overall survival 
PD 
Pharmacodynamics 
PD-1 
Programmed cell death-1 
PD-L1 
Programmed death-ligand 1 
PEGPEM 
PEGylated recombinant human hyaluronidase combined with 
pembrolizumab 
PEGPH20 
PEGylated recombinant human hyaluronidase 
PET 
positron emission tomography 
PFS 
progression free survival 
PK 
Pharmacokinetics 
PR 
partial response 
PT 
prothrombin time 
PTT 
partial prothrombin time 
RECIST 
response evaluation criteria in solid tumors 
RP2D 
recommended phase 2 dose 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
T1/2 
terminal half-life 
TB 
total bilirubin 
 
 
 


Page 8 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
 
TEAE 
treatment emergent adverse event 
Tmax 
time to maximum concentration 
TME 
tumor microenvironment 
ULN 
upper limit of normal 


Page 9 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
 
 
1 
INTRODUCTION 
The purpose of this document is to provide a description of the statistical methods and 
procedures to be implemented in the analysis of data collected in the study HALO-107-101 
conducted by Halozyme, Inc. This document is based on the Protocol HALO-107-101 
Amendment 4 entitled “A Phase 1b Open-Label Study of PEGylated Recombinant Human 
Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected 
Hyaluronan-High Solid Tumors” and dated 6 November 2017. 
 
2 
STUDY OBJECTIVES 
The study has two portions, namely, a Dose Escalation portion and a Dose Expansion portion. 
The objectives for each portion are as follows. 
 
2.1 Dose Escalation 
Primary: 
• To assess the safety and tolerability of PEGylated recombinant human hyaluronidase 
(PEGPH20) combined with pembrolizumab (Keytruda®) (PEGPEM) in subjects with 
relapsed/refractory non-small cell lung cancer (NSCLC) and relapsed/refractory 
gastric adenocarcinoma. 
• To determine the recommended phase 2 dose (RP2D) of PEGPH20 when administered 
with pembrolizumab in subjects with relapsed/refractory NSCLC or 
relapsed/refractory gastric adenocarcinoma. 
Secondary: 
• To assess the pharmacokinetics (PK) of PEGPH20 when given in combination with 
pembrolizumab in subjects with relapsed/refractory NSCLC or relapsed/refractory 
gastric adenocarcinoma. 
• To obtain an early assessment of the antitumor activity of PEGPEM, as assessed by 
objective response rate (ORR), duration of response (DOR), disease control rate 
(DCR) and progression free survival (PFS) based on Response Evaluation Criteria in 
Solid Tumors (RECIST) v1.1, and overall survival (OS) in subjects with 
relapsed/refractory NSCLC or relapsed/refractory gastric adenocarcinoma. 
Exploratory: 
• To assess the PK of pembrolizumab when given in combination with PEGPH20 in 
subjects with relapsed/refractory NSCLC or relapsed/refractory gastric 
adenocarcinoma. 
 
2.2 Dose Expansion 
The objectives described below will be evaluated in hyaluronan-high (HA-high) subjects with 
relapsed/refractory NSCLC and HA-high subjects with relapsed/refractory gastric adenocarcinoma. 


Page 10 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
Primary: 
• To evaluate the efficacy of PEGPEM as assessed by ORR based on RECIST v1.1. 
Secondary: 
• To evaluate the efficacy of PEGPEM as assessed by DOR, DCR, and PFS based on 
RECIST v1.1, and OS. 
• To evaluate the efficacy of PEGPEM as assessed by ORR, DOR, DCR, and PFS based 
on immune-related response criteria (irRC). 
• To characterize the PK of PEGPH20 when given in combination with pembrolizumab. 
• To evaluate the safety and tolerability profile of PEGPEM. 
Exploratory: 
• To evaluate the efficacy of PEGPEM, as assessed by ORR, DOR, DCR and PFS based 
on RECISIT v1.1 criteria and irRC, by programmed death-ligand 1 (PD-L1) 
expression levels. 
• To assess the treatment effect of PEGPEM as follows: 
− Based on HA levels in plasma and tumors, or other potential biomarkers. 
− Based on tumor blood flow and metabolic activity as assessed by dynamic contrast- 
enhanced magnetic resonance imaging (DCE-MRI) and positron emission 
tomography (PET)/computed tomography (CT) scans, respectively. 
• To assess the PK of pembrolizumab when given in combination with PEGPH20. 
 
3 
STUDY OVERVIEW 
3.1 Study Design 
This Phase 1b study of PEGPEM consists of 2 portions: 
• A Dose Escalation portion in subjects with relapsed/refractory Stage IIIB or IV 
NSCLC after failing at least 1 previous platinum-based chemotherapy regimen (refer 
to Inclusion Criterion #2 in the protocol) and subjects with relapsed/refractory locally 
advanced or  metastatic gastric adenocarcinoma after failing at least 1 previous 
chemotherapy  regimen for locally advanced or metastatic disease. 
• Followed by a Dose Expansion portion in: 
− Previously untreated, hyaluronan-high (HA-high) subjects with Stage IIIB or IV 
NSCLC 
− Previously treated, HA-high subjects with relapsed/refractory Stage IIIB or IV 
NSCLC having failed no more than 1 previous platinum-based chemotherapy 
regimen (refer to Inclusion Criterion #3 in the protocol) for locally advanced or 
metastatic disease 


Page 11 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
− HA-high subjects with relapsed/refractory locally advanced or metastatic gastric 
adenocarcinoma having failed no more than 2 previous chemotherapy regimens 
for locally advanced or metastatic disease 
Since PEGPH20 has not been evaluated in clinical studies in combination with pembrolizumab, 
this study will have a Dose Escalation portion to evaluate the safety and tolerability of PEGPEM 
treatment before the Dose Expansion portion is initiated. The Dose Escalation portion will also 
be used to determine the dose of PEGPH20 to be evaluated in the Dose Expansion portion. 
 
3.1.1 Phase 1b Dose Escalation Portion 
This portion of the study is a single-arm, dose escalation study of PEGPH20 in combination with 
pembrolizumab. Using a standard 3+3 dose escalation design, approximately 3 to 6 subjects in 
each cohort will receive PEGPH20 + pembrolizumab. PEGPH20 will be administered on Day 1, 
Day 8 and Day 15 of each 21-day cycle to consecutive cohorts in increasing dose levels (1.6, 2.2, 
2.6, 3.0, and 4.0 µg/kg). Pembrolizumab will be administered on Day 1 of each cycle, 4-6 hours 
after the dose of PEGPH20. If the maximum tolerated dose (MTD) is not reached at 4.0 µg/kg, 
higher doses may be evaluated. If ≥2 subjects experience a dose limiting toxicity (DLT) at the 
1.6 µg/kg dose level, Cohort -1 will be opened and subjects will be dosed at 1.0 µg/kg on Day 1, 
Day 8, and Day 15 of each 21-day cycle. The RP2D of PEGPH20 will be the MTD determined 
in Dose Escalation or the Sponsor may decide to choose a dose lower than the MTD and which 
has completed evaluation in Dose Escalation and is found to be safe and tolerable to evaluate in 
Dose Expansion. 
The number of cohorts studied and number of subjects exposed to a given dose level will depend 
on the doses tested. It is anticipated that up to 5 dose levels will be studied for a total of 
approximately 30 subjects exposed to study medication. The dose allocation for 5 cohorts of 
subjects assigned to the 5 preselected dose levels and the -1 cohort assigned to the preselected 
dose of 1.0 µg/kg (if ≥2 subjects experience a DLT at 1.6 µg/kg dose level) is shown as an 
example in Table 1. Study medication dosing and treatment schedule is shown in Table 2. 
Table 1: 
Dose Allocation and Cohort Schedule - Dose Escalation Portion 
 
Cohort 
PEGPH20 µg/kg 
Pembrolizumab mg/kg 
-1 
1.0 
2 
1 
1.6 
2 
2 
2.2 
2 
3 
2.6 
2 
4 
3.0 
2 
5 
4.0a 
2 
Abbreviations: PEGPH20 = PEGylated Recombinant Human Hyaluronidase 
Note: Each treatment cycle is 21 days. Dose interruption and modifications are permitted. 
a If the MTD is not reached at 4.0 µg/kg, higher doses may be evaluated. 
Safety data from all subjects dosed will be reviewed to determine the RP2D. Dose escalation will 
be guided by safety data from each subject during the 21 days following their first dose of 


Page 12 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
PEGPH20. Intra-subject dose escalation to the next PEGPH20 dose studied may be allowed if 
the Investigator deems it in the best interest of the subject and after discussion with the Sponsor 
and provided the next PEGPH20 dose studied has been determined not to have exceeded the 
MTD. 
• If none of initial 3 subjects in a given cohort experience a DLT within 21 days of 
starting treatment, enrollment and dosing may proceed at the next planned dose level. 
• If 1 of 3 initial subjects at a given dose level experiences a DLT within the first 
21 days of treatment, 3 additional subjects will be enrolled and dosed at the same 
dose level. If ≤1 of 6 subjects experiences a DLT, dose escalation may continue to the 
next planned higher dose. 
• If ≥2 subjects at a given dose level experience a DLT within the first 21 days of 
treatment, that dose level will be considered to have exceeded the MTD and dose 
escalation will be stopped. If the previous dose level did not already have 6 subjects 
treated with ≤1 DLT, enrollment and dosing will then resume in the previous dose 
level with additional subjects up to a total of 6 subjects. The highest dose level at 
which no more than 1 of 6 evaluable subjects has experienced a DLT in the first 
3 weeks of treatment will be considered the MTD for the PEGPEM combination. The 
RP2D will be based on the overall safety profile. 
• If ≥2 subjects at the 1.6 µg/kg dose level experience a DLT within the first 21 days of 
treatment, Cohort -1 will be opened at a lower dose level of 1.0 µg/kg. 
Note: Additional subjects may be enrolled in each cohort to further assess the tolerability of 
PEGPEM and determine an acceptable safety profile prior to the enrollment in the next dose 
level and Dose Expansion portion of the study. 
 
3.1.2 Phase 1b Dose Expansion Portion 
Approximately 51 HA-high subjects will be studied in the Dose Expansion portion at the RP2D 
identified in the Dose Escalation portion: 
• Approximately 30 subjects with Stage IIIB or IV NSCLC, previously untreated or 
treated and having failed no more than 1 previous platinum-based chemotherapy 
(refer to Inclusion Criterion #3) 
• Approximately 21 subjects with relapsed/refractory gastric adenocarcinoma having 
failed no more than 2 previous chemotherapy regimens. 
In Dose Expansion, PEGPH20 will be administered on Day 1, Day 8, and Day 15 of each 21-day 
cycle (i.e., 3 doses / cycle) and pembrolizumab (200 mg every 21 days) on Day 1 of each cycle 
(i.e., 1 dose / cycle), 4-6 hours after the completion of PEGPH20 administration. The dosing 
schedule is shown in Table 2. 
If a dose of PEGPH20 is missed on Day 1 of Cycle 2 or beyond, the cycle will continue as 
scheduled. If it is known that pembrolizumab will be missed or held on Day 1, PEGPH20 should 
also be held and the cycle will not start until the first dose of pembrolizumab is administered. 
This will require planning such that the dose of PEGPH20 can be given before the 
pembrolizumab dose is set to resume. 


Page 13 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
Table 2: 
Study Medication Dosing and Treatment Schedule – Dose Escalation and 
Dose Expansion 
 
Time point 
PEGPEM Treatment by Treatment Group 
Subjects with NSCLC 
Cycle 1 and Beyond (Each Cycle 21 Days) 
Week 1 
Day 1 
PEGPH20 
Pembrolizumab (4-6 hours after PEGPH20) 
Week 2 
Day 8 
PEGPH20 
Week 3 
Day 15 
PEGPH20 
Subjects with Gastric Adenocarcinoma 
Cycle 1 and Beyond (Each Cycle 21 Days) 
Week 1 
Day 1 
PEGPH20 
Pembrolizumab (4-6 hours after PEGPH20) 
Week 2 
Day 8 
PEGPH20 
Week 3 
Day 15 
PEGPH20 
Abbreviations: PEGPEM = PEGPH20 in combination with pembrolizumab; PEGPH20 = PEGylated Recombinant 
Human Hyaluronidase; NSCLC = non-small cell lung cancer 
Notes: Dose interruption and modifications are permitted. 
Subjects with NSCLC will be studied first, followed by subjects with gastric adenocarcinoma. 
Visit window is ±2 days of the specified times. 
 
3.2 Discontinuation of Treatment 
Treatment in both portions of the study will continue until death, withdrawal of consent from the 
study, disease progression, or unacceptable toxicity; however, subjects with asymptomatic 
disease progression will be allowed to continue study treatment at the Investigator’s discretion 
despite evidence of increasing tumor burden or appearance of new lesions for up to 6 weeks if 
the subject is “clinically stable”. Clinically stable is defined as: 
• Absence of symptoms and signs indicating clinically significant PD (including 
worsening of laboratory values) indicating disease progression and 
• No decline in Eastern Cooperative Oncology Group (ECOG) performance status and 
• Absence of rapid progression of disease or of progressive tumor at critical anatomical 
sites (e.g., cord compression) requiring urgent alternative medical intervention. 


Page 14 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
Dose interruptions and modifications of study treatment are permitted. Investigators may also 
discontinue study treatment if it is no longer in the best interest of the subject. 
 
3.3 Study Centers 
Both portions of the study will be conducted at multiple centers. 
 
3.4 Randomization and Blinding 
This is a multi-center, open-label, non-randomized study. 
 
3.5 Study Duration 
The study will consist of an optional prescreening period for HA-testing in Dose Expansion (per 
Protocol Amendment 4), a screening period of up to 28 days, a treatment period (21-day cycles), 
a 30-day post-treatment period (after last dose) for collection of AEs and a long-term follow-up. 
Subjects who discontinue treatment with PEGPH20 and pembrolizumab will be followed every 
12 weeks for survival until death, withdrawal of consent, or lost to follow-up. 
 
3.6 Tumor Response and Disease Progression Assessment 
In both portions of the study, tumor response and progression will be assessed by the Investigator 
at the end of Cycle 2, Cycle 4 and then at the end of every fourth treatment cycle thereafter (i.e., 
Week 3 of Cycles 2, 4, 8, 12, 16 and beyond) based on RECIST v1.1 criteria (Eisenhauer 2009; 
see Appendix C of the protocol). In the dose expansion portion, tumor response and progression 
will also be assessed by the Investigator at the end of above mentioned cycles using a modified 
unidimensional version of the irRC criteria (Nishino 2013, Nishino 2014; see Appendix E of the 
protocol) first introduced by Wolchok (2009). Tumor assessment scans (CT/MRI of chest, 
abdomen, pelvis, and other areas of known or newly suspected disease) should be performed at 
Screening (within 28 days prior to first dose of study drugs) and obtained any time on or after 
Day 15 (of Cycles 2, 4, 8, 12, 16 and every fourth treatment cycle thereafter) to allow enough 
time for the scan to be reviewed locally prior to the subject’s next scheduled dosing visit. 
Additionally, tumor images associated with NSCLC cancer type will be assessed by an 
independent reviewer from a third-party vendor, Imaging Endpoints. Efficacy analyses related to 
NSCLC cancer type using RECIST v1.1 will also be performed based on the tumor assessments 
from Imaging Endpoints. 
A CT/MRI brain scan must be performed at Screening (within 28 days prior to first dose of study 
drugs), to assess potential central nervous system disease and/or metastases. 
For the duration of the study (i.e., post-baseline), CT/MRI of the brain will be performed if 
clinically indicated, and within a target of 1 week after a subject achieves a complete response 
(CR). For NSCLC subjects with a history of treated brain metastases, brain scans will be 
performed at tumor assessment time points. 
For a confirmed best response of CR or partial response (PR) based on RECIST v1.1 and irRC, a 
confirmatory scan must be performed no sooner than 28 days after the initial scan that showed a 
PR or a CR. A confirmatory scan should also be performed to confirm disease progression (PD) 
based on irRC no sooner than 28 days after the initial scan that showed progression. 


Page 15 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
3.7 Disease Progression Criteria 
Disease progression will be defined by the presence of 1 or both of the following, based on the 
Investigator’s assessment: 
• Disease progression documented by CT scan/MRI scan based on RECIST v1.1. 
• Clinical tumor-related progression that is well documented in the absence of scans 
demonstrating radiographic disease progression. 
 
4 
STATISTICAL METHODS 
4.1 General Considerations 
In general, continuous variables will be summarized using descriptive statistics (N, mean, 
standard deviation [SD], median, minimum [min], maximum [max], and quartiles). Categorical 
variables will be summarized using frequencies and percentages. In each summary table, figure 
or data listing, analysis population considered will be included in the title. 
PEGPH20 and pembrolizumab are referred to as study drugs. 
Study day 1 for a subject is defined as the first day that any study treatment is administered to the 
subject. The day before the study day 1 is referred to as study day −1. Unless otherwise indicated, 
the baseline value of a parameter is defined as the latest non-missing value taken prior to the 
administration of any study drug. 
Statistical analyses will be performed and related outputs will be produced using the SAS® 
software Version 9.3 or higher. All tables, figures, and data listings will be independently 
checked for accuracy, consistency, and integrity in accordance with Medpace standard operating 
procedures or work instructions. 
 
4.2 Missing Data 
Time to event parameters will be censored for all subjects who do not experience the event of 
interest (progressive disease or death). In ORR analysis, subjects with no tumor response 
assessment will be treated as non-responders. 
All available efficacy and safety data will be included in data listings and tabulations. In general, 
missing data will be treated as missing and no data imputation will be applied, unless otherwise 
specified. Missing dates will be presented without any imputation in all data listings. 
Missing/Partial Dates in Adverse Events 
AE stop dates that are partially missing will be imputed as follows: 
• If month and year are present but day is missing, the last day of the month will be used to 
impute the missing day. 
• If only year is present but day and month are missing, the 31DEC will be will be used to 
impute the missing day and month. 


Page 16 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
After the imputation, the imputed dates will be compared against the date of death, if available. 
If the date is later than the date of death, the date of death will be used instead. 
If the AE stop date is completely missing, it will remain missing. 
AE start dates that are partially missing will be imputed as follows: 
• If month and year are present but day is missing, the first day of the month will be used to 
impute the missing day unless the month and year are the same as month and year of first 
dose date. In that case, day of first dose date will be used to impute the missing day. 
• If only year is present but day and month are missing, first dose date will be used to 
impute if the year is same as the year of first dose date, otherwise 01JAN will be used to 
impute the missing day and month. 
If the imputed date is later than the stop date, then the stop date will be used instead. 
If AE start date is completely missing, then the first dose date will be used. 
Missing/Partial Dates of Concomitant Medication 
Concomitant medications with start dates that are partially missing will be analyzed as follows: 
• If the start date has month and year but day is missing, the medication will be included in 
the summary table if the month and year of the start date of the event are 
o on or after the month and year of the date of the first dose of study medication 
AND 
o on or before the month and year of the date of the last dose of study medication 
plus 30 days. 
• If the start date has year, but day and month are missing, the medication will be included 
in the summary table if the year of the start date of the event is 
o on or after the year of the date of the first dose of study medication 
AND 
o on or before the year of the date of the last dose of study medication plus 30 days. 
If the start date of a therapy is completely missing, then the therapy will be included in the 
summary table unless a partial or complete end date is before the first dose date. 
 
Missing/Partial Dates of Initial Diagnosis 
Dates of initial diagnosis that are partially missing will be imputed as follows: 
• If month and year are present but day is missing, 15 will be used to impute the missing 
day. 
• If only year is present but day and month are missing, the 01JUL will be used to impute 
the missing day and month. 


Page 17 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
If this imputation rule yields a date of initial diagnosis after enrollment date, then the partial date 
of the initial diagnosis will be imputed as 01JAN when only year is provided and the first day of 
the month when only month and year are provided. 
 
4.3 Study Endpoints 
All PK related analyses of endpoints described below will done independently under a separate 
PK analysis plan and such analyses are not covered under this analysis plan. 
 
4.3.1 Dose Escalation 
Primary: 
• Dose-limiting toxicity, MTD, and RP2D. 
Secondary: 
• PK parameters of PEGPH20: maximum observed concentration (Cmax), minimum 
observed concentration (Cmin), terminal elimination half-life (T1/2), area-under-the- 
concentration time curve (AUC), volume of distribution (VD) and clearance (CL). 
• ORR, DOR, DCR, and PFS based on RECIST v1.1. 
• OS. 
Exploratory: 
• PK parameters of pembrolizumab: Cmax, Cmin, T1/2, AUC, VD and CL. 
 
4.3.2 Dose Expansion 
Primary: 
• ORR based on RECIST v1.1. 
Secondary: 
• DOR, DCR and PFS based on RECIST v1.1, and OS. 
• ORR, DOR, DCR, and PFS based on irRC. 
• PK parameters of PEGPH20: Cmax, Cmin, T1/2, AUC, VD and CL. 
• Incidence of AEs. 
• Changes in clinical safety laboratory values. 
• Changes in cardiovascular parameters (electrocardiogram [ECG]) and vital signs. 
Exploratory: 
• ORR, DOR, DCR, and PFS based on RECIST v1.1 criteria and irRC by PD-L1 
expression levels. 
• Changes from pre-treatment in plasma HA and tumor HA (when available). 
• Correlation between plasma HA levels pre-dose, post-dose and any 
pharmacodynamic response. 


Page 18 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
• Changes in tumor blood flow as measured by DCE-MRI. 
• Changes in tumor metabolism as measured by PET/CT. 
• Correlation of biomarkers in plasma and tumor biopsy to study endpoints. 
• PK parameters of pembrolizumab: Cmax, Cmin, T1/2, AUC, VD and CL. 
 
4.4 Analysis Populations 
4.4.1 Enrolled Population 
The Enrolled Population is defined as all subjects who were enrolled (i.e., subjects who sign the 
informed consent form at the screening and are enrolled in a cohort) in the study. Subjects will 
be analyzed according to the initial cohort actually assigned. 
 
4.4.2 Safety Population 
The Safety Population analysis set is defined as all enrolled subjects in either Dose Escalation or 
Dose Expansion portion of the study, who receive at least 1 dose of any study medication 
(PEGPH20 or pembrolizumab). The Safety Population will be used for drug exposure, 
demographics and safety analyses, including AE, labs, and deaths. Subjects will be analyzed 
according to the initial cohort actually assigned. 
 
4.4.3 DLT Evaluable Population 
The DLT Evaluable Population is defined as all subjects enrolled in the Dose Escalation portion 
who receive at least 1 of the 3 full planned doses of PEGPH20 and 1 complete dose of 
pembrolizumab in Cycle 1 and have been followed for the first 21 days of treatment or have 
experienced a DLT during the initial 21 days (Cycle 1) of the study. DLTs will be assessed for 
each subject during the 21 days of Cycle 1 following their first PEGPH20 dose. The DLT 
Evaluable Population will be used for DLT analysis. 
 
4.4.4 PK Analysis Population 
This analysis plan does not cover PK analysis. As appropriate, a description of PK analysis will 
be provided in a separate PK analysis plan. 
 
4.4.5 Efficacy Evaluable Population 
All HA-high subjects who receive at least 1 dose of the RP2D of PEGPH20 and at least 1 dose of 
pembrolizumab in the Dose Expansion portion and all subjects who receive at least 1 dose of 
PEGPH20 and at least 1 dose of pembrolizumab in the Dose Escalation portion. The Efficacy 
Evaluable Population will be used for all efficacy analyses, except for tumor response related 
analyses. 
 
4.4.6 Tumor Response Evaluable Population 
Subjects in the Efficacy Evaluable Population who have at least one post-baseline tumor 
assessment on or post Cycle 2. Tumor Response Evaluable Population will be used for all tumor 
response related analyses. 


Page 19 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
4.5 Subject Enrollment and Disposition 
For subjects who discontinued from study treatment phase and discontinued from study, the 
primary reason for discontinuation will be summarized for all enrolled subjects by cancer type 
and in total. Further, the number of subjects included in each analysis population will be 
tabulated. 
Major protocol deviations are defined as those deviations from the study protocol that are likely 
to have an impact on the subject’s rights, safety, well-being, and/or on the validity of the data for 
analysis. Examples of possible major protocol deviations include, but are not limited to: 
a. Violation of eligibility criteria 
b. Dosing error of study drugs 
c. Excluded concomitant medication 
d. Subject withdrawal 
e. Study visits and procedures 
The number and percentage of subjects with major protocol deviations by type of deviation will 
be summarized by cancer type and in total. 
 
4.6 Demographics and Other Baseline Data 
Demographics and other baseline data will be summarized by cancer type and using the Safety 
Population and by cancer type using the Efficacy Evaluable Population. 
 
4.6.1 Demographics 
Age at Screening (years), height at Screening (cm), weight at Screening (kg), and body surface 
area (BSA; m2) at Screening will be summarized descriptively (N, mean, standard deviation 
[SD], median, minimum [min], maximum [max], and quartiles). Age category at Screening (< 65 
versus ≥ 65 years), sex, race, and ethnicity will be summarized by frequency counts and 
percentages. 
Age at Screening will be calculated as follows: 
Age at Screening = Integer ≤ [(Date of Screening– Date of birth + 1) / 365.25]. 
BSA at Screening will be calculated using DuBois formula as follows: 
BSA at Screening = 0.007184 * W0.425 * H0.725 
 
4.6.2 Baseline Disease Characteristics 
A descriptive summary of baseline disease characteristics of the subjects in the Safety Population 
and Efficacy Population by cancer type and in total will be produced for the following: initial 
disease stage, time from initial diagnosis to enrollment, current disease stage (months), time from 
current diagnosis to enrollment (months), significant past medical history or ongoing (yes, no), 
tobacco usage status (current, former, or never), alcohol usage status (current, former, or never), 
number of cancer therapy lines, prior cancer therapies/medications (yes, no), prior cancer 
resections (yes, no), prior cancer radiation (yes, no), PD-L1 expression level in tumor tissues on 
tumor cells assessed by NeoGenomics for subjects with gastric adenocarcinoma cancer type and 


Page 20 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
Ventana for subjects with NSCLC cancer type at Baseline along with positive and negative 
status, and ECOG performance status at Screening and on study day 1. 
The positive and negative status for PD-L1 on tumor cells at Baseline are determined based on 
the following (see prescribing information of Keytruda®): 
• Subjects with gastric adenocarcinoma cancer type: the PD-L1 status is provided by 
NeoGenomics based on Combined Positive Score (CPS) where PD-L1 status is assigned 
as negative if CPS = 0 and positive if CPS ≥ 1. 
• Subjects with NSCLC cancer type: the PD-L1 status will be derived based on Tumor 
Proportion Score (TPS) from Ventana data as follows: 
o If pembrolizumab is the first-line treatment, the PD-L1 status will be considered 
as negative if TPS < 50 and positive if TPS ≥ 50. 
o If pembrolizumab is the second-line treatment or beyond, the PD-L1 status will be 
considered as negative if TPS = 0 and positive if TPS ≥ 1. 
A listing of baseline disease characteristics will also be provided. 
 
4.6.3 Medical History and Prior Cancer Treatments 
Medical/surgical history and prior cancer surgeries will be coded using the Medical Dictionary 
of Regulatory Activities (MedDRA) and will be listed for all subjects in the Enrolled Population. 
Prior cancer treatments (medication) will be coded using the World Health Organization (WHO) 
Drug dictionary (WHO Drug) and will be summarized by preferred term for the Safety 
Population by cancer type and in total and also be listed for all subjects in the Enrolled 
Population. 
 
4.6.4 Prior and Concomitant Medications 
Prior medications are those the subject used prior to the first dose date. Prior medications can be 
discontinued before first dosing or can be ongoing during treatment phase. 
Concomitant medications are defined as medications that were either initiated prior to the first 
dose of study drug and continued during the study treatment, or initiated on or after the date of 
the first dose of study drug till the end of the last dose of study drug plus 30 days. A given 
medication can be classified both as a prior medication and as a concomitant medication 
depending on the start and stop dates. 
A summary showing the number and percentage of subjects who took either prior and/or 
concomitant medications will be coded by WHO therapeutic drug class, and summarized 
separately by anatomic therapeutic class (ATC) and preferred term using frequencies and 
percentages for subjects in the Safety Population by cancer type and in total. In these summaries, 
subjects taking more than one medication in the same ATC or preferred name will be counted 
only once under that ATC or preferred term. All prior and concomitant medications will also be 
listed. 


Page 21 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
4.7 Efficacy Evaluations 
All efficacy endpoints regarding response (i.e., ORR, DCR, and DOR) will be analyzed by 
cancer type [i.e., gastric adenocarcinoma and non-small cell lung cancer (NSCLC)] using the 
Tumor Response Evaluable Population for subjects for the Dose Escalation portion, Dose 
Expansion portion, and all subjects in both portions. The median DOR with two-sided 80% 
confidence intervals will be estimated using the Kaplan-Meier survival analysis methods. In 
addition, Kaplan-Meier estimates of rate of subjects with continuing response and the 
corresponding two-sided 80% confidence interval will also be provided. 
All other efficacy endpoints (i.e., PFS and OS) will be analyzed by cancer type using the 
Efficacy Evaluable Population for the Dose Escalation portion, Dose Expansion portion, and all 
subjects in both portions. The median PFS, the median OS and two-sided 80% confidence 
intervals will be estimated using the Kaplan-Meier survival analysis methods. The Kaplan-Meier 
estimates of percent event-free for PFS, percent alive for OS and the corresponding two-sided 
80% confidence intervals will also be provided. 
All efficacy endpoints will be provided in listings for both Dose Escalation and Dose Expansion 
portions. 
 
4.7.1 Definitions 
Objective Response Rate 
Objective Response Rate (ORR) is defined as the proportion of subjects who achieve an 
objective response, which will be calculated as the number of subjects with a CR or PR divided 
by the number of subjects in the analysis population of interest (i.e., Tumor Response Evaluable 
Population) multiplied by 100. ORR is defined using the RECIST v1.1 and irRC by cancer type 
for the Dose Escalation portion, Dose Expansion portion, and all subjects in both portions. 
The primary efficacy endpoint of the study in the Dose Expansion portion is PEGPEM treatment 
effect on ORR. A confirmed response requires a confirmatory scan showing a CR or PR at least 
28 days apart from the initial observation of CR or PR. Any scans done within 28 days that show 
CR, PR or NE (not evaluable) cannot be used as a confirmatory scan. In addition, ORR without 
confirmed response (unconfirmed) will also be analyzed. 
The best overall response categories (CR, PR, SD, PD, and NE) defined using the RECIST v1.1 
and irRC will be analyzed in summary tables. Listings of these response categories will be 
provided for both Dose Escalation and Dose Expansion portions. 
Disease Control Rate 
Disease Control Rate (DCR) is defined as the proportion of subjects who achieve a best overall 
response of CR, PR, or Stable Disease (SD) and will be calculated as the number of subjects with 
a best overall response of CR, PR or SD divided by the number of subjects in the analysis 
population multiplied by 100. DCR defined using the RECIST v1.1 and irRC will be analyzed 
with both summary tables and listings. 
Duration of Response 
Duration of Response (DOR) is defined as the time from the date on which an objective response 
(CR or PR) is first determined until the first date on which radiographic disease progression is 


Page 22 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
determined, and will only be calculated for subjects with an objective response (both confirmed 
and unconfirmed) for the Dose Escalation portion, Dose Expansion portion, and all subjects in 
both portions. Subjects achieving an objective response who do not have radiographic disease 
progression will be censored at the date of the last available post-baseline evaluable tumor 
assessment. DOR defined using the RECIST v1.1 and irRC will be analyzed with both summary 
tables and listings. 
Progression-free Survival per RECIST v1.1 
Progression-free survival (PFS), defined as the time from the first dose date until the first 
occurrence of either radiographic or clinical disease progression or death from any cause during 
the treatment period. Subjects without PFS event by the analysis cut-off date will have their PFS 
censored at the last evaluable post-baseline tumor assessment day or on Day 1 if they have no 
post-baseline tumor assessments. PFS (in months) will be calculated as: 
(Event date or censoring date – First dose date + 1) / 30.4375 
Because the dosing interval between cycles without a dose is 7 days (from Day 15 to Day 21 of 
each cycle), the treatment period will include 7 days after the last dose date. Thus, subjects who 
are not radiologically or clinically progressed, but died within 7 days of the last dose will be 
considered as having PFS events. Deaths after 7 days of last dose without radiological or 
documented clinical progression will not be considered as PFS events in the primary PFS 
analysis. Table 3 below describes the scheme of events and censoring for PFS. 
Progression-free Survival per irRC 
PFS per irRC will be defined analogous to PFS per RECIST v1.1 by replacing RECIST v1.1 
progression by irRC progression (irPD). In the schema shown in Table 3, replace ‘radiological’ 
disease progression per RECISIT v1.1’ by irPD and ‘First date of radiological disease 
progression’ by ‘First date of irPD’. 


Page 23 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
Table 3: 
Scheme of Events and Censoring for PFS per RECIST v1.1 
 
Outcome 
Situation 
Date of Progression 
or Censoring 
PFS Event 
Radiological disease progression per RECIST v1.1 
at scheduled or unscheduled visits or at End of 
Treatment visit 
The earliest date of 
radiological disease 
progression, 
documented clinical 
progression, or death 
Death within 7 days of the last dose 
Documented clinical progression 
Censoring for 
PFS (If no PFS 
Event) 
No radiological or documented clinical disease 
progression, do not die within 7 days of the last 
dose, and have adequate tumor assessment at both 
Baseline and post-Baseline 
Date of last adequate 
tumor assessment 
Discontinuation of treatment due to reasons other 
than radiological disease progression, or 
documented clinical progression 
Death after 7 days of the last dose 
No documented clinical disease progression, do not 
die within 7 days of the last dose, and had no 
adequate tumor assessment at either Baseline or 
post-baseline 
First dose date 
 
 
Overall Survival: 
Overall Survival (OS) is defined as the time from the first dose date until death from any cause. 
OS data from surviving subjects will be censored at date of the last contact. OS (in months) will 
be calculated as: 
(Death or censoring date – First dose date + 1) / 30.4375 
To determine the date of the last contact, the latest date of the following should be used: 
• Hospitalization admission and discharge dates 
• Dosing dates 
• Laboratory test, vital signs test and 12-Lead Electrocardiogram (ECG) test dates 
• Immunogenicity assessment dates 
• AE start and stop dates (full dates) 
• Cancer therapies/medications/resections/radiation start and stop dates (full dates) 
• Tumor assessment dates 
• Brain scan dates 


Page 24 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
 
• Last known alive dates collected in long-term follow-up period 
• Other clinical data which can confirm the subject’s survival status 
 
4.7.2 Analysis of Unconfirmed/Confirmed ORR, DCR and DOR 
The primary efficacy endpoint of the study in Dose Expansion portion is PEGPEM treatment 
effect on confirmed ORR based on tumor assessments from the Investigator using RECIST v1.1. 
The statistical hypothesis tests for the primary endpoint are as follows: 
• NSCLC cancer type: H0: ORR ≤ 23%; H1: ORR > 23% 
• Gastric adenocarcinoma cancer type: H0: ORR ≤ 15%; H1: ORR > 15% 
The hypothesis tests will be conducted using the one-sided exact binomial test at the significance 
level of 0.1. Thus, confirmed ORR and its two-sided 80% exact confidence interval will be 
provided to test each of the hypotheses above. If the lower limit of the exact confidence interval 
lies above 23% or 15% for NSCLC or gastric adenocarcinoma cancer types respectively, the 
respective null hypothesis will be rejected concluding a statistically significant effect of 
PEGPEM treatment in the respective cancer type. In addition, best overall response data will be 
summarized in frequency and percentage format by cancer type and the two-sided, exact 80% 
confidence intervals for the unconfirmed ORR and DCR will also be provided. Further, median 
DOR and its 80% confidence interval will be calculated and reported. Unconfirmed/confirmed 
ORR, DCR, and DOR will also be calculated based on irRC and displayed in summary tables 
and listings. 
Additional efficacy analyses of ORR, DCR, and DOR related to NSCLC cancer type will also be 
performed using RECIST v1.1 data from Imaging Endpoints. 
Note: Halozyme made the decision to discontinue further enrollment into the study on 31 May 
2018. At the time of the early termination, a total of 25 gastric adenocarcinoma cancer subjects 
and 17 NSCLC subjects have been enrolled in the Dose Expansion portion. The planned sample 
size in the Dose Expansion portion is approximately 51 subjects (approximately 30 with 
HA-high tumors in NSCLC and approximately 21 with HA-high tumors in the gastric 
adenocarcinoma cohort). Therefore, a caveat regarding the interpretation of the results will be 
provided for the NSCLC cohort which is underpowered because of the early termination. 
 
4.7.3 Analysis of PFS and OS 
The PFS based on the RECIST v1.1 and irRC, and OS will be analyzed in summary tables by 
cancer type for the Dose Escalation portion, Dose Expansion portion, and all subjects in both 
portions. 
The PFS based on the RECIST v1.1 and irRC, and OS will be presented by listings for both Dose 
Escalation and Dose Expansion portions. KM plots will also be constructed for PFS based on the 
RECIST v1.1 and OS for the Dose Escalation portion, Dose Expansion portion, and all subjects 
in both portions. 
Additional efficacy analyses of PFS related to NSCLC cancer type will also be performed using 
RECIST v1.1 data from Imaging Endpoints. 


Page 25 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
4.7.4 Exploratory Analyses 
PD-L1 expression levels in tumor tissues, plasma HA and tumor HA will be presented in data 
listings. No formal analysis regarding exploratory endpoints will be conducted. 
 
4.7.5 Adjustment for Covariates 
Not applicable. 
 
4.7.6 Multicenter Studies 
The center effect will not be considered for this study. 
 
4.7.7 Multiple Comparisons/Multiplicity 
There will be no adjustment for multiple hypothesis testing. 
 
4.8 Subgroup Analysis 
No subgroup analyses are planned. 
 
4.9 Safety Evaluations 
Safety evaluations include exposure to study medications, DLTs, adverse events (AEs), serious 
adverse events (SAEs), ECGs, vital signs, clinical laboratory and ECOG performance status. All 
AEs will be coded using the MedDRA. All safety summaries will be produced by cancer type 
and overall using the subjects in the Safety Population. The summary of DLTs in the Dose 
Escalation portion will be performed by cancer type, dose level and in total based on the DLT 
Evaluable Population. 
 
4.9.1 Definitions 
Dose Limiting Toxicity 
See the definition stated under “Definition of DLT” in Section 6.1.1 of Protocol HALO-107-101 
Amendment 4 entitled “A Phase 1b Open-Label Study of PEGylated Recombinant Human 
Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected 
Hyaluronan-High Solid Tumors” and dated 6 November 2017. 
Treatment emergent adverse event 
Treatment emergent adverse event (TEAE) is defined as any adverse event with an onset date on 
or after the first dose of any study drug up through and including 30 days after the last dose of 
any study drug. 
In addition, any adverse event deemed related (i.e., eCRF categories: related, probably related or 
possibly related) to any study medication by the Investigator will also be considered as TEAE 
irrespective of the onset date. 
 
4.9.2 Extent of Exposure 
Extent of exposure will be summarized for treatment duration, number of cycles initiated, 
number of doses administered, dose reductions, dose delay, cumulative dose, weight adjusted 


Page 26 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
cumulative dose, average dose intensity, and relative dose intensity by cancer type and in total 
separately for the Dose Escalation portion and the Dose Expansion portion. 
An overall summary of drug exposure will be presented for the number of cycles initiated with 
any study medication and duration of treatment for all study medications. Duration of treatment 
is defined as the time from first dose date of any study medication to the last dose date of any 
study medication. Overall drug exposure will be summarized using descriptive statistics. The 
frequency count and percentages will also be presented for subjects who had number of 
treatment cycles initiated >0, ≥2, ≥4, etc. 
For each study medication (PEGPH20 and pembrolizumab), exposure will be summarized using 
descriptive statistics by cancer type and in total for the following parameters across all cycles. 
• Number of cycles initiated 
• Duration of treatment 
• Number of doses administered 
• Frequency and percentage of subjects with at least one dose omitted 
For subjects with at least one dose omitted: 
− Total number of expected doses up to the last dose received, including doses 
omitted 
− Frequency and percentage of doses omitted 
− Frequency and percentage of dose omission by reason, including PEGPH20 
toxicity, chemotherapy toxicity, other adverse event, scheduling conflict, 
discontinued PEGPH20 and other 
• Frequency and percentage of subjects with at least one dose PEGPH20 reduction 
For subjects with at least one PEGPH20 dose reduction: 
− Total number of doses administered 
− Frequency and percentage of doses with dose reduction 
• Frequency and percentage of subjects with at least one dose delay. A treatment cycle 
is considered delayed if the first dose date of the following cycle is greater than 28 
days after the first dose date of the cycle of interest. 
For subjects with at least one dose cycle delay: 
− Total number of cycles initiated 
− Frequency and percentage of cycles with dose delay 
• Frequency and percentage of subjects with at least one dose interruption 
For subjects with at least one dose interruption: 
− Total number of doses administrated 
− Frequency and percentage of doses with dose interruption 


Page 27 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
− Frequency and percentage of dose interruption by reason, including adverse event 
and other 
− Frequency and percentage of interrupted doses restarted 
• Actual dose intensity (ADI) per cycle is defined as the cumulative dose divided by 
number of adjusted treatment cycles. 
− The weight-adjusted cumulative dose administered for PEGPH20 (in both Dose 
Escalation and Dose Expansion portions) and pembrolizumab (in the Dose 
Escalation portion only) is the sum of the respective doses administered at a given 
visit, divided by the subject’s weight measurement (kg) at Screening. Cumulative 
dose for pembrolizumab (in the Dose Expansion portion only) is defined as the 
sum of administered doses. 
− If the last dosed cycle is Cycle 1, then number of adjusted treatment cycles is 
considered to be 1. If the last dosed cycle is Cycle 2 or beyond, then the number 
of adjusted treatment cycles will be calculated as [(End date of last cycle – First 
dose date + 1) / 21], where the end date of last cycle is calculated as [First dose 
date of last cycle + (Number of doses received or omitted in the last cycle up to 
the last dose received) * 20 / 3] for PEGPH20 and (Dose date + 20) for 
pembrolizumab. For PEGPH20, if the day of the visit of first dose date of last 
cycle is not 1, then an adjustment should be made by subtracting 7 or 14 
depending on whether the day is 8 or 15 respectively. 
• The planned dose intensity (PDI) for PEGPH20 is calculated as follows: 
− For the Dose Escalation portion, if the number of adjusted treatment cycles is 1, 
then the planned dose intensity per cycle (ug/kg) for each individual dosing cohort 
will be calculated as [(Dose level in ug/kg) * Number of doses received or 
omitted up to the last dose received in Cycle 1]. Else, the planned dose intensity 
per cycle (ug/kg) for each individual dosing cohort will be calculated as [(Dose 
level in ug/kg) * 3]. 
− For the Dose Expansion portion, if the number of adjusted treatment cycles is 1, 
the planned dose intensity per cycle (ug/kg) will be calculated as [(RP2D dose in 
ug/kg) * Number of doses received or omitted up to the last dose received in 
Cycle 1]. Else, the planned dose intensity per cycle (ug/kg) will be calculated as 
[(RP2D dose in ug/kg) * 3]. 
• The PDI for pembrolizumab is calculated as follows: 
− For the Dose Escalation portion, the planned dose intensity per cycle is 2 mg/kg. 
− For the Dose Expansion portion, the planned dose intensity per cycle is 200 mg. 
• The Relative dose intensity (RDI) (percent) is defined as follows: 
− [(ADI per cycle) /  (PDI per cycle)] * 100% 
In addition to descriptive summary of relative dose intensity, the frequency and 
percentage of subjects will be presented for the following relative dose intensity 


Page 28 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
categories: ≥90%, 80% to <90%, 70% to <80%, 60% to <70%, 50% to <60%, and 
<50%. 
 
4.9.3 Analysis of DLTs 
Dose Limiting Toxicities (DLTs) will be assessed for each subject in the Dose Escalation portion 
during the 21 days following their first PEGPH20 dose. Number and percent of subjects 
experiencing DLTs in the Dose Escalation portion will be tabulated by cancer type, dose level 
and in total for the DLT Evaluable Population. A listing of DLT events will also be provided. 
 
4.9.4 Analysis of AEs 
Only TEAEs will be tabulated by system organ class or standard MedDRA query (SMQ) or high 
level term, and preferred term for the subjects in the Safety Population by cancer type and in 
total. Summary tabulations include the following: 
• An overall summary of TEAEs. 
• Grade 3 or higher TEAEs 
• Drug-related TEAEs 
• Grade 3 or higher drug-related TEAEs 
• TEAEs with outcome of death 
• Treatment-emergent serious AEs (SAEs) 
• PEGPH20 related treatment-emergent SAEs 
• Pembrolizumab related treatment-emergent SAEs 
• TEAEs leading to discontinuation of study drug 
• TEAEs related to PEGPH20 leading to discontinuation of PEGPH20 
• TEAEs related to pembrolizumab leading to discontinuation of pembrolizumab 
• Summary of Treatment-emergent thromboembolic events by standard MedDRA query 
(SMQ) 
• Summary of Treatment-emergent serious thromboembolic events by SMQ 
• Bleeding TEAEs by SMQ 
• Musculoskeletal TEAEs by MedDRA high level term. 
Subjects experiencing the same AE more than once will have that event counted only once 
within each body system, and once within each preferred term in all summary tabulations. 
Listings will be provided for AEs leading to death, SAEs, grade 3 and above AEs, and AEs 
leading to discontinuation of study drug. Additionally, by-subject listings of the AEs will be 
presented including, but not limited to, verbatim term, preferred term, system organ class, NCI- 
CTCAE grade, and relationship to study drug. 


Page 29 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
4.9.5 Vital Signs and Body Weight 
Vital signs assessments will be performed pre dose on Day 1, Day 8, and Day 15 of all cycles 
and at the End of Treatment visit. On all other days, vital signs will be evaluated for clinically 
significant AEs. 
Vital signs including blood pressure (systolic and diastolic), heart rate (beats/min), respiratory 
rate (breaths/min), body temperature (˚C) and weight (kg) will be summarized by visit and by 
cancer type and in total using descriptive statistics. 
Height (cm), weight (kg) and body surface area (BSA; m2) will be summarized by visit using 
descriptive statistics. BSA is calculated using DuBois formula as: 
BSA = 0.007184 * W0.425 * H0.725 
By-subject listings of vital signs and body weight will also be provided. 
 
4.9.6 Clinical Laboratory Evaluation 
Clinical laboratory evaluations will be performed at specified time points per schedule of study 
events in the protocol. All clinical laboratory evaluations will be performed by a central 
laboratory. In addition, local laboratories may be used if immediate clinical decision making is 
required. The following clinical laboratory tests will be performed: 
• Hematology: Minimally, scheduled hematology collections should include 
hemoglobin, hematocrit, red blood cell count, white blood cell (WBC) count, neutrophils 
(ANC), lymphocytes (absolute), monocytes (absolute), eosinophils (absolute), basophils 
(absolute), granulocytes (absolute), mean corpuscular hemoglobin, mean corpuscular 
volume, and platelet count 
• Serum electrolytes and chemistry: glucose, blood urea nitrogen (BUN), albumin, total 
bilirubin, alkaline phosphatase, AST, ALT, electrolytes (including sodium, potassium, 
calcium, magnesium, chloride, and bicarbonate), and creatinine 
• Coagulation parameters: international normalized ratio (INR), prothrombin time (PT), 
and partial thromboplastin time (PTT) 
• Thyroid function tests: free T3, free T4, and TSH 
• Urinalysis: protein, glucose, ketones, blood, specific gravity, nitrite, pH, and leukocytes 
All lab values will be reported and summarized by cancer type and in total using standard 
international (SI) units. Only central lab data for hematology, serum electrolytes and chemistry, 
coagulation, and thyroid function tests will be used for summarizing laboratory values by visit 
and change from baseline. All lab data for hematology, serum electrolytes and chemistry, and 
coagulation from both central and local labs will be used for summarizing lab parameters with 
worst CTCAE grade at post-baseline visits and their shift from Baseline. Laboratory results will 
be graded using NCI CTCAE V4.03, if applicable. 
All clinical laboratory data will be listed, and values deemed clinically significant will be 
flagged. Frequency and percentage of subjects with laboratory values of ALT, AST, BILI, and 
ALP who meet Hy’s law criteria (ALT > 3×ULN or AST > 3×ULN, BILI ≥ 2×ULN and 
ALP < 2×ULN) at any time point will be summarized by cancer type and in total. 


Page 30 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
4.9.7 12-Lead Electrocardiogram (ECG) 
ECGs are taken at Screening, End of Treatment visit and as needed basis when clinically 
indicated. Frequency and percentage of subjects who had post-baseline abnormal (clinically 
significant or not clinically significant) ECG findings will be summarized by cancer type and in 
total. 
A listing will be provided for the ECG data. 
 
4.10 ECOG Performance Status 
Frequency and percentage of subjects in each ECOG performance status score will be displayed 
at baseline. Listings of ECOG will be provided. 
 
4.11 Immunogenicity Assessments 
A blood sample will be collected from all subjects who receive PEGPH20 and analyzed to 
determine if PEGPH20 is eliciting a humoral immune response. Initial anti-drug antibodies 
(ADA) testing will be done using a multi-tiered approach per the Guidance, and 
immunocompetition will be performed to confirm an initial positive response in the screening 
assay. Any samples confirmed as positive in the ADA assay will then be assayed for neutralizing 
antibodies. ADA status (positive or negative) will be tabulated at each scheduled time point and 
overall at post-baseline for subjects receiving PEGPH20. Number and percent of subjects with 
positive neutralizing antibodies will be summarized descriptively at each scheduled time point 
and overall at post-baseline. For each subject, overall is defined as positive if at least one post- 
baseline neutralization test result is positive. A listing of the ADA data will also be provided. 
 
4.12 Sample Size Determination 
In the Dose Escalating portion, there may be up to 5 dose levels for a total of approximately 
30 subjects. 
In the Dose Expansion portion, approximately 51 subjects with HA-high tumors will be enrolled 
(30 with HA-high tumors in NSCLC cohort and 21 with HA-high tumors in the gastric 
adenocarcinoma cohort). 
KEYNOTE-001 study data presented at the American Society of Clinical Oncology 2016 (Hui 
2016) showed that when treated with pembrolizumab alone, treatment naïve subjects who had 
evaluable PD-L1 Tumor Proportion Score (TPS) levels had an ORR of 29% and previously 
treated subjects who had evaluable PD-L1 TPS levels had an ORR of 21%. Under the assumption 
that no more than 40% of the subjects enrolled in this study will be treatment naïve, ORR in the 
combined NSCLC population is expected to be approximately 24% when treated with 
pembrolizumab alone. A 20% improvement in ORR is considered clinically meaningful when 
PEGPH20 is added to pembrolizumab. Under these conditions, 30 NSCLC subjects would 
provide approximately 80% power at the hypothesized ORR of 44% when the null hypothesis  
H0: ORR ≤24% is tested against H1: ORR >24% using an exact one-sided binomial test at a 10% 
significance level. KEYNOTE-012 study data showed that the ORR in PD-L1 positive gastric 
cancer subjects is about 22% (Muro 2016). Since subjects will not be selected based on PD-L1 
expression levels prospectively in this study, in order to accommodate all subjects (irrespective 


Page 31 of 31 
Statistical Analysis Plan 
Version Number: 1.0 
Protocol Number: HALO-107-101 
Version Date: 19 April 2019 
 
 
of PD-L1 expression levels), a conservative ORR of 15% is assumed with pembrolizumab 
treatment alone and it is further assumed that the addition of PEGPH20 to pembrolizumab will 
lead to a clinically meaningful improvement of 20% in ORR to 35%. Under these assumptions, 
21 subjects will provide approximately 80% power at the hypothesized ORR of 35% when the 
null hypothesis H0: ORR ≤15% tested against H1: ORR >15% using an exact one sided binomial 
test at a 10% significance level. 
 
4.13 Interim Analysis and Early Stopping Rules 
No formal interim analyses are planned for this study. However, since the combination of 
PEGPH20 and pembrolizumab have not been studied previously, to protect safety of the 
subjects, a Data Monitoring Committee (DMC) will review the accumulated safety data 
regularly. Frequency of these data reviews are documented separately in a DMC charter. 
 
5 
CHANGES FROM THE PROTOCOL SPECIFIED STATISTICAL 
ANALYSIS 
• In the protocol, Tumor Response Evaluable Population is defined as subjects in the 
Efficacy Evaluable Population who have at least one post-baseline tumor assessment. 
However, this definition was changed to “subjects in the Efficacy Evaluable Population 
who have at least one post-baseline tumor assessment on or post Cycle 2”. 
• The protocol states that only values derived from the central labs will be utilized for 
study analysis and reporting purpose. However, all lab data from both central and local 
labs will be used for worst CTCAE grade at post-baseline visits and their shift from 
Baseline. 
 
6 
REFERENCES 
1. Keytruda® Highlights of Prescribing Information. Retrieved from 
https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf 
2. Hui R, Gandhi L, Costa EC, Felip E, Ahn M-J, Eder JP. Long-Term Overall Survival for 
Patients with Advanced NSCLC Enrolled in KEYNOTE-001 Study of Pembrolizumab 
ASCO 2016 Annual Meeting, Poster Abstract 9026. 
3. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab 
for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a 
multicentre, open-label, phase 1b trial. Lancet Oncol 2016; 17: 717–26